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Abstract
Hereditary Haemorrhagic telangiectasia (HHT) is an autosomal dominant
disease which is characterised by frequent, severe nose bleeds, muco¬
cutaneous telangiectases, gastro-intestinal haemorrhage and the formation
of visceral arteriovenous malformations, particularly in the pulmonary and
cerebral circulation. The endoglin gene on chromosome 9q34 was shown to
be mutated in a proportion of patients with this disease. Endoglin is a
Transforming Growth Factor-beta (TGF-p) binding protein expressed
predominantly by endothelial cells. The endoglin locus (HHT1) had
previously been excluded in some families by linkage, suggesting that
mutations in a second unidentified gene caused HHT in a proportion of
patients.
The work presented in this thesis aimed to identify the second gene for HHT
(HHT2) and compare features of patients with mutations in this gene, and
those with mutations in Endoglin.
Members of 5 new families who suffer from HHT were assessed. Three of
these families show exclusion of the chromosome 9 locus on linkage
analysis. Linkage analysis of these 3 families in conjunction with analysis of
other families previously described demonstrated a second locus for HHT on
chromosome 12. A candidate interval of approximately 1cM was defined by
haplotype analysis, looking at critical recombination events. A strong
candidate gene was identified within this region. This gene, ALK-1, is a type
I serine-threonine kinase receptor with expression demonstrated solely in
endothelial cells.
A large genomic clone containing the ALK-1 was identified from a PAC
library. The genomic structure of ALK-1 was elucidated. Conditions for the
PCR amplification of each exon of the ALK-1 from genomic DNA gene were
determined, allowing sequencing and mutation analysis of the gene in
patients with HHT. The ALK-1 gene was sequenced in 12 patients.
Mutations in ALK-1 were identified in all 6 patients from families with
evidence of linkage to 12q or exclusion of linkage to 9q34. Three mutations
were also identified in 6 patients from whom no linkage data was available.
The mutations identified left the transmembrane domain of the ALK-1
receptor intact, but are predicted to disrupt either kinase function, or ligand
binding to the extracellular domain. Whether expression of an abnormal
protein is necessary for disease causation, or whether mutations lead to a
null allele remains to be established. The identification of ALK-1 as a
second gene responsible for HHT is the first evidence that there is an
interaction between ALK-1 and Endoglin in the endothelial cell.
The comparison of families with known endoglin mutations and ALK-1
mutations showed a much higher incidence of pulmonary arterio-venous
malformations in patients with endoglin mutations. The incidence of gastro¬
intestinal haemorrhage and hepatic complications was not significantly
different. The reason for this remains to be established.
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Chapter 1. Introduction
A. Hereditary Haemorrhagic Telangiectasia, - a historical perspective
The original name of the disorder, Osler-Rendu-Weber syndrome
originates from three physicians who gave early descriptions of the
disease. Osier (1849 to 1919), a prominent American physician, described
the disorder in 1901 in his paper "Family form of recurring epistaxis
associated with multiple telangiectases of the skin and mucous
membranes". In this paper he referred to an earlier description of the
disease, written by the French physician Rendu in 1896.
The paper by Rendu, "Epistaxis repetees chez un sujet porteur de petits
angiomes cutanes et muqueux." (recurring nosebleeds in a patient with
small cutaneous angiomas of the skin and mucous membranes.) remains
one of the best descriptions of the disease. Rendu described a 52 year old
man admitted with a prolonged nosebleed. He has a history of epistaxis
occurring several times a day, which started at the age of 12 becoming
much more frequent after the age of 35. He was not, however prone to
abnormal bruising, bleeding from the gums, or prolonged bleeding after an
injury. He was anaemic and mildly jaundiced, although showing no overt
signs of liver failure. The telangiectases are described:
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"II existe sur la peau du nez, des joues, de la levre superieure et du
menton de petites taches pourprees ...les plus grosses atteignant les
dimensions d'une lentille, et qui sont de veritables angiome cutanes,
produit par une dilatation des vaisseaux superficiels de la peau..."
On the skin of the nose, cheeks, upper lip and chin, there are small purple
marks the largest approach the size of a lentil, and these are true
cutaneous angiomas produced by a dilatation of the superficial vessels of
the skin....
The distribution of these telangiectases on the face, lips and mucous
membranes, sparsely on the trunk but not on the limbs is noted, as is their
tendency to blanche incompletely and refill quickly after ceasing pressure
on them. The patient's father died of gastro-intestinal haemorrhage, and
his brother, who died of other causes, suffered from frequent nosebleeds.
Parkes-Weber was an English physician had a lifelong interest in vascular
lesions wrote an article in the Lancet in 1907 describing a mother and 9
children, noting that the features in some of the children, even after the
age of 30 were so subtle as to make diagnosis difficult. He also reviewed
previous descriptions by Legg in 1876 and Chiari in 1887 of diseases
similar to Osler-Rendu-Weber syndrome and of a family with a history of
nosebleeds reported by B.G. Babbington in the Lancet in 1865.
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Earlier descriptions may well have described Osler-Rendu-Weber
syndrome. H.G. Sutton in the Medical Mirror in 1864 described a possible
association between haemoptysis in later life (presumed to be due to the
phthisis or TB) and epistaxis. He cites a case described by Sir Henry
Marsh of a 46 year old lady with haemoptysis. Her father who had frequent
epistaxis died following a haemoptysis. Her brother and 3 of her sons had
frequent nosebleeds, whereas her daughter did not. This association
between epistaxis and haemoptysis was well recognised long before this.
Referring to this association in a dissertation presented to the Royal
Medical Society in Edinburgh in 1800, C.Rattray wrote:
"Haemoptysis, or the spitting of blood from the lungs...This disease is
frequently observed in those of the most sensible and irritable disposition,
of a weak slender make, with long necks and flat breasts and those in any
way malformed about the thorax, those in their youth have been subject to
epistaxis..."
The more descriptive name "Hereditary Haemorrhagic Telangiectasia"
originated in a comprehensive discussion of the disorder written by Hanes
in 1909, while a resident at Johns Hopkins Hospital. This name is
descriptive and avoids giving insult to the shades of many early physicians
who described the disease, but who are not remembered in the
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eponymous name. Throughout this text, therefore, the name Hereditary
Haemorrhagic Telangiectasia (abbreviated to HHT) will be used.
B. Clinical Description of Hereditary Haemorrhagic Telangiectasia.
HHT is an autosomal dominant disease characterised by recurrent
epistaxis, muco-cutaneous telangiectasis and arteriovenous
malformations, particularly in the lungs and brain. Vascular complications
also affect the hepatic and gastro-intestinal systems, with involvement of
the genito-urinary system and heart reported more rarely.
i.Incidence of HHT.
Two studies have attempted to arrive at an estimate of the incidence of
HHT based on epidemiological recruitment of cases. A study of the French
population (Bideau et.al.1980,1992) estimated an overall prevalence of 1
in 8,345 people. However, several areas had a much higher local
prevalence, such as the Jura region (1 in 5062) and Deux-Sevres (1 in
4,287). This is in considerable contrast to estimates of between 1 in 40,000
and 1 in 100,000 made prior to this by other authors but not based on an
epidemiological^ recruited study.
The point prevalence in the North of England was estimated at 1 in 39,216
based on questionnaires sent to general practitioners, ENT surgeons and
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haematologists, revealing a minimum reported incidence of 79 cases in a
population of 3.1 million (Porteous et.al 1992).
However, given the wide variation of severity of HHT, with its potential for
under-diagnosis by the medical profession, it is likely that many cases in
the population remain unidentified. The true prevalence may therefore be
considerably higher than 1 in 40,000. A study in Vermont based on known
cases of HHT, estimated the frequency in the Vermont population at about
1 in 16,500 (Guttmacher et.al. 1994).
Even though it is considered a rare disorder, with a prevalence of 1 in
40,000, over 1,000 people in the UK suffer from HHT. If the higher
estimates are accurate, this figure may rise to over 5,000 affected
individuals.
ii.Mucocutaneous Telangiectases.
The appearance of these is classically as described by Rendu (1896):
"...small purple marks, the size of a pinhead with the largest attaining the
size of a lentil, which are true cutaneous angiomas, produced by a
dilatation of the superficial vessels of the skin. They blanche on pressure,
but do not completely disappear, blood returning immediately that pressure
ceases."
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As previously described elsewhere by several authors (Osier 1907, Bird
et.al. 1957), the telangiectases can become raised and nodular, usually in
later life. Spider angiomas have been reported (Bird et.al. 1957) but are
not as characteristic, as these may have other causes.
Figure 1.1 shows typical mucocutaneous telangiectases.
A study in the French population found telangiectases in 74% of 240
patients on careful examination (Plauchu et.al. 1989). About half of all
patients who could remember the time of onset of lesions reported first
appearance before the age of 30. They reported the most common site of
telangiectases as the face (63% of patients) followed by the mouth (48%)
and hands (37%). Lesions on the trunk, arms and lower limbs were much
less common (less than 10% of patients) with many fewer lesions at these
sites. For patients with oral involvement, the lower lip and tongue were
most frequently involved. The palate was involved in 13% of patients as
were the ears. The floor of mouth, conjunctiva, eyelids and gums were
involved in 5% or fewer of patients.
In a British study, (Porteous et.al. 1992) the sites most frequently affected
with telangiectases were reported as the palm and nailbed (71% of all
patients), lips and tongue (66%) and the face (20%).
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Figure 1.1 Typical muco-cutaneous lesions on the lips of a patient with
hereditary haemorrhagic telangiectasia. This patient also has pulmonary
arteriovenous malformations and cerebral arteriovenous malformations, in
addition to daily heavy nosebleeds.
7
iii Epistaxis.
Epistaxis is usually the first symptom of HHT to be described, although the
frequency and severity are very variable. Some people are only ever mildly
affected, whereas in others epistaxis can be prolonged and at times, life
threatening. Plauchu (Plauchu et.al.1989) found more than half his
patients had epistaxis before the age of 20, with 90% complaining of the
symptom by age 45. 70% of those between the ages of 45 and 60 had
heavy episodes lasting more than 10 minutes.
Porteous (Porteous et.al. 1992) reported that out of 40 patients over the
age of 50, 16 said the epistaxis had stayed the same, 16 said it had
deteriorated and 8 said it had improved.
In a study of a population of patients screened for pulmonary arteriovenous
malformations (Aasar et.al. 1991), an increase in frequency of epistaxis
with age was seen, increasing from an average of 8 per month under age
20, to 22 per month over age 40.
Despite its frequency, epistaxis is one of the most difficult symptoms of
HHT to treat. Local treatment such as cautery seems to have limited
success (Porteous et.al. 1992), although laser treatment may prove better.
Hormonal treatment with oestrogen and progesterone has been
advocated, but reports of its efficacy vary. It is also of limited value in
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treating male patients. (McCaffrey et.al. 1977, Harrison et.al 1982, Vase
et.al. 1981). Nasal septo-dermoplasty is one of several operative
approaches that have been used, but after initial improvement of
symptoms, epistaxis tends to recur. (McCaffrey et.al. 1977).
iv.Gastro-lntestinal Haemorrhage.
This complication was less commonly encountered in the population based
studies and usually starts in later life. 16% of patients seen in the French
study (Plauchu et.al. 1989) were affected, but half the patients with this
complication were over 58, only 1.5% of those under the age of 30 had
gastro-intestinal haemorrhage. Porteous et.al reported 16 patients out of
56 suffering this complication, mainly from the upper gastro-intestinal tract.
A Danish study (Vase and Grove 1986) found gastro-intestinal
haemorrhage in 35 out of 139 patients, only 2 of whom were under 40.
Median age of onset was 55 compared to a median age of 11 for the onset
of epistaxis. These patients had predominantly gastric and duodenal
telangiectases, although 5 also had colonic telangiectases.
Various treatments for gastro-intestinal haemorrhage are available. Laser
treatment can be effective if lesions are few in number (Bown et.al. 1985),
but the long term results may be less promising (Naveau et.al. 1990).
Desmopressin has been used with success to control acute bleeds
refractory to normal management (Quitt et.al. 1990) Successful treatment
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of those with severe haemorrhage using oestrogens is now established,
(Van Cutsem et.al. 1988,1990, Van Cutsem and Piessevaux 1996). The
current regime uses 0.05mg ethinyloestradiol and 1mg norethisterone for 6
months. The reduction in haemorrhage is durable after treatment has been
withdrawn after several months (Van Cutsem and Piessevaux 1996).
Currently this seems the best first line treatment for those with refractory
gastro-intestinal haemorrhage and transfusion dependence, when
endoscopic treatment is not possible and the side effects of oestrogen
treatment can be tolerated.
v. Hepatic Complications
The incidence of symptomatic hepatic lesions is low. In the french cohort,
(Plauchu et.al. 1989) 8% of patients had either hepatomegaly, jaundice,
cirrhosis or a hepatic murmur. Onset of symptoms was usually in later life.
Several families have been reported to have a much higher incidence of
hepatic involvement than expected. A family with a father, 3 daughters and
a grandson who all had symptomatic liver lesions with other classical
features of HHT has been reported (Martini 1978). His review of all autopsy
evidence to date suggested that fibrovascular lesions were a common
finding, with evidence of cirrhosis in some patients. Angiographic findings
in those with symptomatic hepatic lesions usually show diffuse small
arteriovenous communications, precluding treatment by transcutaneous
embolisation. A further small family of Northern Italian origin with
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predominantly hepatic manifestations is reported by Ninkowictz (personal
communication). A large Italian family has been described (Piantinada
et.al.1996). Occasionally liver transplant has proved the only available
treatment. (Bauer et.al. 1995).
vi Ocular Involvement
Conjunctival telangiectasia is not uncommon in HHT, affecting up to a third
of patients (Brant et.al.1989). Blood stained tears have also been reported.
(Wolper et.al. 1969). Retinal telangiectases have not been well studied
frequently, but haemorrhage from presumed retinal lesions have been
reported. (Davis et.al.1971) The incidence of retinal lesions reported varies
between by 10% (Brant et.al 1989) and 1/250 (Forker et.al 1963). This
may represent a difference of ascertainment, or of the population studied.
vii Pulmonary Complications.
Pulmonary Arteriovenous Malformations (PAVMs) are one of the most
characteristic lesions of HHT. They vary in size from insignificantly small to
very large, and may be single or very numerous. An angiogram showing a
PAVM is shown in figure 1.2.
Different reports give very varied estimates of incidence of this
complication. Plauchu (Plauchu et.al. 1989) estimated that 4.6% of his
population had PAVMs. In the North of England, (Porteous et.al.1992)
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Figure 1.2 Characteristic arteriovenous malformations associated with
hereditary haemorrhagic telangiectasia.
a. A pulmonary angiogram showing an unusually large pulmonary
arteriovenous malformation in the right middle lobe. Multiple feeding vessels
are visible.
b. A cerebral CT scan with contrast and a left carotid angiogram showing an
arteriovenous malformation on the left hand side.
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PAVMs were reported in 13/56 individuals. A Danish study (Vase et.al.
1985) found 16/95 patients had PAVMs on screening by chest X-ray. In a
study of patients and their first degree relatives in Holland, (Haitjema et.al.
1995a,b) PAVMs were seen in 12/36 patients. Some early case reports
found no PAVMs in families (Bird et.al. 1957, Hodgson et.al. 1959) whereas
a high incidence has been seen in other families (Hodgson et.al. 1959,
Shovlin et.al. 1994). This difference observed between families seemed too
great to explain solely by differences in study technique. As discussed
later, it was proposed that there are two forms of HHT, one with a higher
incidence of visceral arteriovenous malformations.
Complications of PAVMs can arise as a result of a large pulmonary shunt.
This manifests as cyanosis and hypoxia with finger clubbing and exercise
limitation. More commonly, PAVMs are assymptomatic until they present
with haemoptysis, stroke or cerebral abscess.
Haemoptysis or haemothorax has been reported as a complication in
11/143 patients with PAVMs and HHT (Ferrence et.al.1994). Bleeding in
some of these cases may have come from endobronchial telangiectases
(Wirth et.al. 1996). In an unpublished study (Charnas personal
communication) a series of 102 patients referred for embolisation of
PAVMs were screened by CT or MRI. 9 patients had clinically silent
infarctions, 13 had subtle focal neurological findings and 21 had a history
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of stroke confirmed on scanning. PAVMs may therefore have been
causative of cerebral infarcts in up to 43 out of 102 patients. In 11 patients
the stroke pre-dated the diagnosis of PAVM. Cerebral abscesses had
affected 9 of this patient series.
Presence of a PAVM also confers a higher risk of complication in
pregnancy, although it is difficult to accurately quantify this. Worsening of
the pulmonary shunt is well documented and improves to some extent
after delivery (Swinburn et.al. 1986). There is also a high incidence of
stroke and pulmonary haemorrhage documented in women who become
pregnant who are known to have a pre-existing PAVM. A series of 161
pregnancies in 47 women with HHT (Shovlin et.al. 1996) showed
worsening shunt in 6 patients, stroke in 3 and fatal pulmonary
haemorrhage in 2. In all but one case, complications occurred in the 12
mothers with known PAVMs, suggesting a much lower risk in mothers who
have screened negative for a PAVM.
Screening of patients with HHT for assymptomatic PAVMs is advocated by
most authors. However, not all authors agree on the best method of
screening. Chest X-ray and pulse oximetry, measuring the saturation drop
between supine and erect positioning has been advocated as a simple test
(Hughes 1994), but never truly validated (Kjeldsen et.al. 1996). The use of
lung perfusion scan, when a right to left shunt would lead to increased
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deposition of radiolabeled macro-aggregates in the kidneys may prove to
be a more useful test (White et.al.1992). Measurement of arterial oxygen
saturation or right to left shunt have been shown to be both sensitive and
specific as screening tests. A shunt fraction of over 5% was seen in all
except one of 35 patients with known PAVMs (Haitjema et.al.1995).
Contrast echo-cardiography has been advocated as a sensitive screening
test, although it remains to be fully assessed in this role.(Kjeldsen et.al
1996). Helical CT scanning is expensive but allows the demonstration of
architecture of complex lesions. Angiography remains the gold standard for
investigation of suspected lesions.(Wirth et.al. 1996, Hughes et.al. 1994)
Embolisation of PAVMs is advocated for all lesions with feeding vessels
greater than 3mm. (White 1992, White et.al. 1996). Rare complications of
treatment include localised pleurisy, arrhythmia and rarely, paradoxical
embolism of occluding device (White et.al. 1996, Haitjema et.al. 1996b,
Haitjema et.al. 1995) . Early recurrence of an AVM can be due to failure to
occlude all feeding vessels, late recurrence can occur following re-
canalisation of a lesion (White et.al.1996, Sito et.al.1996). Small previously
unidentified PAVMs may also increase in size and become significant
during follow-up. Not all lesions are amenable to embolisation, some are
still too large for embolisation and can be safely removed surgically.
Treatment of patients with multiple small PAVMs remains a difficult
problem (Wirth et.al. 1996).
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viii Complications of the Central Nervous System.
Some complications affecting the central nervous system such as embolic
stroke and cerebral abscess result directly from loss of the pulmonary
filtering capability due to direct arteriovenous communications. This has
already been discussed.
Migraine occurs more commonly in hereditary haemorrhagic
telangiectasia. (Steele et.al. 1993). The reason for this is unknown,
possibly small assymptomatic cerebral arteriovenous malformations cause
migrainous symptoms, or loss of pulmonary filtering capacity allows some
vascular mediators to circulate in abnormal concentrations to the cerebral
circulation, producing migrainous symptoms.
The frequency of cerebral arteriovenous malformations occurring in
association with HHT is uncertain. Few studies have screened patients
using cerebral CT scanning. An example of a characteristic high flow lesion
is shown in figure 1.2.
Cerebral arteriovenous malformations (CAVMs) were found in 4/36 Dutch
patients on CT scanning (Haitjema et.al. 1995). Most lesions are
assymptomatic, but catastrophic complications can develop without
warning. Reports of CAVMs often show clustering within a family (Kikuchi
et.al 1994, Lesser et.al. 1996, King et.al. 1977). This may be due to
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genetic background influencing occurrence of CAVMs or specific gene
mutations predisposing to such lesions as discussed later. Treatment of
asymptomatic CAVMs is controversial, and whether or not to operate on a
lesion depends on size and position of the lesion and estimated likelihood
of bleeding.
ix Penetrance and Diagnostic Difficulties.
To date, the only assessment of penetrance of HHT is based on clinical
criteria and incidence of unaffected obligate carriers of the disease. Three
assymptomatic obligate carriers were seen in the French series of 103
patients (Plauchu et.al. 1989). When looking at penetrance in relation to
age in this cohort, it was estimated it to be 75% by age 25 and 90% by age
45. In the British series, (Porteous et.al. 1992) 83% were symptomatic by
age 26 and all by age 40.
Clinical diagnosis has always been based on the combinations of the
presence of affected first degree relatives, frequent epistaxis, presence of
a PAVM and classical telangiectases. Current opinion is to take the
presence of two of these to denote affected status. However given the
frequency of nosebleeds in the general population, Shovlin (Shovlin
et.al. 1994) recommended the proviso that frequent epistaxis with an
affected relative should not be sufficient for a diagnosis in a research
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setting. In a clinical setting, it may be appropriate to have a higher index of
suspicion.
x. Pathological findings in Hereditary Haemorhagic Telangiectasia.
It is debatable whether the skin lesions in HHT are caused by an
uncontrolled proliferation of endothelial cells, a developmental abnormality
of blood vessels, or reduced resistance of the blood vessel to pressure,
leading to dilatation and loss of normal capillary structure.
Three studies have looked at the microscopic structure of skin lesions. A
study of a series of biopsies of skin lesions built up a picture of lesion
development overtime (Braverman and Jacobson 1992). Very early
lesions showed dilatation of the post capillary venule with preservation of
the capillary bed. As the lesions increased in size, the capillary segments
disappeared, leaving a direct arteriovenous connection which enlarged
under pressure. The lesions were associated with a perivascular cell
infiltrate which consisted of a mixture of lymphocytes and monocytic cells.
Electron microscopy on a number of mucosal and cutaneous
telangiectases showed that the lesions were dilated small venules with a
thin endothelial cell wall (Hashimoto et.al. 1972). There was some
evidence of weakness of junctions between endothelial cells. Often
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dilatation resulted in cavernous spaces filled with fibrin and erythrocytes.
The abnormal regions were not in association with smooth muscle cells or
fibroblasts, implying that the primary pathology was one of endothelial
cells.
A further study, (Menefee et.al 1975) confirmed the presence of dilated
post-capillary venules, but noted that the basal lamina was often
duplicated and thickened. This suggested that there was considerable
endothelial cell death and regeneration. This might also be due to
abnormal turnover of old basal membrane. Evidence of extravasation of
blood was seen, including erythrocytes and deposition of fibrin, which
could form the basis for new capillary sprouts, although no such sprouts
were noted.
On balance, these studies suggest that HHT lesions develop as a result of
progressive dilatation of post capillary venules, rather than as a result of
endothelial proliferation. The triggering factor leading to the dilatation is
unknown, and the reasons that only specific areas of skin and mucous
membranes are affected are also uncertain. It has been suggested that
thermal insult, ultraviolet light or a second genetic mutation may initiate
dilatation of blood vessels.
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C. Identification of Disease Genes
When there is no protein implicated in the causation of a genetic disease,
the techniques used to identify the gene responsible are termed "reverse
genetics". Typically the search for a gene takes place in four stages, initial
linkage of the disease to a chromosomal location, narrowing the candidate
interval within which the locus lies, identification of candidate genes within
the candidate interval, and mutation analysis of candidate genes.
i. Linkage Analysis
Mendel's laws state that 2 loci segregate independently of each other, and
at random. However, if two loci are close together on the same
chromosome, they will co-segregate at a rate dependant on the distance
between them. The greater the distance between the two loci, the greater
the chance of a crossover event occurring at meiosis. The recombination
fraction (denoted by the symbol 0) between two loci is therefore a measure
of the distance between them. For two loci very close together such that
there is never a recombination between them, 0=0. For two loci so far apart
that they segregate independently, 0=0.5. Two loci are said to be linked
when 0<O.5, that is, when they segregate together more often than is
expected by chance.
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Linkage analysis is the method of statistical analysis for estimating 9, and
determining whether the deviation of 0 from 0.5 is statistically significant.
The statistic used is the LOD score (denoted by Z). This value is a
likelihood ratio derived using the formula:
L(0)
Z (0) = Log10
L(0 = 0.5)
where the denominator is the likelihood of the marker data given that the
recombination fraction is 0.5.
By convention, a LOD score of greater than 3 is taken as a significant
score, demonstrating linkage. This approximates to a level of significance
of 95% (Ott 1991). A LOD score of less than -2 is taken as exclusion of
linkage.
Linkage analysis is commonly performed using the LINKAGE suite of
programs (Terwilliger and Ott 1984). The MLINK program is used to
calculate 2 point LOD scores for a range of recombination fractions
between 2 loci.
For a rare autosomal dominant disease, it can be assumed that patients
with the disease are heterozygous for a normal and a mutated allele. The
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computer analysis also incorporates disease penetrance, usually estimated
from clinical studies. Allele frequencies are also taken into account. Two
point LOD scores are calculated between disease locus and highly
polymorphic DNA markers. LOD scores derived from different families can
be added together. However, if there is heterogeneity of disease locus, this
may conceal a significant linkage result. Microsatellite markers are taken
from published maps, typically that published by Genethon (Guapay et.al.
1994).
ii. Narrowing the Candidate Interval.
Once a chromosomal region is identified, further markers known to map to
the region are analysed. Data from these markers can be formed into
haplotypes within families. Critical recombination events within affected
families, allow the identification of a smaller chromosomal region
containing the gene.
iii. Identification of candidate genes and mutation analysis.
Once the smallest possible candidate interval is identified, candidate
genes can be identified. Published genes or expressed sequence tags
known to map to the region may then be assessed. Construction of a
contig across the candidate region allows exact positioning of the
candidate genes in relation to the microsatellite markers. Further genes
can be identified from the clones of the contig using a variety of techniques
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such as exon trapping and DNA direct selection (Parimoo et.al. 1991, Duyk
et.al. 1990).
There are many ways of identifying mutations in candidate genes. If the
gene is expressed at high enough levels in peripheral blood leucocytes,
Reverse transcription followed by PCR (rtPCR) and sequencing allows
rapid screening of larger genes. PCR amplification from genomic DNA
(White et.al. 1989) allows use of a variety of mutation screening
techniques. These include single stranded conformation polymorphism
(Ainsworth et.al. 1990) , hydrolinkTM gel electrophoresis (Keen et.al. 1991),
denaturing gel electrophoresis, or chemical cleavage of mismatched bases
(Cotton et.al. 1988). For smaller genes, sequencing may be practical
(Sanger et.al. 1977). Genomic rearrangements can be sought by southern
blotting following standard agarose gel electrophoresis or pulsed field gel
electrophoresis. (Southern 1975, Schwartz and Cantor 1984).
D Identification of Endoglin as the HHT1 gene.
I. Linkage of HHT1 to Chromosome 9
In retrospect, the first evidence for linkage to chromosome 9 was in the
Danish study (Vase and Grove 1986 ), which noted an association
between HHT and blood group O in his population. Combined with the
likelihood that the population studied from an isolated region of Denmark
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has a high incidence of HHT due to a founder effect, this suggested that in
this population, the mutation causing HHT is in linkage disequilibrium with
the ABO locus. This was 8 years before linkage to this region was formally
established.
Following a genome-wide search using polymorphic markers, linkage of
HHT to chromosome 9 was established in a proportion of families.
(McDonald et.al.1994, Shovlin et.al. 1994). More detailed analysis showed
that the locus lay on 9q34 between markers D9S61 and D9S63, a 4cM
interval.
ii.Identification of Mutations in the Endoglin Gene
Several genes lay close to, or within the candidate interval for HHT. As well
as the COL5A1 gene and ZNF79, a recently identified protein, endoglin
mapped to this region.
Endoglin is a TGF-p binding protein expressed predominantly in
endothelial cells, and therefore a promising candidate for HHT. Further
details of the role of Endoglin in cell signalling are given later.
The genomic structure of endoglin was elucidated by sequencing from a
cosmid identified from a gridded genomic library. 3 mutations were
identified in endoglin on screening a panel of 68 DNA samples from
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unrelated HHT patients. (McAllister et.al. 1994a). The first three mutations
identified, a premature stop, a 39 basepair insertion and a 2 bp deletion; all
disrupted the endoglin molecule before the extracellular domain.
Five further mutations were identified on further screening of this panel.
(McAllister et.al. 1995). None of these mutations occurred as a population
polymorphism, and all would be expected to disrupt the endoglin molecule,
confirming that mutations in the endoglin gene caused HHT.
Most of the British families with HHT did not show linkage to chromosome
9. Formal multipoint linkage analysis demonstrated exclusion of the 9q34
locus, indicating that there was a second unidentified locus for HHT. This
was confirmed by other workers. (Heutink et.al. 1994, McAllister et.al
1994b, Porteous et.al. 1994, Shovlin et.al. 1994). This second unidentified
locus was designated HHT2, and endoglin designated HHT1.
A subjective observation was made that the families which were linked to
endoglin on 9q34 seemed to have a much higher incidence of pulmonary
arteriovenous malformations reported than families for whom this locus
was excluded.(Porteous et.al. 1994, McAllister et.al. 1994)
25
E. Initial identification of a second HHT locus on chromosome 12.
Initial linkage of 2 French families with HHT to chromosome 12 was
reported (Vincent et.al. 1995). These families both came from the cohort
of French patients previously published (Plauchu et.al. 1989), which had a
low reported incidence of pulmonary arteriovenous malformations. This
study defined a large candidate region between D12S345 and D12S368 of
over 10cM, in the peri-centromeric region of chromosome 12.
F. Endoglin and its role in TGF-beta signalling.
An understanding of TGF-p signalling in the cell, and the role endoglin has
in these pathways assisted in the identification of other molecules which
are potential candidate genes for causing or modifying the HHT
phenotype.
i.The TGF-beta receptor complex
The TGF-p receptor molecules are members of the serine-threonine
kinase receptor family. These are a subgroup of receptor kinases that
phosphorylate serine and threonine residues as a mechanism of
downstream signalling, (ten Djike 1994a, Massague and Weis-Garcia
1996).
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Initially the TGF-p receptors were classified by size. Two categories were
identified, type I receptors of about 53kDa and type II receptors of 75kDa
(Chiefetz et.al 1987). Later studies using both the TGF-p receptors and
other family members have built up a model of the interaction between
different receptor types. Association of TGF-p with the TGF-p type II
receptor causes formation of a complex between ligand, type II receptor
and type I receptor. The type II receptor phosphorylates the type I
receptor, activating it. The type I receptor is then capable of downstream
signalling alone (Ebner et.al. 1993, Franzen et.al. 1993, Attisano et.al.
1993, Attisano and Wrana 1996, Massague and Weis-Garcia 1996).
The type I receptor is therefore characterised by an inability to bind ligand
alone, but it is essential for downstream signalling. All type I receptors
identified to date have a specific intracellular region, the GS domain with a
key amino acid sequence, TTSGSGSG. (Franzen et.al. 1995) This is the
site of phosphorylation for activation. Mutations of this site reduce
downstream signalling. A specific mutation downstream from this site can
cause constitutive activation of the receptor molecule. (Attisano et.al
1996).
It is not known whether the type I receptor, once activated is inactivated by
dephosphorylation, dissociation or internalisation and degradation.
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ii.Endoglin and Betaglycan - "type III" receptors.
Two molecules have been identified which bind TGF-p and are not classical
serine threonine kinase receptors in the model discussed above.
Betaglycan, is a proteoglycan which can either be membrane bound or
released in a soluble form. The intracellular domain is small and has no
discernible signalling motifs. (Lopez-Casillas et.al. 1991). When co-
expressed with TGF-p receptors type I and II, it increases the binding
affinity for TGF-P2. Cells lacking betaglycan but expressing TGF-p receptors
type I and II are insensitive to TGF-p2, but can be sensitised to it by
expression of betaglycan. (Lopez-Casillas et.al 1993). Soluble betaglycan
can sequester TGF-p and in vivo may act as a reservoir in the extracellular
matrix. (Lopez-Casillas et.al. 1994).
Endoglin is related to betaglycan, with considerable homology of the
extracellular domain and a short intracellular domain. It was initially
identified in a pre-B leukaemic cell line and later shown to be expressed in
endothelial cells, activated monocytes and placenta. Studies in mice have
also shown expression in the stromal cells in connective tissue of many
different organs. (O'Connel et.al. 1992, Cheifetz et.al. 1992, St.-Jacques
et.al. 1994a,b, Lastres et.al. 1992, 1996). It can be found in a soluble form
in blood, presumably after release from the endothelial cell surface (Lopez-
Casillas et.al 1994). It has a high affinity for TGF-pi and 3, but not
TGF-P2. Studies suggest formation of a signalling complex between TGF-p
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receptors and Endoglin. (Yamashita et.al. 1994a,b, Lastres et.al. 1996).
The true effect of endoglin on signalling in-vivo remains to be determined.
iii TGF-p and related Cytokines.
TGF-p belongs to a group of related cytokines that are the ligands for the
serine-threonine kinase receptor family. This diverse family of intercellular
signalling molecules includes the different isoforms of TGF-p, as well as the
bone morphogenic proteins, inhibins, mullerian inhibitory substance and
glial cell derived neurotrophic factor. Each signalling molecule is made up of
a heterodimer or homo-dimer. The monomeric subunit of all signalling
molecules in this group each have an internal structure of 6 cysteines
forming 3 disulphide bonds and a seventh cysteine that forms a bond with
another monomer. (Massague and Weiss-Garcia 1996,). The monomer is
synthesised as a larger precursor, with activation by removal of the N-
terminal portion of the molecule after dimerisation.
There are 3 different potential subunits of TGF-p, which usually form
homodimers to give the TGF-p isoforms 1,2 and 3. Affinity of receptors for
these molecules varies, the TGF-p receptor complex has a lower affinity
for TGF-p 2, however its affinity is increased in the presence of betaglycan
(Cheifetz et.al. 1990, Lopez-Casillas et.al. 1994). Endoglin has higher
affinity for TGF-p 1 and 3 than TGF-p 2 (Yamashita et.al. 1994).
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The different function of these molecules in vivo is highlighted by the
different phenotypes shown in knockout mice. The TGF-p 3 knockout
mouse shows cleft palate and pulmonary hypoplasia ( Kaartinen et.al. 1995,
Proetzel et.al. 1995 ), whereas, the TGF-p 1 knockout mouse shows a
chronic inflammatory disease or defects in yolk sac formation depending on
genetic background ( Dickson et.al. 1995, Martin et.al. 1995 ). A putative
modifier locus has been mapped in the mouse ( Bonyadi et.al. 1997),
located on mouse chromosome 5.
iv.Intracellular Signalling.
Advances have been made very recently into understanding the
mechanism for intracellular signalling of serine-threonine kinase receptors.
The specificity of downstream signalling of a serine-threonine kinase
receptor complex appears to be determined by the kinase domain of the
type I receptor (Carcamo et.al. 1994, Attisano et.al 1993, Massague and
Weiss-Garcia 1996). The TGF-p receptor type I and Activin IB receptor
both signal via the same pathway in mink lung epithelial cells but require
their specific type II receptor and ligand for the signalling to take place.
Their kinase domains are 90% identical at the amino acid level (Carcamo
et.al. 1994).
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Studies to look for proteins interacting with the intracellular domain of the
TGF-p receptor type I have shown several possible candidates for
downstream signalling. These include Farnesyl Transferase (Kawabata
et.al. 1995) and FKBP12 (Wang et.al 1994), both of which were identified
in a yeast two hybrid assay.
Recent attention has focused on the family of MAD (Mothers against
decapentaplegic) proteins. MAD originally identified as a protein involved in
signalling of DPP (decapentaplegic) in Drosophila (Niehrs 1996, Liu et.al.
1996, Graf et.al. 1996, Hoodless et.al. 1996) which was then shown to
activate transcription of a reporter construct (Liu et.al. 1996). The human
homologue, MADR1 has been shown to move from the nucleus in
response to BMP2 (Bone morphogenic protein 2) signalling in conjunction
with the BMP type I and II receptors (Hoodless et.al. 1996). An entire
family of MAD proteins was subsequently identified (Riggins et.al. 1996).
Five new human members of this group were identified by their homology
to drosophila MAD (Riggins et.al. 1996). Previously identified members
include the DPC4 (deleted in pancreatic carcinoma ) gene, which shows
less homology to the other known MAD proteins.
All MAD proteins identified to date have a two highly conserved domains,
the N- terminus MH1 domain and the C-terminus MH2 domain. The region
between is highly variable. Two serines at the C-terminus are thought to be
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the site for phosphorylation of the molecule when it interacts with the type-l
receptor. (Attisano personal communication). Phosphorylation of the
molecule leads to nuclear localisation ( Hoodless et.al. 1996, Chen et.al.
1996, Liu et.al. 1996 ) However, DPC4 lacks the phosphorylation site, but
can localise to the nucleus only in presence of activated MADR1.
( Zhang et.al. 1996). It is thought, therefore to be a component of the same
signalling pathway.
v.Other serine-threonine kinase receptors.
There are many other members of this receptor family that have been
identified in different species. In drosophila, punt is a type II serine
threonine kinase receptor (Letsou et.al. 1995), which in combination with
either Sax orTkv type I receptors, responds to DPP (and human bone
morphogenic protein 2) as a ligand.
In humans, the activin type la and lb receptors signal in combination with
the activin type II receptor and activin (Attisano et.al. 1996 ). They signal
through different pathways, the type lb receptor using the same pathway
as the TGF-p type I receptor (Carcamo et.al. 1994). In humans, bone
morphogenic protein receptors and the mullerian inhibitory substance
receptor have been identified (Baarends et.al. 1994, Massague and
Weiss-Garcia 1996). A further receptor, the Activin receptor like kinase I
(ALK-1) has been identified (Attisano et.al. 1993, Ten Djike et.al. 1993).
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This type I receptor is expressed predominantly in endothelial cells,
demonstrated by rtPCR from a range of cell lines (Attisano et.al. 1993).
Neither its true ligand in vivo nor its downstream signalling mechanism are
known.
The large number of serine threonine kinase receptors and ligands make it
possible for both inter-related and completely separate serine threonine
kinase pathways to exist within the same cell. The combination of specific
type I and type II receptors expressed by a particular cell decide if and how
it responds to molecular signals from surrounding cells.
vi.The role of TGF-p in the endothelial cell.
Several studies have looked at the effect of TGF-p 1 on the growth of
endothelial cells in culture. Microvascular endothelial cell monolayers in 2
dimensional culture grow rapidly, but addition of TGF-pi inhibits this and
induces differentiation with expression of alpha-smooth muscle actin,
PDGF a and PDGF p receptors and fibronectin ( Mandriota et.al. 1996,
Sankar et.al. 1996, Folkmann and D'Amore 1996, Lastres et.al. 1996).
When the cells are growing in a 3 dimensional matrix, the addition of TGF-
P induces the formation of tubules by the cells, but does not affect the
growth rate. It still induces fibronectin production by the cell. (Madri et.al
1988, Merwin et.al 1991, Merwin et.al 1990, Sankar et.al 1996). TGF-P2
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can have the same effect on cell proliferation but requires the expression
of betaglycan for the cells to be sensitive. (Sankar et.al 1996).
The TGF-p type II receptor is expressed at lower concentration in cells
which are growing in three dimensional culture, suggesting that the
concentration of this receptor may be important in controlling cell
responsiveness (Sankar et.al. 1996). Potentially this receptor may interact
with other type I serine threonine kinase receptors as well as the TGF-p
type I receptor.
Studies in vivo have shown that TGF-pi can cause increased vascular
proliferation and fibrosis, but can also accelerate wound healing. (Roberts
et.al. 1986, Mustoe et.al 1987).
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2. Materials and Methods
A. Aims of Investigation
To identify the HHT2 gene, with comparison of clinical features between
HHT1 and HHT2.
B. Plan of Investigation
1. Assessment of new families with HHT.
2. Analysis of clinical data from HHT families.
3. Initial linkage studies to identify the locus involved in each family.
4. Haplotype analysis of families to define the candidate region for HHT2.
5. Study of known genes and ESTs in this region as candidates for HHT2.
6. Determination of the genomic structure of the HHT2 gene.
7. Further mutation analysis of the HHT2 gene.
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C. Ascertainment of Families with HHT
Samples and data were already available from British and American
families that had previously been assessed and published. (Porteous et.al.
1994, McAllister et.al. 1994a, Heutink et.al. 1994). Further British families
were identified through family members that had contacted the Clinical
Genetics Service in Edinburgh. 2 large American families contacted the
department of Genetics at Duke University, wishing to participate in HHT
research.
Initial diagnostic criteria used for a definite diagnosis of HHT were the
presence of two of the following:
1. Affected first degree relative
2. More than monthly nosebleeds
3. A classical telangiectasis
4. Presence of a known Pulmonary Arteriovenous Malformation
Subsequent experience as described in the text led to modification of
these criteria, individuals with an affected relative and nosebleeds alone
were classified as of uncertain diagnosis during haplotype analysis. This
was due to a perceived high frequency of unnaffected individuals who had
monthly nosebleeds.
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All families were assessed during large family gatherings. Individuals were
asked to fill in a questionnaire, before being briefly interviewed to clarify
details. The questionnaire was designed to record details necessary for
diagnosis of HHT as well as to gather clinical information on presence,
frequency and severity of the reported complications. These included
nosebleeds, gastro-intestinal haemorrhage, hepatic complications,
arteriovenous malformations and migraine. A data recording sheet was
also used to note and summarise clinical findings. The questionnaire and
recording sheet are given in appendix C.
After completion of details in the questionnaire, the individual was
examined for telangiectases on the hands, face and mucous membranes.
Pulse oximetry was performed to screen for pulmonary arteriovenous
malformations. The oxygen saturation was measured for 5 minutes when
supine and then 5 minutes standing. A drop of saturation of 2% was taken
as possibly indicative of a PAVM, requiring further investigation.
Unfortunately, when seen in American family members it was not possible
to pursue this, except by detailed history. 2 British family members were
further investigated by the Department of Respiratory Medicine at the
Hammersmith hospital in London. Neither individual had a PAVM.
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A blood sample of 10mls was anticoagulated with potassium EDTA for
later DNA extraction. Blood samples were either stored at -20 Celsius until
DNA was extracted, or DNA was extracted within 24 hours. DNA extraction
was performed using the protocol given below.
D. Analysis of Polymorphic Markers and Linkage Analysis
Polymorphic markers chosen from the regions of interest were amplified
from patient DNA using the polymerase chain reaction and analysed by
polyacrylamide gel electrophoresis using the protocol given. Allele sizes
were either arbitrarily assigned or estimated using the standard CEPH
individual 134702.
2 point linkage analysis of the British families was initially performed using
MLINK from the LINKAGE version 4.9 suite of programmes running on
IBM compatible computers (Terwilliger and Ott 1994). A penetrance of
90% was assumed for HHT2 gene carriers, with equal allele frequencies.
Multipoint analysis for family 5 was performed using the LINKMAP
program.
Later analysis of the British families and of the American families was also
performed using MLINK, with the following age related penetrance profile:
age 0-20, penetrance 0.24, age 21-40 penetrance 0.73, age >40
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penetrance 0.97. Allele frequencies for each marker were taken from
published data.
Haplotype analysis was performed manually adding allele data for each
marker in order of position to a printed family tree. Sites of definite
recombination were noted. For the families described in this study, no
inconsistent haplotypes were found to suggest non paternity or sample
error.
The smallest candidate interval defined by haplotype analysis was
compared to the physical map supplied by R.Kucherlapati. This gave more
precise details of the size of candidate interval, marker position and genes
contained within it.
E.Comparison of Clinical Data.
Clinical data between families was inspected, both as raw data, and in the
form of a two by two table. Typically the two by two table was used to
compare the presence or absence of a feature with linkage or exclusion of
HHT1 on chromosome 9. Statistical analysis was performed using the
Fishers exact test or the %2 test depending on sample size. Results were
calculated using the MINITAB or SPSS, packages.
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F.Characterisation of ESTs in the Candidate Region.
Phage clones from the endothelial cell cDNA libraries EC1 and EC2
(Ginsburg et.al. 1985) corresponding to ESTs were isolated using standard
techniques. After 3 rounds of plaque purification, the single clones
identified were PCR amplified and sequenced using 33P labelled dideoxy
termination reactions as described below. Sequence identified was entered
into a computer file using the MAC-vector package. Sequence was
inspected using this software for overlap, open reading frames, and
restriction sites. Homology to known proteins was sought using the BLAST
program to search the GENBANK non-redundant nucleotide and non-
redundant protein databases.
G.Identification of a PAC clone containing the ALK-1 gene.
DNA pools from a 3 dimensionally arrayed PAC library (described in
lannou et.al 1994) were screened by PCR using the primers
5' CGCGTGTCACACTTCATGGCTC 3' and
5' ATCAGAAGGCCTTTCCTGGGGG 3'
which are known to specifically amplify a fragment of the 5' untranslated
region of the ALK-1 gene. (Attisano et.al. 1993)
This reaction identified the co-ordinates 5X3 5Y1 5Z1 in the grid, indicating
a 384 well plate number 265. An imprint of this plate was stamped into
agarose, the colonies were grown and lifted onto Hybond N membrane,
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before being probed using the ALK-1 cDNA.(Kindly supplied by Attisano)
This identified a single colony in position C-14. This clone 265_C_14
(renamed GA-1) was digested using a range of common restriction
endonucleases, resolved by agarose gel electrophoresis and southern
blotted to hybond-N membrane. This was hybridised to radiolabeled ALK-1
cDNA as described below.
H.Subcloning of GA-1
A Bgl II digest of this subclone was purified using phenol-chloroform
extraction and ligated into the BamHI site of the stratagene pBluescript
phagemid. Clones which hybridised to the ALK-1 cDNA were isolated and
characterised by digestion with EcoRI and Not1.
These digests were also resolved on southern blots and hybridised to
specific primers complementary to the ALK-1 cDNA sequence, to identify
which fragment of the gene was contained in each clone.
I.ldentification of Intron-Exon Borders in the ALK-1 gene.
Intron exon borders within the ALK-1 gene were identified by PCR using
the PAC clone GA-1 as template, and primers from the cDNA sequence of
ALK-1. The sequence of primers used for this analysis is given in table
2.1. Wherever a PCR fragment generated was larger than the fragment
expected from the cDNA sequence, the fragment was assumed to contain
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an intron. Such fragments were sequenced as described. The sequence
generated was compared to known cDNA sequence, and the intron/exon
border was identified where the derived sequence diverged from that of the
cDNA. For some of the intron/exon borders more sequence was generated
directly from the subclones to clarify sequence of regions not clearly
sequenced from PCR products.
J.Mutation analysis of patient samples.
Primers were designed to amplify each of the coding exons of ALK-1
(exons 2 to 10). The sequence of these primers is given in table 2.2. The
amplification conditions were optimised to give a clear single product band,
using either buffer supplied by Boehringer-Mannheim, or that described
(Gyapay et.al. 1994). In all cases, the magnesium concentration used was
1.5mM.
The single product band was isolated on low melting point agarose gel
electrophoresis and extracted by freezing followed by compression in a
micro-centrifuge. The supernatant was sequenced as described below. For
each termination reaction, samples for all 12 individuals were loaded
adjacent to each other on the sequencing gel, making identification of
sequence variations easier. One set of 4 sequencing reactions was loaded
in the conventional order ACGT as a ladder on each gel.
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Figure 2.1 Sequence of key primers used for the identification of intron-exon
borders in the ALK-1 gene.
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EExon 5' Assay primer 3' Assay primer Annealing
Temp.
II CTCTGTGATTTCCTCTGGGCA TACATTCTCCCCAGCTTCTCAA 62
III AGCTGGGACCACAGTGGCTGA GGAGGCAGGGGCCAAGAAGAT 64
IV AGCTGACCTAGTGGAAGCTGA CTGATTCTGCAGTTCCTATCTG 60
V AGGAGCTTGCAGTGACCCAGCA ATGAGAGCCCTTGGTCCTCATCCA 68
VI AGGCAGCGCAGCATCAAGAT AAACTTGAGCCCTGAGTGCAG 60
VII TGACGACTCCAGCCTCCCTTAG CAAGCTCCGCCCACCTGTGAA 65
VIII AGGTTTGGGAGAGGGGCAGGAGT GGCTCCACAGGCTGATTCCCCTT 65
IX TCCTCTGGGTGGTATTGGGCCTC CAGAAATCCCAGCCGTGAGCCAC 68
X TCTCCTCTGCACCTCTCTCCCAA CTGCAGGCAGAAAGGAATCAGGTGCT 65
Table 2.2 Primers used to amplify each exon of the ALK-1 gene for mutation
analysis. The annealing temperature of the PCR reaction used with each
primer set is given.
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Sequence variations that were identified were entered into MACvector and
the effect of the sequence variation calculated. Where possible, a change
of predicted enzyme digest pattern was identified, for use as a
polymorphism screen.
For each putative disease causing mutation identified, a panel of over 100
individuals from the normal population was screened to check that the
mutation did not arise as a common population polymorphism. The
samples used for this came from married-in members of the families
collected and control samples available locally. In all but one mutation, 112
individuals were screened, estimated to give a 90% chance of identifying a
population polymorphism. The remaining mutation was checked in a panel
of 106 individuals.
The mutated region was also compared to related proteins in GENBANK
using the BLAST program, to estimate the degree of homology present in
the region that was mutated.
K.Degenerate PCR to identify MAD protein homologues
To determine the sequence of degenerate primers calculated to amplify
MAD protein homologues, sequence of known MAD protein genes was
aligned manually. Conserved motifs from the MH1 and MH2 domains were
used to design forward and reverse primers respectively. PCR conditions
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were varied as described in the protocol. Template used was either cDNA
prepared from endothelial cell lines, or DNA extracted from an aliquot of
the EC-1 or EC-2 libraries. Product of interest was cloned using the T/A




(Adapted from local laboratory protocol)
DNA extraction was performed according to the protocol below for all
samples originating from the U.K. All American samples were extracted
using the Puregene DNA extraction kit (Gentra Systems) with the protocol
supplied.
10mls of blood is mixed with 30mls of red cell lysis buffer in a closed 50ml
tube. This was placed on ice for 30 minutes with intermittent inversion of
the tube. When the mixture had become clear, indicating red cell lysis, the
tube was centrifuged at 3000g for 10 minutes, and the supernatant
discarded. The white cell pellet was resuspended in 5ml of red cell lysis
buffer, and re-centrifuged at 3000g, with discarding of the supernatant, this
step was repeated if necessary until the pellet was white.
The pellet was resuspended in 3ml of nuclear lysis buffer,200pl of
10%SDS and 300pl of 10mg/ml proteinase K. The tube is incubated
overnight at 37°C. After 16hours, 1ml of 6M NaCI was added, with vigorous
agitation for 15 seconds. The tube was then centrifuged at 3000rpm for 20
minutes at 4°C. The supernatant was transferred to a new container, and 2
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volumes of ethanol added, before being inverted several times. The
resulting DNA precipitate was spooled out and resuspended in 250 to
500pl of TE solution. This was mixed for at least 16 hours on a rotating
mixer to allow resuspension of the DNA.
ii. Restriction endonuclease digestion.
Restriction endonuclease digestion was performed using the same
protocol for all types of DNA substrate. Using 1X concentration of the
recommended buffer for an enzyme, 1 to 10 units of enzyme were used
per 1 pg of DNA. Where double digest was performed, a buffer was chosen
that permitted digest by both enzymes, according to manufacturers
recommendations.
iii. Phenol-chloroform DNA extraction / DNA precipitation
(Adapted from Sambrook et.al. 1989)
The DNA sample to be purified is mixed with an equal volume of
phenol/chloroform solution, and mixed vigorously. The aqueous layer is
removed and mixed with an equal volume of chloroform/isoamyl alchohol.
The aqueous layer is removed once more. A tenth volume of 3M sodium
acetate was added and 2 volumes of ethanol. The mixture was frozen at -
70°C and then centrifuged at 14000g for 20 minutes. The supernatant was
removed and the pellet washed in 70% ethanol before being air dried and
resuspended in water or TE solution pH 8.0.
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iv. Polymerase chain reaction (PCR)














The buffer used was either that supplied by Boehringer-Mannheim or that
use by Gyapay et.al. (1994), referred to in this text as "Weissenbach"
buffer, which gave a final concentration of 10mM Tris pH9, 50mM KCI,
1.5mM MgCI2, 0.1% Triton x-100 and 0.01% gelatin.
All reactions were overlayed with mineral oil and thermocycling was
performed using a range of purpose built machines for single tubes or 96-
well plates. All reactions started with an initial denaturing temperature of
95°C for 5 minutes. Then typically 95°C for 45 seconds, annealing
temperature for 1 minute and 72° C for a variable length of time. 35 to 40
cycles were used. A terminal extension step of 10 minutes was used in
most reactions.
Variables in the PCR reaction
Hot Start:\r\ most cases the fidelity of the PCR reaction was improved by
the addition of the TAQ polymerase during the initial 95°C denaturing step.
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This reduces non-specific product in the initial reaction steps, as the
primers do not have the opportunity to anneal at a temperature below the
annealing temperature chosen for the PCR reaction. It also reduces
primer-dimer formation by a similar mechanism.
Extension time: The extension time was determined by the length of the
anticipated product. For fragment less that 200bp 30 seconds was used.
Otherwise, 1 minute per kb length of product was used. For exon to exon
PCR reactions, extension times of 5 to 7 minutes were used for initial trials
of primer pairs.
Annealing temperature: At higher annealing temperatures, primer
annealing is more specific, however product yield is usually reduced. The
annealing temperature was usually set at 2°C below the TM (melting
temperature) of the primer with the lowest TM. This was estimated by
allowing 4°C for each C or G in the sequence and 2°C for each A or T.
When a reaction failed to work, a lower annealing temperature was tried. If
there were additional undesirable products in the reaction, the annealing
temperature was raised by 2°C to attempt to remedy this.
Primer design: Most primers were designed manually. The ideal sequence
was felt to be 50-60% GC content with a TM of around 65°C. Short
repeated stretches in the primer were avoided where possible. There was
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a subjective impression that primers ending in an A or a T gave better
results.
Touchdown PCR programmes: To increase product specificity, touchdown
PCR starts with a high annealing temperature, producing small amounts of
specific product, increasing the concentration of correct template. A typical
touchdown programme started with an annealing temperature 6° above
that normally used for 3 cycles, 4° above for 3 cycles and then 2°above for
3 cycles, followed by 30 cycles at the normal annealing temperature.
Magnesium concentration: For all reactions, a constant magnesium
concentration of 1.5mM was used. Increasing the concentration to 2.0 or
2.5mM would have been expected to increase product concentration but
reduce specificity of the product formed.
Degenerate PCR reactions: using degenerate PCR primers, which are a
mixture of 500 to 1000 different primer sequences causes a range of
difficulties, some of which can be compensated for by altering reaction
conditions. Primer concentrations were varied between 10 and 100 fold
that usually used. To increase reaction specificity, hot start was used in all
cases. All successful reactions used a touchdown sequence to increase
specific product while reducing background. A range of annealing
temperatures were used, based on the average TM of the primers
designed.
Exon to Exon PCR reactions: For the exon to exon PCR reactions, many
different primer combinations were used. The TMs of the different primers
were often very widely spaced. The length of product was unknown.
Reactions all used a hot start with an extension step of 5 to 7 minutes.
Using PAC DNA as a template this proved effective.
v. Agarose gel electrophoresis
(Adapted from Sambrook et.al. 1989).
Agarose gel electrophoresis was used for the size separation of DNA
fragments between the sizes of 100bp and 15kb. The size of expected
fragment determined the gel concentration used; 0.7% for the largest
fragments, 1 % for fragments up to 1 kb and 1.5 to 2.5% for smaller
fragments. Gels were made with 0.5X TBE containing 0.3|ug per ml of
ethidium bromide.
Gels were run in 0.5X TBE running buffer, and photographed with UV
transillumination to visualise the ethidium stained DNA.
52
Fragment sizes were calculated by comparison to standard ladder (Gibco
BRL 1 kb ladder, or Gibco BRL 100bp ladder). Samples were mixed with
loading dye, before being loaded on the gel.
vi. Southern blotting
(Adapted from Sambrook et.al. 1989, Southern 1975)
In all cases, DNA was transferred from agarose gels to Hybond-N
membrane (Amersham) using the same protocol. The gel was
photographed under UV transillumination, adjacent to a ruler to allow
sizing of fragments. The gel was then inverted onto a standard capillary
blotting apparatus. The blotting solution used was 0.4M NaOH in all cases.
A piece of Hybond-N membrane was placed on the inverted gel, and a
layer of 3MM paper followed by paper towels on top of this. Blotting was
allowed to take place for at least 12 hours.
The membrane was then removed and washed in 2XSSC. It was fixed by
exposure to UV light (1200J on the automatic setting of a stratagene
stratalinker).
vii. Pulsed Field gel electrophoresis
(From pharmacia gene navigator protocol)
This was used for the size separation of fragments between 10kb and
100kb in size. Running conditions for a pharmacia gene navigator were
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calculated empirically. A 1.2% agarose gel, with 0.15X TBE running buffer
was used. A gene navigator (pharmacia) electrophoresis apparatus was
used with a hex electrode. Gels were run for 6 hours with a switching time
starting at 0.4 seconds increasing by 0.1 seconds per hour.
Gels were stained in ethidium bromide solution (0.1 pg per ml),
photographed and southern blotted as described above. A depurination
step was not found to be necessary.
viii 32P labelling of DNA probes
Random oligo-labelling. Used for all sizeable DNA fragments. For some
probes, random hexamer primed labelling using the protocol given by
Feinberg and Vogelstein (1984) was used. For others, the prime-it kit
(stratagene) which uses random nonamers was used, a- P dCTP was
used as the incorporated label. Labelled probe was heated to 100°C with
1000pg of salmon sperm DNA before addition to the hybridisation mix.
End labelling: Oligonucleotides, when used as probes were labelled using
y-32P ATP and T4 kinase (gibco-BRL) according to the following protocol:
Probe was heated to 100°C before addition to the hybridisation mixture.
y-32P ATP 10pCi/pl
100ng Oligonucleotide + water








Prehybridisation of the membrane was performed at 65°C with 15 to 25ml
of hybridisation mixture (depending on size of hybridisation jar) for at least
1hour. Probe was boiled as described above and added directly to the
hybridisation jar. Random hexamer and nonamer labelled probes were
hybridised for 4 to 24 hours at 65°C. Oligonucleotide probes were
hybridised for 4 to 24 hours at 48°C.
The membrane was then washed several times for 10 minutes at room
temperature, with further, more stringent washes at 48°C and 65°C if
required. Autoradiography was performed with intensifying screens at
-70°C for 4 to 48 hours.
ix. Purification of PCR product.
PCR products were loaded into a 1% low melting point agarose gel
prepared with ethidium and 0.5X TBE as described above. Electrophoresis
was carried out for an appropriate length of time to separate the required
fragment size from other bands. This band was then excised under UV
transillumination, and wrapped in parafilm. This package was frozen at
-70°C for 20 minutes. Manual pressure was then applied to the gel slice at
room temperature, and the resulting solution pipetted into a fresh tube.
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Where DNA quality was particularly important, notably for ligation
reactions, the Qiaex II (Qiagen) kit was used as an alternative method.
x. Sequencing
All sequencing was performed using the thermosequenase cycle
sequencing kit (Amersham). This uses a variation of the dideoxy
termination method of Sanger(Sanger et.al. 1977), with 33P radiolabeled
dideoxy terminators. This protocol proved effective across a wide range of
template concentrations.
All PCR products were gel purified as described above before sequencing.
For plasmid clones, 100ng to 1000ng of DNA template from any form of
DNA preparation (as described below) was used.
xi. Sequencing gel electrophoresis
Sequencing reactions were resolved by electrophoresis through a 7M
urea/6% poly-acrylamide sequencing gel using 1X TBE as the running
buffer. Run times were between 2 and 6 hours, with a constant power of
65W. Samples were denatured at 95°C with formamide loading buffer
provided by Amersham, before loading on the gel.
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Gels were fixed with 10% methanol /10% acetic acid, transferred to 3MM
paper and dried. Autoradiography was carried out without intensifying
screens for 12 to 48 hours.
For microsattelite markers, 25pl of sample was mixed with 6 pi of
formamide loading dye (95% formamide, 10mM NaOH,
0.005%bromophenol blue, 0.005% xylene cyanol). This was heated to
95°C before loading 3 to 7pl on a gel. Run times were between 90 minutes
and 4 hours.
xiv. Bacterial colony isolation
(Adapted from Sambrook et.al. 1989)
BamHI digested pBluescript vector (stratagene) was treated with alkaline
phosphatase (Gibco BRL) before phenol chloroform extraction. The
ligation reaction contained 10ng of digested vector and approximately 80ng
of insert in a final volume of 20pl. 1 unit of T4 DNA ligase was used (Gibco
BRL). The reaction was allowed to take place at 12°C overnight.
3pi of ligation reaction was used to transform DH5a competent cells
(Gibco-BRL) by heat shock, according to the protocol supplied. 10% and
40% of each transformation was plated onto LB agar plates containing
40pg per ml of X-gal and 100pg per ml of ampicillin. These plates were
incubated overnight at 37°C. Single white colonies were picked with a wire
loop and transferred to a second LB/ampicillin plate in a 10 by 8 grid.
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After an overnight incubation, an impression of the grid was transferred to
a circle of hybond-N membrane. This was placed on 3MM paper soaked in
0.4M NaOH, 1.5M NaCI for 2 minutes, and then transferred to 3MM paper
soaked in Tris HCL pH 7.5. for 2 minutes and then 2XSSC for 2 minutes.
The filter was then air dried, before being UV fixed using a stratalinker
(stratagene) on the auto-crosslink setting. The membrane was then probed
by hybridisation to radiolabeled ALK-1 cDNA probe. The resulting
autoradiogram was aligned to the original agar plate with gridded colonies
and positive clones picked for culture.
Single clones were grown with constant agitation overnight at 37°C in 2ml
of LB medium with 100pg per ml of ampicillin. DNA was prepared using
either Qiaprep kits (Qiagen) or the modification of the boil-lysis preparation
given below:
2ml of bacterial culture was centrifuged at 14000Xg for 5 minutes and
supernatant discarded. The cell pellet was resuspended in 50pl of boil lysis
solution, agitated at room temperature for 5 minutes, heated to 100°C for 1
minute and placed on ice. The resulting solution was centrifuged at
14000xg for 15 minutes, and the DNA contained in the supernatant
removed to a separate tube for digestion or other processing.
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xv. Reverse transcription
Reverse transcription was carried out according to the protocol supplied
with superscript II reverse transcriptase (Gibco-BRL) 1st strand synthesis
was primed using random oligomer primers or (T)18. 2pg of total
endothelial cell RNA and 500ng of primer were used in each reaction.
xvi Phage plaque purification
This was carried out according to the protocol provided in Sambrook et.al.
1989.
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M. Solutions and Buffers.




(41,45g NH4CI, 5g KHCO3, 1,85g EDTA pH adjusted to 7.4 with Cone HCI,









1mM EDTA pH 8.0
(1,21g Tris HCI, 0.37g disodium EDTA, pH adjusted to 8.0 with HCI, to a
final volume of 11 in water. Solution filtered and autoclaved.)
Phenol/Chloroform
25:24:1 mixture of buffered phenol, chloroform and isoamyl alchohol
Chloroform/lsoamylAlchohol
24:1 mixture of chloroform and isoamyl alchohol








(540g Tris base, 275g Boric acid, 37.2g EDTA made up to 51 in water)
Hybridisation solution











0.1mg/ml Bovine Serum Albumin
Other Solutions.














Chapter 3. Clinical Ascertainment and Linkage Analysis
A. Assessment of New Families with HHT.
In addition to 4 large British families which had already been investigated
and shown not to be linked to chromosome 9q34 (Porteous et.al. 1994),
five new families were identified, 3 in the United Kingdom and 2 in the
USA. The pedigrees of these families, numbered 5,6,7,8 and 9 (USA) are
shown in figure 3.1.
Individual data was recorded on the questionnaire and data sheets given in
appendix C. All individuals were screened for pulmonary arteriovenous
malformations by pulse oximetry as described. The spectrum of features
within each family is given in tabular form in appendix B.
Table 3.1 summarises the proportion of individuals in each family with
each recognised complication. It is notable that in families 6 and 8, the
incidence of pulmonary arteriovenous malformations was 2/5 and 2/8
respectively, while in families 5,7 and 9, there was no history of PAVM or
evidence of such a lesion on oximetry.
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The total incidence of hepatic involvement is low at 2/45, both these
individuals being asymptomatic. The incidence of gastro-intestinal
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B. Markers for the endoglin region on chromosome 9
Family 8 was shown to be linked to chromosome 9 by other workers. A
mutation was subsequently identified in the endoglin gene (a 4 base pair
deletion in the extracellular region ACAGA 1078-81).
Markers D9S61 and D9S195 flank the endoglin region on chromosome 9
and are situated 11cM apart. D9S63 lies within 1cM of endoglin, and close
to D9S61. These markers were used to test for linkage to the endoglin
region in families 5 and 6.
Family 6 showed no recombination with D9S63 and with a two point LOD
score of 1.3 at 0=0. With 5 informative meioses in the analysis, the
maximum possible LOD score expected would be 1.5. A LOD score of 1.3
therefore suggested linkage to 9q34.
2 point linkage analysis for family 5 gave negative LOD scores with these
markers. Linkage of family 5 to the region between D9S61 and D9S195
was formally excluded with a LOD score of less than -2 across the region
on multipoint linkage analysis.




0.0 0.01 0.05 0.10 0.20 0.30
D9S61 5 -4.7 -1.7 -0.39 0.05 0.29 0.25
D9S195 5 -14 -5.1 -3.0 -2.1 -1.1 -0.57
D9S63 6 1.3 1.3 1.3 1.3 1.2 1.0
Table 3.2a. (above) Two point LOD scores for families 5 and 6, for
markers close to the endoglin locus. Generated using the MLINK
program. Markers D9S61 and D9S195 are 11cM apart, spanning the
endoglin locus. D9S63 is within 1cM distance of endoglin.
(below) Results of multipoint analysis for family 5. The LOD score is
less than -2 across the entire interval, excluding the region between





C. Initial Linkage to the HHT2 Locus on Chromosome 12
A second locus in the peri-centromeric region of chromosome 12 was
identified by Vincent (Vincent et.al 1995, with linkage to this region also
seen in the previously published American families 17 and 33 (Johnson
et.al. 1995).
Markers from this region were analysed in British families 1,2 and 3
previously described (Porteous et.al. 1994), and the newly ascertained
families detailed in this chapter, families 5 and 9. LOD scores for these
markers are given in table 3.2b, with map positions of the markers used.
Families 3 and 9 each individually gave two point LOD scores greater than
3 for markers D12S339 or D12S368, confirming linkage to the
chromosome 12 locus.
Family 2 gave a LOD score of 2.0, suggesting linkage to this locus.
Initially family 5 failed to give either significantly positive or negative LOD
scores with these markers on chromosome 12. The most likely cause for
this was felt to be inaccurate diagnosis of individuals. Using more rigid
diagnostic criteria, only classifying those with monthly nosebleeds and 2 or
more telangiectases as affected, and including only affected individuals, the




345 85 339 368
Family Number 0 D12S345 D12S85 D12S339 D12S368
0.0 -2.8 - - -2.8
1 0.01 0.09 - - -0.16
0.05 0.67 - - 0.47
0.1 0.81 - - 0.65
0.2 0.76 - - 0.63
0.3 0.55 - - 0.45
0.0 -6.8 - - 2.0
2 0.01 -1.5 - - 2.0
0.05 -0.29 - - 1.8
0.1 0.09 - - 1.5
0.2 0.25 - - 1.1
0.3 0.16 - - 0.61
0.0 -10 1.5 2.2 3.2
3 0.01 -3.6 1.5 2.2 3.1
0.05 -1.9 1.3 2.0 2.8
0.1 -1.14 1.14 1.7 2.4
0.2 -0.43 0.78 1.2 1.6
0.3 -0.15 0.43 0.70 0.84
0.0 - - - -
9 0.01 -2.1 0.71 3.8 -0.70
0.05 0.27 0.93 3.9 -0.20
0.1 1.2 1.0 3.8 0.07
0.2 1.6 0.97 3.2 0.21
0.3 1.3 0.75 2.2 0.17
0.4 0.66 0.42 1.0 0.07
0.0 - -7.3 -1.7 -3.1
5 0.01 - -2.8 -0.42 -1.7
0.05 - -0.88 0.74 -0.47
0.1 - -0.17 1.1 -0.02
0.2 - 0.27 1.0 0.27
0.3 - 0.28 0.71 0.29
0.0 - -2.7 1.9 0.28
5* 0.01 - -0.16 1.8 0.27
0.05 - 0.40 1.7 0.25
0.1 - 0.53 1.5 0.22
0.2 - 0.47 1.1 0.17
0.3 - 0.26 0.61 0.12
Table 3.2b Pairwise LOD scores between HHT and markers D12S345,
D12S85, D12S399 and D12S368. Approximate map distances for the
markers based on Gyapay et.al. (1994) are given on the bar above the table.
marks a LOD score that has not been calculated. Zmax is marked in bold.
The analyses were run using MLINK as described in materials and methods.
Analysis with family 5 was run firstly using original diagnostic criteria, and
then using more rigid criteria (marked as 5*) as described in the text.
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total number of potentially informative meioses in this analysis was 7,
leading to an expected maximum possible 2 point LOD score of
approximately 2.1. It was therefore felt likely that family 5 was linked to
HHT2 on chromosome 12.
D. Haplotype Analysis to Narrow the Candidate Interval for HHT2.
Figure 3.2 shows a simplified physical map of a 1.38Mb YAC contig
spanning a part of the candidate region for HHT2. The locations of
polymorphic markers, expressed sequence tags and known genes are
given. Additional markers were analysed from this region to identify critical
recombinations in families 2, 3 and 9, narrowing the candidate interval for
HHT2. The haplotype analysis of these markers for families 3 and 9 is
shown in figure 3.3.
Looking only at critical recombinations in affected individuals, family 2
showed a recombination between D12S347 and D12S297 placing HHT
telomeric of D12S347. In family 67 a recombination between D12S359 and
D12S368 placed HHT2 centromeric of D12S359. This reduced the
candidate region to 4 centiMorgans. An unaffected individual in family 67
has a recombination between D12S368 and D12S297 placed HHT2
centromeric of D12S297 reducing the candidate interval further to
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approximately 1 centiMorgan. These recombinations are shown
diagramatically in figure 3.4.
The genes known to map within this region were the ALK-1 gene, an
endothelially expressed serine-threonine kinase, and ALK-4, the



































Figure 3.2 Physical map of a part of the HHT2 candidate region surrounding marker
D12S368.(Supplied by Kucherlapati et.al.) The thin black line represents a portion of the
long arm of chromosome 12 with the centromere at the top. The locus names are given on
the left hand side. Markers used in this study are marked in bold. Arrows mark the position
of each locus. Where a genetic distance for a marker is given, adjacent to an arrow, it is
derived from the Genethon linkage map. the lines on the right hand side represent a YAC
tiling path spanning the region. The number of the YAC is given adjacent to the line
representing it. The black squares mark the position of each locus on the YACs. The white
circle represents a marker not found, presumeably due to internal deletion of YAC 717g8.
Figure 3.3a. Haplotype analysis of polymorphic markers from the Critical region
of chromosome 12 in family 9. Only a proportion of individuals and haplotypes
are shown for clarity. The letters or numbers represent alleles at each locus. A
is used where marker data was not available. The order of loci along
chromosome 12 is given above.
The dark grey bars mark the haplotype linked to HHT2 in the family. Where a
critical crossover ocurrs, the portion of the haplotype derived from the
unaffected chromosome in the affected parent is marked as a light grey bar.
Black lines mark the estimated position of the recombination at meiosis.
Critical crossover in affected individual iv.2 between D12s368 and D12S359
defines a 4cM critical interval for HHT2. A crossover in unnaffected individual
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Figure 3.3b Simplified pedigree of family 3, showing haplotype analysis for
the same markers as family 9. The critical recombination event in individual





















Figure 3.4. Diagram showing the critical region defined by the recombinations
in family 9 individuals iv.2 and iv.7 and family 2 individual iii. 11.
The thin black line represents the chromosomal segment with loci marked on
the right hand side. The map distances given, marked in centiMorgans by the
arrows are derived from the physical map of the region.
The broad lines indicate the chromosomal regions defined by the crossovers.
4. Investigation of genes mapping within the HHT2 Candidate Region.
Several genes mapped within the initially defined candidate interval for
HHT2. As well as the known genes ALK-1, ALK-4 (the activin IB receptor),
and several keratin genes, there were two uncharacterised ESTs, WI-8355
and WI-6754. Expression of these in endothelial cells had previously been
demonstrated by rtPCR. (D. Johnson unpublished data). Initially the
Integrin-a5 gene was also felt to be a strong candidate for the HHT2 gene,
as it mapped close to the region and is thought to play an important role in
cell-cell and cell-matrix interaction of endothelial cells.
Investigation of ESTs WI-8355 and WI-6754
A. Using PCR to amplify directly from cDNA libraries.
The first approach attempted was to amplify fragments of the desired ESTs
directly from an endothelial specific cDNA library. The cDNA libraries
available were provided by Dr. D. Ginsburg (Ginsburg et.al. 1985). cDNA
had been cloned bidirectionally into the EcoR1 site of A,gt11. Both a library
made from oligo-dT primed cDNA (designated EC-1) and one from random
primed cDNA (designated EC-2) were used.
Repeated attempts to perform a hemi-nested PCR from EST specific
primers to a vector specific primer were made using different dilutions of
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starting template library. Between 106and 1010 clones were used as
template.
No product fragments for WI-8355 were generated repeatably or at
sufficient concentration to justify sequencing.
Using primers made to EST WI-6754, several fragments were generated
which were sequenced. One fragment had a significant open reading
frame of 96 codons. Blast search of this open reading frame at the
nucleotide and protein level revealed that it was the human c-yes-1 gene
known to map to chromosome 18. Further inspection of the sequence
identified an EcoR1 site between the open reading frame and the known
WI6574 sequence. This suggested that the clone which amplified was
chimaeric and contained 2 inserts, one of which was c-yes-1. No other
fragments were generated reliably or had a significant open reading frame.
Owing to these problems, this approach was abandoned in favour of
directly screening the cDNA libraries.
B Screening the cDNA libraries for WI-6754 and WI-8355
After titreing, the EC-1 and EC-2 libraries were plated out at a density of
2X104 per 15cm circular plate. 10 plates were prepared for each. If the
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proportion of the desired RNA species was as low as 1 in 50,000,
screening these 10 filters would be expected to yield 4 clones.
Screening with WI-6754 identified no positive clones. Screening with Wl-
8355 identified multiple clones, 20 of which were isolated with two further
rounds of plaque purification.
Clones isolated were then checked by PCR between EST specific primers
and vector specific primers. As the library was cloned non-directionally,
both orientations had to be tried. Three clones which gave consistent
results in this assay were chosen for further sequencing. The PCR results
for these clones, 8355-2, 8355-11 and 8355-12 are shown in figure 4.1.
Sequencing 150 bp of the 3' end of these fragments yielded identical
sequence to the published EST. 120 to 220 base pairs of sequence was
generated from the 5' end of each of the 3 clones. None of these short
sequences overlapped. However, each contained an open reading frame
in the expected orientation.
The nucleotide sequence and deduced protein sequence was used to
search Genbank using the Blastn and Blastp programmes.
At the nucleotide level, clone 12 was identical to a 500 base pair random
human cDNA clone ym50co2.r1 (gb|H24106). At the protein level, there
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was extensive homology of predicted amino acid sequence from the clone
12 fragment to helicase proteins from many different species. However, no
exact matches with human proteins were identified. Sample alignments are
shown in figure 4.2. Re-running the database search with the entire
sequence of ym50co2.r1 (Last performed April 1997) did not identify any
complete mRNA sequences.
The 5' end of clones 2 and 11 had weak homology to human U1 small
nuclear ribonuclear protein at the protein level.
Helicases have been identified as mutated in the alpha-thalassaemia and
mental retardation syndrome (Ion et.al. 1996). They are also implicated in
disorders of DNA repair and cancer predisposition such as Bloom
syndrome, Werner Syndrome and Xeroderma pigmentosum (Epstein and
Motulsky 1996). This did not seem a likely class of gene for a candidate for
HHT2. At this point it became known that WI-8355 also fell outwith the












Fig 4.1. PCR results from clones 2, 11 and 12. 2 clones were analysed for each. In
all cases, the reactions were loaded
Lane 1. PCR using vector specific primers A.gt11 forward and A.gt11 reverse.
Lane 2. PCR using A,gt11 forward primer and an EST specific reverse primer.
Lane 3. PCR using A.gt11 reverse primer and an EST specific reverse primer.
For each clone there is a marginally larger product in lane 1 than in 2 or 3, as
would be expected. Each clone also gives a product in lane 2 or 3 but not both, as
predicted from experimental design.





Human p68 RNA Helicase..DMVGVAQTGSGKTLSYLLPAIVHINHQPFLER
Figure 4.2
Alignment of 49 amino acids from the translated sequence from the 5' end of
clone 12. This stretch had significant homology (p<10~4) to 22
published helicases. However, at the time of doing the blast search
no full length human cDNA had been identified.
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5. The Structure of the Activin Receptor Like Kinase 1 Gene.
A. A human genomic PAC clone containing the ALK-1 gene.
From the YAC contig described in chapter 4, it was anticipated that the
ALK-1 gene was contained within CEPH YAC 717_g_8. Southern blots of
digested 717_g_8 YAC DNA probed with an ALK-1 cDNA probe showed
no specific hybridisation. A specific PCR reaction designed to amplify a
120bp fragment from the 5' UTR of the ALK-1 gene also failed to give a
product from the 717_g_8 YAC DNA template. (Data not shown).
The human genomic PAC library supplied by Pieter de Jong (loannou et.al.
1994) was screened. Using the same PCR described above which
specifically amplifies a 120bp fragment from the 5 UTR of the human ALK-
1 gene, positive results were found for DNA pools E3, E5 and E9
corresponding to co-ordinates 5X3, 5Y1 and 5Z1 of the 3 dimensional grid
into which the plates were arrayed. This identified a single plate number
265 as containing a genomic clone corresponding to ALK-1.
An impression of plate 265 was stamped into LB agar with kanamycin,
followed by overnight incubation at 37 °C. Clone DNA was transferred to
Hybond N membrane as previously described. Hybridisation to a
radiolabeled ALK-1 cDNA probe identified a single clone as containing
ALK-1 sequence. This clone at position c-14 was designated GA-1.
B. GA-1 has an insert of 120kb and contains two Not 1 sites
DNA from the clone GA-1 was digested with a variety of restriction
endonucleases and resolved using both conventional electrophoresis and
pulsed field gel electrophoresis.
Not 1 digestion of the clone yielded fragments of approximately 60 kb,
45kb and 15kb as well as a vector fragment of 20kb when resolved on
pulsed field gel electrophoresis, as shown in figure 5.1. This gave an
estimate of the total insert size as around 120kb.
A standard southern blot of Bgl II, EcoR1 and Hindlll digests of GA-1 was
probed with the total ALK-1 cDNA coding region. The results are shown in
figure 5.2 and summarised in table 5.1. The fragment sizes correspond
with those found on a human genomic southern blot. These results
suggest that the coding region of the ALK-1 gene contained within GA-1







Figure 5.1 Pulsed field gel electrophoresis of a NOT1 digest of PAC clone
GA-1. The ladder (Gibco high molecular weight marker) is on the right
hand side. Fragment sizes of the digest are given on the left hand side.
H E B
Figure 5.2 Southern blot of digests of the PAC clone GA-1 probed with
the complete cDNA for ALK-1. Sizes of the fragments for the HinDIII (H),
EcoRI (E) and Bgl ll(B) digests are given in table 5.1 below
Enzyme Digest Size of Fragments (kb) Total Size (kb)
Bgl II 7, 5.5, 3.8, 2.3, 0.8 19.4
EcoR I 8, 6, 4.5, 2.5, 1.5, 1.7 24.2
HinD III (22) 22
Table 5.1. Approximate fragment sizes (in kilobases) indicated by the
bands identified in the autoradiogram shown in figure 5.2. The size of the
HinD III fragment is given in parentheses, as it was calculated by pulsed
field gel electrophoresis rather than from the autoradiogram shown.
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C. Subcloning of GA-1
A Bgl II digest of GA-1 DNA was subcloned into the BamH1 site in
pBluescript (Stratagene). 24 clones that hybridised to ALK-1 cDNA were
selected. Double digestion with EcoR1 and Not1 identified 3 different
groups of clones. The fragment sizes generated for each of these clones
by this digestion are given below.
Group 1 : Insert digested to give fragments of 3kb and 2kb.
Group 2 : Insert digested to give fragments of 4kb and 1.4kb.
Group 3 : Insert digested to give fragments of 4.2kb, 2.2kb and 1,8kb.
A southern blot of these clone digests was sequentially probed with
specific primer 460, located at the 5' end of the coding region of ALK-1 and
primer 505 from the coding 3' end the gene. Clones from group 1
hybridised specifically to primer 460, and those from group 2 hybridised
specifically to primer 505. Clones from group 3 were shown to hybridise
specifically to a probe from the 5' untranslated region of ALK-1.
Subclones 2b (group 1), 1a (group 2) and 6d (group 3) were selected as
representative of their groups. The position of each clone in relation to the
ALK-1 gene is shown as a part of figure 5.3.
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In addition to digest patterns, the clones 6d and 2b were characterised
further by PCR from an ALK-1 specific primer to the stratagene T7 and T3
primers on either side of the multiple cloning site of the pBluescript vector
used. This demonstrated that clone 6d contained 2.2kb of sequence
between the 3' end of ALK-1 exon 1 and the T7 primer. Clone 2b contains
approximately 3kb of sequence between the 5' end of ALK-1 exon 2 and
the T7 primer, (data not shown).
D. Determination of Intron Position in the ALK-1 Gene.
Intron position in the ALK-1 gene was determined using two techniques,
exon to exon PCR and sequencing from genomic subclones 2b, 1a and
6d.
Using PCR, it was possible to amplify the genomic DNA between one exon
and the next by using the DNA from the GA-1 clone as template. Primers
designed to the published cDNA sequence of ALK-1 were used. An
example is given in figure 5.4. Wherever a fragment generated was longer
than that expected from the known cDNA sequence, an intron was
identified. This was confirmed by sequencing, the exact intron-exon border
being identified by a consensus splice sequence followed by divergence
from the established cDNA sequence. Table 5.2 gives the fragment sizes
generated from genomic PCR compared to the sizes expected from PCR








Figure 5.3. The Genomic structure of ALK-1. Drawn approximately
to scale.
The exons are numbered with Roman numerals
| Exon, untranslated region
] Exon, translated region
— Intron






Figure 5.4 Examples of PCR between exons of ALK-1 used to identify intron
position.
lanes 1 and 2 show product from PCR reactions using human genomic DNA as
template, lane 3 used DNA from PAC clone GA-1 as template.
Lanes 1,2 and 3 show the fragment size of 1.2 kb generated using primers 460
and 283,this product would be expected to contain the second intron of ALK-1
(900bp). The product generated using the PAC clone as a template shows no
additional bands and is easier to identify and sequence when compared to the
product generated using genomic DNA as template.
Lane 4 shows the product generated using primers 148 and 280. This product
contains the 3rd intron of ALK-1 which is 140bp in size. The product in lane 5

















561 -41 (2) 460 171 (3) 1,2kb 2 (900bp)
561 -41 (2) 280 564 (5) 1.9 kb 2 (900bp)
3 (140bp)
4 (160bp)
124 473 (4) 280 564 (5) 250bp 4 (160bp)
124 473 (4) 490 724 (6) 700bp 4 (160bp)
5 (200bp)
489 659 (6) 125 1032 (7) 1.2kb 6 (800bp)
501 895 (7) 504 1179 (8) 750bp 7 (450bp)
505 1182(8) 506 1290(9) 2.9kb 8 (2.8)kb
507 1316(9) 560 1544(10) 1.7kb 9(1.5kb)
Table 5.2 Table giving primer pairs used in the PCR reactions to estimate
intron sizes and positions. The primer identification number corresponds with
that given in table 2.1.
The position of the primer in the cDNA sequence is given as the position of the
first base of the primer in relation to the start codon of the published ALK-1
cDNA sequence. The approximate size of fragment generated using the primer
pair on the GA-1 DNA template is given. This allowed the estimate of intron
position and size given in the table.
The fragments generated were sequenced from a variety of primers to identify
the intron-exon boundaries given in Table 5.3,and shown diagrammatically in
Figure 5.4, as well as to generate the sequence data for the GENBANK
submission given in appendix A.
Figure 5.5 gives the coding ALK-1 cDNA sequence with the position of
each intron identified. For some intron-exon borders the sequence gained
using this approach was not sufficiently clear. To get better sequence for
these areas, further sequencing was performed directly using clones 1b
and 2a as template.
Table 5.3 gives the sequence of each intron/exon boundary for the coding
exons. The Genbank submission containing this sequence and extended
sequencing into the introns is given in appendix A.
The 5' side of intron 6 does not have the usual consensus splice
sequence. There is the splice donor sequence TAG/gcaag instead of the
usual AG/gt.
From this it can be seen that the coding portion of the ALK-1 gene is
contained within 9 exons and lies within just under 15kb of genomic DNA.
E. Further Characterisation of the Region Containing Exons 1 and 2
The 5' end of the ALK-1 gene that contains exon 1 and exon 2 is of
particular interest as it would be expected to contain the promoter
elements controlling the endothelial specific expression of ALK-1.
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Figure 5.5
Annotated Sequence of the Coding Region of ALK-1. Exact Intron Position is
marked by an arrow.
The Exon number is marked above the sequence. The start codon, and stop
codon are marked in bold. The putative signal peptide for membrane localisation,
putative transmembrane region, the GXGXXG motif, GS domain and start of the
kinase domain are marked.
1 0 30 50
Exon 2
ATG acc ttg ggc tcc ccc agg aaa ggc ctt ctg atg ctg ctg atg gcc ttg gtg acc cag
MTLGSPRKGLLMLLMALVTQ
start Putative Signal peptide....
70 90 1 10
a Exon 3
ga gac cct gtg aag ccg tct egg ggc ccg ctg gtg acc tgc acg tgt gag age cca cat
GDPVKPSRGPLVTCTCESPH
13 0 150 1 70
tgc aag ggg cct acc tgc egg ggg gcc tgg tgc aca gta gtg ctg gtg egg gag gag ggg
CKGPTCRGAWCTVVLVREEG
19 0 210 2 30
agg cac ccc cag gaa cat egg ggc tgc ggg aac ttg cac agg gag etc tgc agg ggg cgc
RHPQEHRGCGNLHRELCRGR
25 0 270 2 90
ccc acc gag ttc gtc aac cac tac tgc tgc gac age cac etc tgc aac cac aac gtg tcc
PTEFVNHYCCDSHLCNHNVS
31 0 330 3 50
,.Exon 4 .
ctg gtg ctg gag gcc acc caa cct cct teg gag cag ccg gga aca gat ggc cag ctg gcc
LVLE ATQPPSEQPGTDGQLA
37 0 390 4 10
ctg ate ctg ggc ccc gtg ctg gcc ttg ctg gcc ctg gtg gcc ctg ggt gtc ctg ggc ctg
LILGPVLALLALVALGVLGL
Putative Transmembrane Domain
43 0 450 4 70
tgg cat gtc cga egg agg cag gag aag cag cgt ggc ctg cac age gag ctg gga gag tcc
WHVRRRQEKQRGLHSELGES
49 0 510 5 30
a .Exon 5
agt etc ate ctg aaa gca tct gag cag ggc gac acg atg ttg ggg gac etc ctg gac agt
SLILKASEQGDTMLGDLLDS
55 0 570 5 90









ga aaa ggc cgc tat ggc gaa gtg tgg egg ggc ttg
KGRYGEVWRGL
GXfGXXG Motif
67 0 690 7 10
tgg cac ggt gag agt gtg gcc gtc aag ate ttc tee teg agg gat gaa cag tee tgg ttc
WHGESVAVKIFSSRDEQSWF
Start of serine/threonine kinase domain
73 0 750 7 70
» Exon 7




79 0 810 8 30
gee tea gac atg ace tee cgc aac teg age acg cag ctg tgg etc ate acg cac tac cac
ASDMTSRNSSTQLWLITHYH
85 0 870 8 90
gag cac ggc tee etc tac gae ttt ctg cag aga cag acg ctg gag ccc cat ctg get ctg
EHGSLYDFLQRQTLEPHLAL
91 0 930 9 50
agg eta get gtg tee gcg gca tgc ggc ctg gcg cac ctg cac gtg gag ate ttc ggt aca
RLAVSAACGLAHLHVEIFGT
97 0 990 10 10
cag ggc aaa cca gcc att gcc cac cgc gac ttc aag age cgc aat gtg ctg gtc aag age
QGKPAIAHRDFKSRNVLVKS
103 0 10 70
. . Exon 8
aac ctg cag tgt tgc ate gcc gac ctg g
NLQCCIADL
gc ctg get gtg atg cac tea cag ggc age gat
GLAVMHSQGSD
109 0 1 110 11 30
tac ctg gac ate ggc aac aac ccg aga gtg ggc acc aag egg tac atg gca ccc gag gtg
YLDIGNNPRVGTKRYMAPEV
115 0 1 170 11 90
ctg gac gag cag ate cgc acg gac tgc ttt gag tee tac aag tgg act gac ate tgg gcc
LDEQIRTDCFESYKWTDIWA
121 0 1 230
ttt ggc ctg gtg ctg tgg gag att gcc cgc egg acc ate gtg aat g
FGLVLWEIARRTIVN
Exon 9
gc ate gtg gag gac
I V E D
127 0 1 290 13 10
tat aga cca ccc ttc tat gat gtg gtg ccc aat gac ccc age ttt gag gac atg aag aag
YRPPFYDVVPNDPSFEDMKK
°u
133 0 1 350 13 70




139 0 1 410 14 30
Exon 10
etc tea ggc eta get cag atg atg egg gag tgc tgg tac cca aac ccc tct gee cga etc
LSGLAQMMRECWYPNPSARL
145 0 1 470 14 90
acc gcg ctg egg ate aag aag aca eta caa aaa att age aac agt cca gag aag cct aaa
TALRIKKTLQKISNSPEKPK
151 0 1 530 15 50
gtg att caa TAG ccc agg age acc tga ttc ctt tct gee tgc agg ggg ctg ggg ggg tgg
V I Q *
Stop
157 0 1 590 16 10
ggg gca gtg gat ggt gee eta tct ggg tag agg tag tgt gag tgt ggt gtg tgc tgg gga










Table 5.3 Showing the splice junctions at the 5' and 3' sides of each of the
coding exons of ALK-1. Exonic sequence is in uppercase, intronic sequence
in lower case. The 5'splice site in exon 2 that leads to the cDNA sequence
published by ten-Djike is given. The start and stop codons are marked in bold.
The non-consensus splice junction on the 3' side of exon 6 is underlined.
<\%
The two cDNA sequences published for ALK-1 have different 5'
untranslated regions. The sequence published by Atissano et.al. is
contained entirely in exon 2 upstream from the expected start codon. The
sequence published by ten Djike et.al. would arise as a result of exon 1
splicing into exon 2 at a consensus splice sequence 7 base pairs upstream
from the start codon.
Specific primers, JB3 and JB4 designed to the cDNA sequence from exon
I were used to amplify the intron between exon 1 and exon 2, giving a
5.5kb fragment (shown in figure 5.6). This fragment contains a single Bgl
II site confirming that the Bgl II subclones described above, 6d containing
exon 1 and 2b containing exon 2 are adjacent. It had previously been
established by PCR that the insert of clone 6d contained approximately
2.2kb of sequence 3' of exon 1, and clone 2b contained approximately 3kb
of sequence 5' of exon 2
Partial restriction mapping of this region was also carried out using pulsed
field gel electrophoresis. Using the known Not 1 restriction site in exon 1 and
a series of double digests combining Not 1 digestion with HinDIII, EcoR1
and BamH1 digests were resolved in the 5 to 50kb size range by pulsed field
gel electrophoresis and Southern blotted, before being hybridised to specific
oligonucleotides complementary to exon 1 and exon 2.
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The oligonucleotides JB3 (exon 1, 3' of Not 1 site) and 647 (in exon 2) both
hybridised specifically to the largest Not 1 fragment of approximately 50kb
as well as a to the largest HinD III fragment of 22kb. The Southern blot of
the Not1/HinDIII digest showed specific hybridisation to an 8kb fragment.
Digestion of clone 6d with Not 1, EcoR1 or both, gave the fragment sizes
shown in table 5.2. Combined with the estimation of distance between
exon 1 and the 3' end of the insert of 2.2kb derived by PCR and described
above, this gave the restriction map shown in figure 5.7.
F. Conservation of Intron Position in the Kinase Domain of ALK-1.
The full genomic structure of one other type I serine-threonine kinase
receptor has been published. This is the TSK-7L receptor isolated from
mouse. Comparison of the splice junctions at the protein level between
ALK-1 and TSK-7L are shown in figure 5.8.
All 3 splices between exons 5,6,7 and 8 all fall in exactly the same
position, between 1st and second base of a glycine codon. The splice
between exon 8 and 9 falls after the 1st base of a codon for Isoleucine,
another neutral amino acid.
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L 1 2
Figure 5.6 PCR product amplified using primers JB3 and JB4,
amplified using clone GA-1 as template. Lane 2 shows the 5.5kb
undigested product. Lane 1 shows the Bgl II digest which shows a
single site in the fragment, lying between exon 1 and exon 2 as
described in the text.
The ladder in lane L is Gibco BRL 1 kb ladder. The size bands for
2kb and 3kb are marked with an arrow.
lo\
Bgl II EcoR1 Not I Bgl II
Figure 5.7 Partial restriction map of the 5' end of the ALK-1 gene.
The position of exon 1 and 2 is given in relation to the Not1 site in exon 1,
and the flanking Bgl II sites. There is also an EcoR1 site 1,6kb 5' of exon 1.
The positions of primers JB3, JB4, 648 and 647 are marked. These primers
were used as oligo-nucleotide probes for southern blotting and in PCR
reactions to calculate the distances given.
The curved arrow marks the putative alternative splice between exon 1 and
exon 2 as described in the text. The sequence at this splice junction is given
with the start codon common to both variants marked in bold.
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Exon 4 Exon 5 Exon6 Exon 7
TSK-7L: Leu Ala Glu Leu....Cys Val G Ly Lys Gly Leu G ly Phe lie
ALK-1: Leu Gly Asp Leu....Cys Val G ly Lys Gly Leu G ly Phe lie
Exon 7 Exon 8 Exon 9
TSK-7L: Asp Leu G Ly Leu....Asn Gly I Le Val Glu....Asp ProjThr Leu
ALK-1: Asp Leu G ly Leu....Asn G ly lie Val Glu....Asn Pro Val Leu
Figure 5.8. Comparison of the splice sites at the amino acid level
between human ALK-1 and the mouse serine-threonine kinase type I
receptor TSK7L. The comparison is confined to the kinase domain as
there is little homology between the extracellular domains of the
molecules.
Marks the position of each splice in the amino acid sequence.
As noted in the text, the splice sites between exons 5,6,7,8 and 9 all
fall between 1st and second bases of a codon which encodes a
neutral amino acid, most commonly glycine.
6. Mutation Analysis of the ALK-1 Gene.
Initial mutation analysis of the ALK-1 gene by rtPCR and sequencing from
whole lymphocyte RNA was carried out by D. Johnson. Mutations in ALK-1
were identified in 3 families using this approach. These included a 3 base
pair deletion identified in family 9, deleting a serine in kinase subdomain II
downstream from the ATP-binding site. Mutations were also identified in
families 33 and 40 (Johnson et.al. 1996) ascertained previously. Details of
these mutations are included in table 6.1 and figure 6.1.
A. Families Used for Mutation Analysis.
The ALK-1 gene was sequenced in 12 individuals. Six of these individuals
came from HHT families that had evidence of linkage to 12q, either by a 2
point LOD score greater than 2 at 0 = 0 for a marker close to the ALK-1
region or formal exclusion of linkage to the endoglin region of chromosome
9q34. The remaining 6 individuals analysed were reported as having HHT,
but came from families too small for linkage analysis, or for whom we only
had a sample from a single affected individual.
Details of each linkage group are given below.
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i. Definite 12 linked Families:
Family 2
A British family showing definite linkage to 12q34 as described in chapter 4. The
family member chosen for sequencing had severe nosebleeds and gastro¬
intestinal haemorrhage as well as many classical telangiectases.
Family 3
A British family with HHT linked to 12q34 (Porteous et.al. 1994). An
individual from this family had a recombination that was crucial in
narrowing the candidate interval for FIHT2.
Family 17
An American family from the Northern United States with 6 affected
members, This family is described in (McAllister et.al. 1994b). Linkage to
12q was demonstrated by other workers.
ii. Families with Exclusion of Linkage to 9q34
Family 1
A large kindred previously published as showing definite exclusion of
linkage to 9q34 on multipoint and 2 point linkage analysis (Porteous et.al.
1994). However as described previously, few markers in the ALK-1 region
gave significantly raised LOD scores, but failed to exclude the region.
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Family 5
This large family showed exclusion of 9q34 by multipoint analysis.
However no markers from the ALK-1 region gave conclusive linkage or
exclusion of linkage on two point analysis. As discussed in chapter 4,
individuals in this family with nosebleeds and an affected first degree
relative were erroneously diagnosed as affected.
Family 92
A large kindred from the Southern United States who have many members
who might be mildly affected. This diagnostic confusion led to the use of
only a small set of samples from a core kindred, allowing exclusion of 9q34
by other workers, but not providing sufficient data to confirm linkage to
12q34. The individual sequenced had frequent nosebleeds and
unequivocal telangiectasis on the lips, ears and tongue.
iii. Individuals for Whom No Conclusive Linkage Data Was Available.
Individual A
An Individual from a small Dutch family. The individual was diagnosed as
being affected by his own physician and has an affected sister.
Individual B
An individual assessed in person, with frequent nosebleeds and
telangiectases. He thought that he might be a distant member of a large
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Mormon family with HHT, who also come from the Salt-Lake City region.
This family has been reported in an abstract as having a maximum 2 point
LOD score of 2.4 for markers close to ALK-1, indicating possible linkage.
Individual C
A member of a very small British family who have no crossovers with
markers from the ALK-1 region, but insufficient members are available to
establish definite linkage.
Individual D
The only member of a large family from Texas who was assessed. They
reported more than monthly nosebleeds with an affected parent. On
examination by their own physician they had a few suspect red marks on
the lips but no definite telangiectases. Two other family members had a
history of pulmonary arteriovenous malformations.
Individual E
An American individual assessed by their own family physician with a
history of severe nosebleeds and muco-cutaneous telangiectases. A
member of a large family that has not been investigated in depth.
Individual F
A British individual, assessed in person with frequent nosebleeds and
muco-cutaneous telangiectases. While the only member of this family from
whom we had a sample, there is an extensive history of other family
members with nosebleeds, muco-cutaneous telangiectases and severe
gastro-intestinal haemorrhage.
B. Identification of Nine Novel Mutations in the ALK-1 Gene.
For each sample, the entire coding region of the ALK-1 gene was amplified
in 9 separate PCR reactions and sequenced using the methods described
previously.
Nine mutations were identified in the ALK-1 gene. Of these, there were 2
amino acid changes in the extracellular domain, 3 created premature stop
codons, one was a one base pair insertion and there were 3 amino acid
changes in the kinase domain. The mutations found are summarised in
table 6.1, and their position in the ALK-1 protein shown diagramatically in
figure 6.1. For each mutation identified, a rapid assay was developed
which enabled a population screen to be carried out on over 100
individuals. Details of these assays are also given in table 6.1.
Figure 6.2 shows an example of the family tree, sequence data generated





Effect on Protein Assay for Mutation No Of Normal
Chromosomes
Screened









IV G to A (423)
G to T (475)
Intracellular Stop
Intracellular Stop
Creates Afl II site




VI 3 bp deletion
(694)
Deletion of serine in
kinase domain*
VII Ins T (865)
C to A (925)






Creates Stu I site




VIII C to T (1120)
T to G (1126)
G to A (1232)
Arg to Trp
Met to Arg *
Arg to Glu*
(In kinase domain)
Creates Dra III site 232




Table of the Mutations found with their position in the ALK-1 gene. As well
as the 9 mutations described in the text, the 3 mutations described
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Figure 6.2. Example of data generated during mutation analysis.
a. Family tree of a section of family 92. (not ascertained in this study)
b. PCR assay for the mutation C925A identified in exon 7 in this study,
which causes a premature stop. The sequence change creates a Stu1 site.
All the affected individuals therefore show a wild-type PCR product of
350bp size as well as 2 digested bands where the mutated PCR product is
cut by Stu1. The ladder in the left hand lane is Gibco-BRL 100bp ladder.
c. Sequence of exon 7 from subcloned PCR product showing the sequence
of the normal and mutant alleles.
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C. Confirmation of Significance of Mutations.
i. Polymorphism Screen.
For each of eight of the mutations described above, a panel of over 112
unrelated individuals was screened to ensure that the mutation found did
not arise in the general population as a common polymorphism. The
remaining mutation was not seen in 106 unnaffected individuals. The
polymorphism panel comprised unaffected "married in" members of the
HHT families. They were therefore unrelated, and, on the whole
representative of the population from which the families came.
The chance of a single individual carrying an allele that occurs with an
frequency (q) of 0.01, in a population in Hardy-Weinberg equilibrium is
2pq+q2=0.02 (assuming q2 is negligible). The probability of the individual
not having the polymorphism approximates to 1-2pq=0.98. When
screening 112 normal individuals from the same population the probability
that all 112 will not carry the allele is (0.98)112=0.1 or 10%. Screening 112
individuals would therefore give a 90% probability of detecting a population
polymorphism with an allele frequency of 0.01 or greater.
ii. Significance of the Amino Acid Substitutions.
Where a mutation caused an amino acid change in ALK-1, a BLAST
search was performed using the surrounding amino acid sequence to
estimate the degree of conservation of the region that was changed. Six
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published sequences were taken to represent the serine-threonine kinase
receptor family from humans and other frequently studied species.
Alignment was performed using the BLASTp program, and by eye. The
results of this approach used to look at the 3 intracellular amino acid
changes are given in figure 6.3. There was also conservation of the amino
acid that was changed across many other gene family members.
A similar method used for the two extracellular mutations was less
successful as the only proteins to show similarity in the extracellular
domain are the rat and mouse homologues of ALK-1. However, in both
these, the amino acid that was changed is conserved across species. This
is shown in figure 6.4.
D. Efficiency of detection of Mutations
Table 6.2 shows the proportion of mutations detected in each of the three
groups, described at the beginning of this chapter.
In all families with evidence of linkage to chromosome 12, or exclusion of
linkage to 9q34, a mutation was found. Mutations were also found in 3 of
the 6 individuals for whom no linkage data was available. Of the 3
individuals in whom no mutation was found, the individual D was
incidentally re-assessed before results were released, by the physician
who originally saw them. This individual was felt to be unnaffected. A
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subsequent linkage study on this family also demonstrated linkage to 9q34
(D.Marchuk personal communication). Data from this individual was
therefore not included in table 6.2.
Including the 3 mutations already identified, sequencing has therefore
found 12 mutations in 14 affected individuals, representing every 12q34
linked family that has been identified , every family with definite exclusion
of 9q34 and 3/5 individuals for whom no definite linkage data was
available.
E. Identification of two polymorphisms within the ALK-1 Gene
Two polymorphisms were identified within the ALK-1 gene. The first, a
single base change in exon 8 did not result in an amino acid change and
was only seen once. The second was a common variant in the intron 3' of
exon 3. The sequence is shown in figure 6.5. Of the 12 controls run, 6
were homozygous for the C, 4 were heterozygous and 2 were homozygous
for the T. Of the two healthy volunteers who were homozygous for the T,
both had had severe nosebleeds as children, requiring cauterisation. The
significance of this in the normal population or as a modifying factor for
symptoms of HHT remains uncertain.
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Figure 6.3 Alignment either manual or by BLAST search of Amino Acid
sequence surrounding each of the 3 amino-acid changes in the kinase
domain of the ALK-1 gene. This shows conservation of the mutated
amino acid across members of the same gene family in both humans and
other frequently studied organisms, both vertebrate and invertebrate.
Where the one letter amino acid code is given there is exact alignment of
the residue.is used to denote a different amino acid in that position.
C1120T leading to Arginine to Tryptophan
Mutant Sequence
Normal Sequence
Human TGF-b type I receptor
Human Activin type I receptor












G998T leading to Serine to Isoleucine
Mutant Sequence
Normal Sequence
Human TGF-b type I receptor
Human Activin type I receptor























Human TGF-b type I receptor
Human Activin type I receptor





Figure 6.4 Alignment by BLAST search of Amino Acid sequence
surrounding each of the 2 extracellular amino-acid changes in the ALK-1
gene. The one letter amino acid code is given where there is exact
alignment. is used to denote a different amino-acid.
This figure shows conservation of the mutated amino acid in the known
ALK-1 homologues in other species.





Rattus Norwegicus SKR3 Receptor
Mus Musculus Activin IB receptor
-c-g-wctvvlv
-c-g-wctvvlv
G200A Leading to Arginine to Glutamine
Mutant Sequence hpqehqgcgnlh
Normal Sequence hpqehrgcgnlh
Rattus Norwegicus SKR3 Receptor hpq--rgcg-l-







Families Linked to 12q 6 6
Linkage Excluded to 9q 3 3
No Linkage data Available 5 3
Total 14 12
Table 6.2 Showing the proportion of mutations found in the three groups,
families known to link to chromosome 12q, families with exclusion of 9q34
(HHT1) on linkage, and individuals for whom no linkage data was available. All
12 known mutations are included in this table.
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Figure 6.5. Sequencing reaction to show the
polymorphism 3' of exon 3. 12 individuals were
sequenced. All 12 of each termination reaction were
loaded adjacent to each other on the gel. The sequence
is labelled in the orientation of the coding strand.
The arrows mark the sequencing lanes 10 and 11, from
individuals who are homozygous for the T in the position
shown, with no band seen in the "C" lane. Similarly, lanes
1,2,5,6,7 and 9 do not have a band in the "T" lane at this
position, these individuals are homozygous for the "C" variant.
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7. Identification of MAD Proteins Expressed in Endothelial Cells.
A. Design of Primers for degenerate PCR
Alignment of published amino acid sequences for different MAD proteins
reveals domains of marked homology in the 5' and 3' ends of the protein
with a variable region between. These domain have been named the MH1
and MH2 domains (Attisano personal communication). The sequence
alignment used is given in figure 7.1. Primers were designed to these
homologous domains to allow amplification of the variable central region.
Although this would potentially necessitate the amplification of fragments
up to 1.8kb in the largest identified MAD homologues, this also allows
more accurate identification of the fragment as the 5' and 3' domains do
not have sufficient diversity of sequence. Table 7.1 shows the primer
sequence chosen, corresponding amino acid sequence and level of
degeneracy.
B. Amplification of a single fragment corresponding to DPC4.
An initial degenerate PCR reaction using cDNA from the ECRF24 cell line
and conditions outlined in the materials and methods gave 2 bands around
the 220 and 110 bp size. When cloned and sequenced, these were
identified as RNA binding proteins L24 and L18. As they do not have exact
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amino acid sequence homology to the primers used and are apparently not
related to MAD proteins, this was taken as a non-significant result.
A subsequent PCR reaction using a more stringent "touchdown" program
gave three fragment at low concentration. These fragments were of size
600bp, 800bp and 900bp, The bands were gel extracted and T/A cloned
(see materials and methods). Only the 800bp fragment proved to be
present at high enough concentration to allow cloning.
Sequencing of the several clones of this fragment from both ends identified
the fragment as being derived from DPC4, a MAD homologue previously
described as deleted in pancreatic carcinoma.
The PCR reaction was repeated using the EC1 and EC2 libraries
(described previously) as template. PCR products corresponding to
MADR1 and DPC4 were obtained.
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5' Domain
MADRl 110. . . .EFPFGSKQKEVCINPYHYKRVESPVLPPVLVPRHSEYNP. . .
JV18-1 150. . . .EYAFNLKKDEVCVNPYHYQRVETPVLPPVLVPRHTEILT. . .







Figure 7.1 Alignment of parts of the conserved 5' and 3' domains of MAD
protein family members. Amino acid residues common to all 3 human
molecules are given in bold. CE-Sma-2 is a MAD homologue from
C.elegans. The sequences used to identify the best consensus sequence
for degenerate PCR are underlined and are common to members of the
gene family from widely divergent species.
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5' Primer
Amino Acid Sequence P Y H Y (K/E) R V
Nucleotide Sequence CCU UAU CAU UAU AAA AGA GU




Amino Acid Sequence H I G K G V
Nucleotide sequence CAU AUU GGU AAA GGU GUU
C C C G C C
A A A A
G G G
Table 7.1 Degenerate primer sequence derived from conserved domains
of MAD proteins. The 5' primer has 1024 possible permutations, with a
possible approximate TM in the range of 50 to 66. The 3' primer has 768
permutations with a TM range of 48 to 60.
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8. Comparison of 9-Linked and 12-Linked Families
Table 8.1 shows a comparison of the incidence of PAVMs and gastro¬
intestinal haemorrhage between the chromosome 9 linked families 6 and 8
and the chromosome 12 linked families 5 and 9. Even within this small
data set, the higher number of PAVMs in endoglin linked HHT compared to
non chromosome 9 linked HHT is significant. There is no significant
difference in incidence of gastro-intestinal haemorrhage.
This data set is expanded to include the incidence of PAVMs in all
published families in table 8.2. From these tables it is evident that there is
a much greater reported incidence of pulmonary arteriovenous
malformations in families with linkage to chromosome 9, than those with













families (6 and 8)
4 10 14
Endoglin excluded
families (5 and 9)
0 32 32
Total 4 42 46












families (6 and 8)
1 13 14
Endoglin excluded
families (5 and 9)
6 26 32
Total 7 39 46
NS (Fisher's exact test)
Table 8.1 Comparison of incidence of PAVMs and Gastro-intestinal
(Gl) bleeding between families linked to chromosome 9 and endoglin
(6 and 8) and families showing exclusion of this region on linkage
analysis.(5 and 9). The incidence of PAVMs is higher in endoglin
linked HHT, there is no significant difference in frequency of Gl


















Total 38 178 216
p<0.001 by x2 analysis
a: Data from families 01,02,32,56 (McAllister et.al., families F and A
(Shovlin et.al.) as well as families 6 and 8.
b: Data from families 1,2,3,4 (Porteous et.al.), 17 and 33 (McAllister
et.al.) and family T (Shovlin et.al.), as well as families 5 and 8.
Table 8.2. Comparison of PAVM frequency between endoglin linked and
endoglin excluded families, using all available data from published as
well as newly ascertained families. The very low frequency of PAVMs in
the non endoglin linked HHT families is highly significant.
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Chapter 9. Discussion
A.CIinical Features of Hereditary Haemorrhagic Telangiectasia.
i. Clinical Differences between HHT1 and HHT2
Data from patients were, on the whole, obtained during short visits to large
family groups. Data collection from the American families was further
complicated by lack of permission to contact the patient's own medical
practitioner, preventing detailed examination of case notes for confirmation
of all symptoms reported. In this situation it was not possible to request any
detailed screening tests as a part of the research project.
All conclusions are, therefore, based on reported symptoms and simple
screening tests available during the family visits.
Patients with mutations in either Endoglin or ALK-1 were prone to severe
epistaxis and transfusion dependant gastro-intestinal haemorrhage. The
incidence of gastro-intestinal haemorrhage was the same in Endoglin and
ALK-1 patients.
However, in families with mutations in the endoglin gene, or those with
established linkage to chromosome 9, the incidence of pulmonary
arteriovenous malformations (PAVMs) was statistically much higher than in
those with ALK-1 mutations.
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The higher incidence of PAVMs in those with endoglin mutations remains
to be explained. To date none of the British or American families with
known ALK-1 mutations, either contacted in this study, or the earlier one by
Porteous et.al. (1992) have evidence of a pulmonary arteriovenous
malformation. There have been preliminary reports of two patients with
PAVMs in a large Mormon kindred with a known ALK-1 mutation.
(Macdonald personal communication).
There are clinical implications for patient management arising from this
finding. People with endoglin mutations are at a definite high risk of having
assymptomatic PAVMs and developing the associated complications. They
represent a particularly high risk subset of HHT patients and should be
carefully screened with an established effective technique for detecting
PAVMs. Patients with a family history of PAVMs are more likely to have
endoglin mutations and should also be considered to be at high risk.
Current evidence would suggest that chest x-ray and arterial blood gas
measurement or pulmonary arteriovenous shunt measurement are the
best modalities for clinical screening.
Clinical screening for patients with ALK-1 mutations is a more complex
issue. Given the very small number of patients with known ALK-1
mutations and PAVMs, none of whom have been published, patients with
ALK-1 mutations can be reassured that their risk of having a PAVM is low.
Currently it is still sensible to advocate simple screening techniques such
as chest x-ray and pulse oximetry for patients with ALK-1 mutations, until
this situation is clarified.
There have been several reports of CAVMs clustering within families and
occurring in association with PAVMs. Family 6 described in this text has
two living individuals with PAVMs, one of whom had a symptomatic CAVM
which required neuro-surgery. In the same family, an individual who died
shortly before they were assessed had both PAVMs and a CAVM.
As yet, the case for screening for CAVMs in HHT is unproven, as it
remains uncertain whether pre-symptomatic screening or treatment of
CAVMs is beneficial.
iii Potential Diagnostic Tests.
While many people with HHT have florid symptoms and present no
diagnostic difficulty, particularly at a young age, patients can show few
symptoms.
Mutation analysis from genomic DNA is now possible both for Endoglin
(McAllister et.al. 1995, Marchuk 1997) and ALK-1 (data presented above).
An early diagnostic test will allow pre-symptomatic testing of individuals. In
those who are unaffected, it will allow them to be reassured that they are
not at risk of developing symptoms, and they will not need screening for
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PAVMs and CAVMs. In the future, with increased understanding of the
disease, it may be possible to initiate treatment before symptoms develop,
or at least to avoid factors which may be shown to cause deterioration of
skin, gut and nose lesions. Presence of an Endoglin mutation in an
asymptomatic patient would justify screening for PAVMs.
As discussed above, being able to differentiate between HHT1 and HHT2
is of some benefit in sparing patients screening investigations that are both
expensive and uncomfortable. Further studies are necessary to establish
whether this can usefully be applied to a clinical setting. In the future,
assays of endoglin protein expression by monocytes may be useful in
replacing DNA analysis.
B How Mutation in the ALK-1 Gene Leads to Disease.
i.The effect of mutation on the ALK-1 gene expression and function
All the mutations reported so far in the ALK-1 gene leave the
transmembrane domain of the protein intact,10 mutations disrupt the
kinase domain, either by frame shift, premature stop or altering a highly
conserved amino-acid. Two of the mutations would be expected to alter
important amino acids in the extracellular domain, but do not cause a
frame shift.
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It is possible that all the mutations lead to a null allele for ALK-1 or a null
allele equivalent, a version of the protein which has no biological action.
The initial studies of ALK-1 using rtPCR from whole blood RNA showed the
mutant allele in some reactions but not others. However as expression of
ALK-1 in blood is probably at a very low level, rtPCR is not a reliable
indicator of ALK-1 expression in endothelial cells.
Alternatively, a defective ALK-1 protein product that is necessary for the
disease pathogenesis might be produced. There are, therefore, three
possible hypotheses for the way mutation in ALK-1 affects the endothelial
cell. These will be dealt with in turn.
a.Haploinsufficiency forALK-1
The absence of one functioning ALK-1 allele in endothelial cells may be
sufficient to cause the disease. Cells with a lower level of ALK-1
expression than normal might be more susceptible to an insult which
irreversibly triggers the formation of a telangiectasis. Such an insult could
be an external stimulus with subsequent failure of a normal repair
mechanism due to insufficient ALK-1 signalling, or the level of ALK-1
expression might drop below a particular threshold, causing susceptibility
to hydrostatic pressure in the vessel. This mechanism is consistent with
the location of telangiectases which arise more or less at random, but in
very specific locations. The mouth, ears, nose and fingers are particularly
exposed to heat, cold and trauma, whereas the trunk is less vulnerable.
b. A Second Genetic Hit at the ALK-1 Locus
A second somatic mutation leads to loss of the wild type ALK-1 allele in an
endothelial cell with subsequent formation of a telangiectasis. The genetic
insult may arise during foetal life, but the lesion will remain dormant until a
further external stimulus causes it to enlarge. However the microscopic
studies of the skin lesions, showing dilatation of the terminal venule as the
first visible lesion, rather than a proliferative event makes this hypothesis
seem less likely.
However, in adult polycystic kidney disease type 1 (APKD-1), the epithelial
cells lining cysts have been shown to have loss of the functioning copy of
the APKD-1 gene. (Brassier and Henske 1997, Quian et.al. 1996). The
cysts are not usually present in the kidney at birth, but appear in varying
numbers during childhood and adult life. Their enlargement as cysts is not
a neoplastic process. Similarly, in HHT, loss of a functioning copy of ALK-1
in endothelium during embryological development may predispose a region
to the formation of vascular malformations, without predisposing to cell
proliferation.
c. A Dominant Negative Effect on Receptor Function.
Expression of the mutant ALK-1 protein might interfere either with the
activity of the normal ALK-1 protein, or with another signalling molecule,
causing a greater than 50% reduction in effective ALK-1 signalling within
the cell. For this to be the case, the component of the signalling complex
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has to be present in limiting concentrations. This could be either ALK-1
itself, the type II receptor, ligand or the downstream signalling molecule. In
favour of this hypothesis, several workers have shown that the
overexpression of a non functioning type I receptor can act in a dominant
negative fashion (Feng et.al. 1995, Yamomoto et.al. 1996). However,
these experiments were performed in cultured cell systems and are
unlikely to accurately demonstrate the true effect in vivo. One study has
shown a low TGF-(3 receptor type II level in endothelial cells dividing in 3
dimensional culture, which has decreased from when the cells are grown
as monolayers, suggesting that TGF-p receptor type II concentration may
be a control mechanism and may indeed be at a limiting concentration
(Sankaar et.al. 1996). This model, however fails to explain how discreet
lesions occur at random locations.
The mechanism by which endoglin mutation causes HHT also remains
unclear, haploinsufficiency, two hit and dominant negative hypotheses
have all been suggested, although recent discovery of several true null
mutations has made the dominant negative hypothesis seem unlikely for
this gene. (Shovlin et.al. 1997, Marchuk et.al. personal communication).
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C. The Interaction Between Endoglin and ALK-1
I. Interaction at the cellular level.
The discovery that mutations in both endoglin and ALK-1 could cause a
very similar phenotype suggested an interaction between these two
molecules in the endothelial cell. There are three possible ways that this
interaction could occur, either individually or in combination. These are
shown diagramatically in figure 9.1.
a.Endoglin interacts directly with ALK-1 in a signalling complex.
The presence of endoglin on the endothelial cell surface facilitates
signalling by ALK-1 (Figure 9.1a). This need not be an exclusive
interaction, and endoglin may be involved with the TGF-p receptor complex
as well. However there is, as yet, no direct evidence of a direct interaction
between ALK-1 and Endoglin, but a protein molecule of the size of ALK-1
has been shown to co-precipitate when endoglin is precipitated with a
monoclonal antibody.
B. Endoglin changes local concentration of TGF-p without involvement in
signalling.
Endoglin acts as a TGF-p binding protein in its own right without apparent
signalling activity. It has been shown to be present in serum and extracellular
matrix, where it has presumably been released from the endothelial cell
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surface. In a similar situation, betaglycan has been shown to sequester TGF-
P2 in the extracellular matrix, possibly acting as a slow release mechanism.
Lower endoglin concentrations in extracellular matrix might be responsible for
higher peak activity of TGF-p signalling through the ALK-1 receptor, followed
by rapid fall-off in signal. (Figure 9.1b)
c.Endoglin acts through a separate signalling complex to ALK-1.
Endoglin interacts with a different signalling complex to ALK-1, but that the
pathways of these two signalling complexes interact within the cell (Figure
9.1c).
ii. Why Endoglin mutations cause a higher incidence of PAVMs
The reason why endoglin mutation predisposes individuals to developing
PAVMs remains unclear. Recent evidence also suggests that patients with
endoglin mutations have earlier onset of symptoms (Porteous et.al. 1997).
This implies one of three possibilities.
a. Endoglin has an effect on other pathways in addition to ALK-1 signalling.
The expression of endoglin in cell types other than endothelial cells, and the
interaction between endoglin and the TGF-p receptor type I suggest that
this is the case. It may or may not be significant in the pathogenesis of the
disease.
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Figure 9.1a. The first hypothesis that endoglin interracts
directly with the ALK-1 signalling complex.
IH
Figure 9.1b. Endoglin, possibly located in the extracellular
matrix, acts as a reservoir for TGF-p, releasing it to allow
signalling through the ALK-1 signalling complex. Alternatively,
the presence of endoglin on the cell surface might increase the
concentration of TGF-p close to the cell surface without
interacting directly with the receptor complex.
\IS~
Figure 9.1c. Endoglin functions in conjunction with the TGF-p
receptor complex. ALK-1 signals independantly (with either the
same or a different ligand and type II receptor), the signalling
pathways interact within the cell.
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b. Inability of the endothelial cell to compensate for endoglin deficiency.
The endothelial cell may be less able to compensate for endoglin
deficiency than ALK-1 deficiency. Endoglin may have a unique role in the
endothelial cell, whereas ALK-1 is known to have several homologues
expressed in the same cell type. These include the activin and TGF-p
receptor type I. One of these may be partially active in the same signalling
pathways as ALK-1. Loss of ALK-1 signalling may therefore be partially
compensated by these receptors. This conservation may be a important in
early lung development and similarly may make the enlargement of pre¬
formed lung lesions to clinically detectable size less likely in the case of
ALK-1 deficiency.
c. Endoglin is important earlier in fetal development.
Endoglin might have an important role in early development of fetal
vasculature that is not shared by ALK-1, particularly in the lung. The
possibility that PAVMs are abnormalities of fetal development is not a new
idea (Wirth et.al. 1996), enlargement of lesions to detectable size could
occur with age and hormonal change.
iii A new model for ALK-1 and Endoglin interaction in HHT causation.
Given the small amount of knowledge, any model for the interaction
between endoglin and ALK-1 is purely speculative. Such a model has to be
designed to take into account the known facts of endoglin interaction with
the TGF-p receptor complex (Lastres et.al. 1996) with apparent
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modification of TGF-p signalling in the monocyte, as well as the degree of
shared phenotype between endoglin and ALK-1 mutation. The existence of
other receptors, signalling pathways and downstream interacting proteins
in the cell cannot be ignored.
At the cell surface, it could be hypothesised that endoglin enhances ALK-1
signalling, but inhibits aspects of TGF-p signalling through the TGF-p
receptor type I. Increased expression of endoglin in an endothelial cell
would decrease TGF-p receptor type I signalling, but increase ALK-1
signalling.
If the ligand for ALK-1 is TGF-p, this would lead to a balance between
TGF-p and ALK-1 signalling in the cell, which would in part be controlled by
level of endoglin expression (Figure 9.2). Loss of ALK-1 signalling would
therefore reduce ALK-1 signalling alone without direct effect on the TGF-p
receptor. Reduction in endoglin would not only cause reduced ALK-1
signalling, but also increased TGF-p signalling. There would also be an
effect of endoglin mutation in situations where ALK-1 was not expressed,
but TGF-p receptor I signalling was important.
Further experimentation, determining the true ligand for ALK-1 and effect
of ALK-1 signalling on endothelial cell growth in conjunction with endoglin






Figure 9.2. Model for the role of ALK-1 and endoglin. The expression of
endoglin increases signalling through the ALK-1 signalling complex, and
reduces signalling through the TGF-p complex. This would alter the balance
between endothelial cell differentiation and endothelial cell proliferation.
D. The Genomic Structure of ALK-1
i.Potential start sites and promoters of ALK-1 transcription
The two published sequences for the full length ALK-1 cDNA are identical
in the coding region, but have different alternative 5' untranslated regions.
The sequences diverge 7 base pairs upstream from the putative start
codon.
When a comparison is made between the genomic structure and the
published sequences, the sequence published by Attisano (Attisano et.al.
1993) begins in exon 2, reading through the transcription start site which is
also in exon 2. The sequence published by ten Djike et.al. starts in exon 1
and splices to a consensus splice junction 7bp upstream from the start
codon. Both published sequences were determined by 5' race, and it is
possible that the sequence published by Attisano is the result of genomic
contamination in one of the RACE reactions.
Alternatively, there may be two alternative transcription start sites for
ALK-1, implying the existence of two different promoter regions. This might
be a control mechanism, with the two different promoters responsive to
different factors, either in the same type of cell, or in different tissues.
A large (approx 4.4kb) transcript as well as a 2.2 kb transcript is identified
on northern blotting by using the extracellular domain of ALK-1 as probe.
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This could be an alternative 5' untranslated region or an alternative 3'
untranslated region, which may have a regulatory mechanism. The size
differences between the published ALK-1 cDNA sequences are not
sufficient to explain the different transcript sizes, although the published
sequences may not be full length. Alternatively the large transcript may
represent an alternative coding region or an undiscovered homologue of
ALK-1.
ii Splice positions within the ALK-1 gene.
None of the ALK-1 gene exons are exceptionally large or widely spaced.
The coding region of the gene spans less than 20kb of genomic DNA with
exon 1 lying 5.5kb upstream. A comparison of the splice junctions between
intracellular domains of ALK-1 and the mouse putative TGF-(3 receptor
type I TSK-7L. showed homology within the kinase domain, but marked
differences in the extracellular domain. The position of introns in both ALK-
1 and TSK-7L is almost identical between exons 4 and 10. All four splice
sites between exons 5,6,7,8 and 9 fall between 1st and second bases of a
codon encoding a neutral amino acid. This is the case in both human ALK-
1 and mouse TSK-7L. This may be a result of the common ancestry of the
intracellular domains, but the degree of conservation suggests a possible
function. The positioning of splice sites would allow alternatively spliced
products of ALK-1 to be formed which would remain in the same frame, but
would be expected to have variant kinase activity. However, at present,
there is no current evidence to suggest that alternate splicing is
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physiologically important. Alternative splicing of a different nature has been
shown to occur with other members of the serine-threonine kinase receptor
family in both humans and Drosophila. (Attisano et.al. 1992)
The conservation of position of introns within the kinase domain of two
related type I serine threonine kinase receptors from different species,
indicates that this is likely to be conserved in many other related
molecules, facilitating the determination of genomic structure of other
type I serine-threonine kinase receptors.
iii Non-Consensus splice sequence 5' of exon 6
The splice sequence 5' to exon 6 varies marginally from the expected
consensus. Rather than the expected donor splice consensus CRG/gtagag
the sequence at this site is TAG/gcaag. While this is unusual, a
computerised survey of such non-consensus splice donors (Senapathy
et.al. 1990) has shown the TAG/gcaag to be the most common variant.
The function of this variant splice sequence is unknown, it may be of no
functional significance. The recently described variant consensus AT-AC
has been shown to require its own family of proteins for splicing (Tarn and
Steitz 1996), adding a specific splicing control mechanism. However, there
is no reason to suspect that this is the case for the G/gcaag splice variant.
If the splice variant at this site has a function, it may affect the proportion of
correctly spliced ALK-1 message containing exon 6 that is formed.
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E. Degenerate rtPCR revealing the presence of DPC4 in endothelial cells.
The only members of the MAD protein family identified by degenerate
rtPCR from endothelial cell RNA were DPC4 and MADR1.
As the DPC4 was successfully amplified in a single round of PCR, using
primers to amplify from the 5' conserved domain to the 3'conserved
domain, it seems likely that DPC4 is expressed at significant levels in
endothelial cells. The absence of other MAD protein homologues in the
reaction is most likely to be due to one of several factors which enhanced
DPC4 amplification preferentially. The reaction conditions used may have
favoured DPC4 amplification, or the DPC4 may have been in higher
concentration and therefore preferentially amplified. Alternatively the other
homologues may have had a variation in sequence at the primer sites, not
taken into account during primer design.
It is not known whether the ALK-1 signalling pathway itself involves DPC4.
DPC4 (OMIM *600993) was first identified as a tumour suppresser gene
deleted in pancreatic carcinoma. It seems unlikely that DPC4 gene
mutations would cause HHT, as a phenotype involving other tissues,




Clinical Features of HHT
At the clinical level, this study has shown that despite diagnostic
difficulties, due to the frequency of nosebleeds in the general population,
clinical diagnostic criteria can be drawn up which if fulfilled enable a
positive diagnosis to be made. There will still remain a number of patients,
usually at a younger age for whom diagnosis is difficult on clinical grounds.
It has also been conclusively demonstrated that patients with endoglin
mutations have a much higher rate of pulmonary arteriovenous
malformations and therefore of associated complications. In this study, no
patients came to light who had ALK-1 mutations and a pulmonary
arteriovenous malformation. It is unknown whether PAVMs will remain
exclusively associated with endoglin mutations. There is a subjective
impression that cerebral arteriovenous malformations are more commonly
associated with endoglin mutation, but this remains to be confirmed. It has
not, so far, been possible to draw conclusions about other features of the
disease.
The presence of an endoglin mutation in a family, or a family history of
PAVM is therefore an indication for early screening of all family members
for asymptomatic PAVMs. Further work is required to say whether patients
with ALK-1 mutations are genuinely "safe" from the point of view
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of PAVMs and CAVMs, or should be screened, but in a less aggressive
manner.
Molecular genetics of HHT.
The detection of a large number of mutations in ALK-1 in patients with
HHT confirms that this is the HHT2 locus. The additional fact that all the
large families we have studied either show linkage to chromosome 9q34,
chromosome 12q 13, or have mutations in ALK-1 (on 12q13) suggests that
involvement of any third locus for HHT is likely to be rare, possibly with a
distinct phenotype. The Italian family reported with a high incidence of liver
involvement may be an example of such a family.
The method for genomic sequencing of ALK-1 proved very successful
(detecting mutations in all of the chromosome 12q34 linked families
studied) and is applicable in a clinical setting. The low incidence of PAVMs
in this group makes discovery of a mutation reassuring for the individual
affected, although ideally, a good laboratory test for endoglin mutations
would also be clinically useful.
The nature of mutations found in combination with in vitro data on other
serine-threonine kinase receptors is compatible with the hypothesis that
expression of a mutant ALK-1 protein is necessary for disease to occur.
However there is currently no direct evidence to favour this dominant
negative hypothesis over the hypothesis that haploinsufficiency for ALK-1
is sufficient to cause disease. The implications for novel therapeutic
approaches to HHT include pharmacological means of raising ALK-1
expression or signalling in endothelial cells.
ALK-1 receptor function.
The function of ALK-1 remains unknown, although its identification as the
HHT2 gene suggests that it has an important role in vascular endothelium.
This could be either in controlling the response of differentiated vessels to
injury, in maintaining the structure of differentiated small vessels, or in
controlling angiogenesis and blood vessel formation.
The fact that mutations in both ALK-1 and Endoglin cause a similar
disease suggests that they both have a role in the same endothelial cell
pathway. The nature of this interaction, either directly at the cell surface, or
intracellularly remains to be determined.
The true ligand and intracellular signalling pathway for ALK-1 remain
unknown. The demonstration of DPC4 expression in the endothelial cell is
the first report of this, but mainly serves to underline that these molecules
are involved in signalling in many cell types. It is not known from this study
whether DPC4 is involved in ALK-1 signalling.
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Future Research.
With the availability of a gene-based test for ALK-1 mutations, the potential
clinical impact of this needs to be assessed in a formal trial. For endoglin
mutations, molecular testing requires further refinement, and in the long
term, endoglin expression levels by monocyte derived cell lines may prove
a quicker and more effective test.
The ability to differentiate at the molecular level between HHT1 and HHT2
will enable further study to identify the clinical differences between the two.
This will allow future targeting of screening on those at risk of specific
complications. Identification of the genetic factors that act as modifier loci
for HHT, for example, pre-disposing to development of PAVMs may prove
possible in the future. As well as providing further insight into the genetic
basis of HHT, this may also allow identification of individuals at particular
risk.
Study towards further understanding of how ALK-1 and Endoglin interact
and signal will be important, both for understanding signalling in the
endothelial cell, as well as identifying future means of treatment for HHT.
Further investigation of the promoter region may identify factors which
enable up-regulation of ALK-1 expression as a possible means of
treatment for HHT. Identification of promoter elements which control
endothelial specific gene expression may prove important in future gene-
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therapy approaches aiming to introduce cell-specifically expressed genes
into cells.
The expression pattern of ALK-1 remains to be fully determined. As well as
the tissue distribution, it is unknown whether ALK-1 is expressed at
different stages of the cell cycle, and what effect ALK-1 signalling has on
the cell.
The construction of knockout mice for endoglin and ALK-1 is the next step
likely to give significant insight into how these genes function and cause
disease. They may also prove to be valuable models for novel therapeutic
approaches.
Understanding the control of blood vessel growth and differentiation may
prove important in the treatment of disorders other than HHT. Many
common disorders involve abnormal blood vessel development or function.
Diabetic retinopathy and retinopathy of prematurity involve the
development of fragile blood vessels at the back of the eye. All forms of
tumour require the recruitment of blood vessels in order to grow. Control of
blood vessel growth is, therefore, one potential therapeutic target in the
treatment of many common forms of disease.
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Appendix A. Genbank submission of sequence generated during this work.
LOCUS HSALK01 460 bp DNA PRI 01-JUL-1997







Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Hominidae;
Homo.
REFERENCE 1 (bases 1 to 460)
AUTHORS Berg,J.N., Gallione.C., Stenzel.T. and Marchuk.D.
TITLE The activin receptor like kinase 1 gene - genomic structure of the
coding region
JOURNAL Am. J. Hum. Genet. (1997) In press
REFERENCE 2 (bases 1 to 460)
AUTHORS Berg,J.N., Gallione.C., Stenzel.T. and Marchuk.D.
TITLE Direct Submission
JOURNAL Submitted (08-NOV-1996) Department of Genetics, Duke University,








BASE COUNT 99 a 132 c 135 g 941
ORIGIN
1 tttccccaag ctctcagtca cttaaacatt gctctccacc cttcacctct aacaggatgg
61 tttccatggg gaagtgaacc aggacttccc ctgcaggccc cgccccaaag ccaggcggca
121 gggagtaggg aggcggcctc cctgcctccc ctccaaaaaa aactctgtga tttcctctgg
181 gcaggaggga gccacggcca gcggctgtca cacttcatgg ctcttactcc acctctcttg
241 ctcctctctg cagggaccat gaccttgggc tcccccagga aaggccttct gatgctgctg
301 atggccttgg tgacccaggg tgagtactgg gggagcagtt aggaaacagg aacctggata
361 cagaaagggc tatctgggcc cagatcagct ctgcctgggg ctgaacttga gaagctgggg
421 agaatgtagg agcttgactg gagagtggag gacagtgagg
LOCUS HSALK02 1371 bp DNA PRI 01-JUL-1997








Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Hominidae;
Homo.
REFERENCE 1 (bases 1 to 1371)
AUTHORS Berg,J.N., Gallione.C., Stenzel.T. and Marchuk.D.
TITLE The activin receptor like kinase 1 gene - genomic structure of the
coding region
JOURNAL Am. J. Hum. Genet. (1997) In press
REFERENCE 2 (bases 1 to 1371)
AUTHORS Berg,J.N., Gallione.C., Stenzel.T. and Marchuk,D.
TITLE Direct Submission
JOURNAL Submitted (08-NOV-1996) Department of Genetics, Duke University,


















BASE COUNT 246 a 353 c 516 g 2561
ORIGIN
1 gttctaggga aggatgactg aggatgaaag taagagacca aagcttcaag gtgtttgtct
61 gaggggtcag acgagaggga cagtaggaca gaaatgggtg tcgggctcag cctgggggag
121 ctgggaccac agtggctgag cttccggtgt gtcttccagg agaccctgtg aagccgtctc
181 ggggcccgct ggtgacctgc acgtgtgaga gcccacattg caaggggcct acctgccggg
241 gggcctggtg cacagtagtg ctggtgcggg aggaggggag gcacccccag gaacatcggg
301 gctgcgggaa cttgcacagg gagctctgca gggggcgccc caccgagttc gtcaaccact
361 actgctgcga cagccacctc tgcaaccaca acgtgtccct ggtgctggag ggtacgtcca
421 gctgccctag cactccctcc ccatcttctt ggcccctgcc tcccttccct cctttcctct
481 catgctctgg ccaataaagg ggctgggggc gggggagcgg gtgggcagga ctctgggatc
541 taactggcag agtggtctgg cccgaggtgg ggggagctga cctagtggaa gctgagcctc
601 agtgtccccc tccctcagcc acccaacctc cttcggagca gccgggaaca gatggccagc
661 tggccctgat cctgggcccc gtgctggcct tgctggccct ggtggccctg ggtgtcctgg
721 gcctgtggca tgtccgacgg aggcaggaga agcagcgtgg cctgcacagc gagctgggag
781 agtccagtct catcctgaaa gcatctgagc agggcgacag catgttgggg gtatgggcct
841 ggggacctgg gacacagggt gtaggagggg cagataggaa ctgcagaatc agaggggtca
901 cccagagatt agagccggtg gggagctggg cgagtgagga gcttgcagtg acccagcagg
961 tcccaggtcg aggatagaga agggggctgt ggctggttgt ggcagcctct cagtggcctc
1021 tccgtacccc caggacctcc tggacagtga ctgcaccaca gggagtggct cagggctccc
1081 cttcctggtg cagaggacag tggcacggca ggttgccttg gtggagtgtg tgggtgagca
1141 gtgggtgagc ccggtggatg aggaccaagg gctctcatga gctggagggg tgagggagtt
1201 tttggctact ggaatcacag gcggtgcagg cctgggtcag ggagtgggct ggagacgggc
1261 cagggctagg ttcttctttc tgcaggaccg gggtggaacg agaggcagct gggggtggcc
1321 tgccactggg tttgggtctg gattaagtta aacctaaggg tctggggttc t
LOCUS HSALK03 317 bp DNA PRI 01-JUL-1997







Eukaryotae: mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Hominidae;
Homo.
REFERENCE 1 (bases 1 to 317)
AUTHORS Berg.J.N., Gallione.C., Stenzel,T. and Marchuk.D.
TITLE The activin receptor like kinase 1 gene - genomic structure of the
coding region
JOURNAL Am. J. Hum. Genet. (1997) In press
REFERENCE 2 (bases 1 to 317)
AUTHORS Berg.J.N., Gallione.C., Stenzel.T. and Marchuk.D.
TITLE Direct Submission
JOURNAL Submitted (08-NOV-1996) Department of Genetics, Duke University,







/note="encodes an ATP binding site and a kinase domain;
the 3' splice junction of exon 6 has a non-consensus
sequence AGgcaag, this has been reported previously in
other genes"
/number=6
BASE COUNT 67 a 84 c 101 g 641 1 others
ORIGIN
1 agggaggcag cgcagcatca agatgggggg ctcttccagg gctctgtgtg cccagtgtgt
61 aaccctcacc ttcccctctg gccatcagga aaaggccgct atggcgaagt gtggcggggc
121 ttgtggcacg gtgagagtgt ggccgtcaag atcttctcct cgagggatga acagtcctgg
181 ttccgggaga ctgagatcta taacacagtg ttgctcagac acgacaacat cctaggcaag
241 gggagaggcc agctgtgcca ggcctggggc tttgccnctg cactcagggc tcaagtttgc
301 agacctccag acattaa
II
LOCUS HSALK04 441 bp DNA PR! 01-JUL-1997







Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Hominidae;
Homo.
REFERENCE 1 (bases 1 to 441)
AUTHORS Berg.J.N., Gallione.C., Stenzel.T. and Marchuk.D.
TITLE The activin receptor like kinase 1 gene - genomic structure of the
coding region
JOURNAL Am. J Hum. Genet. (1997) In press
REFERENCE 2 (bases 1 to 441)
AUTHORS Berg.J.N., Gallione.C., Stenzel.T. and Marchuk.D.
TITLE Direct Submission
JOURNAL Submitted (08-NOV-1996) Department of Genetics, Duke University,







/note-'encodes a kinase domain"
/number=7
BASE COUNT 81a 166 c 115 g 791
ORIGIN
1 cagtgaccca gtccattccc tctcccccaa ccccaccctg accctgacga ctccagcctc
61 ccttagcccc agccccttgc tgagtcaccc aacctttctg cacacaggct tcatcgcctc
121 agacatgacc tcccgcaact cgagcacgca gctgtggctc atcacgcact accacgagca
181 cggctccctc tacgactttc tgcagagaca gacgctggag ccccatctgg ctctgaggct
241 agctgtgtcc gcggcatgcg gcctggcgca cctgcacgtg gagatcttcg gtacacaggg
301 caaaccagcc attgcccacc gcgacttcaa gagccgcaat gtgctggtca agagcaacct
361 gcagtgttgc atcgccgacc tgggtgagcc gggcggggca ggggcgcgcc cttcacaggt
421 gggcggagct tgtgcgctct c
LOCUS HSALK05 522 bp DNA PRI 01-JUL-1997







Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Hominidae;
Homo.
REFERENCE 1 (bases 1 to 522)
AUTHORS Berg,J.N., Gallione.C., Stenzel.T. and Marchuk.D.
TITLE The activin receptor like kinase 1 gene - genomic structure of the
coding region
JOURNAL Am. J. Hum. Genet. (1997) In press
REFERENCE 2 (bases 1 to 522)
AUTHORS Berg,J.N., Gallione.C., Stenzel.T. and Marchuk.D.
TITLE Direct Submission
JOURNAL Submitted (08-NOV-1996) Department of Genetics, Duke University,







/note-'encodes a kinase domain"
/number=8
BASE COUNT 93 a 168 c 151 g 1091 1 others
ORIGIN
1 atggttctct ctgtggccac tgccttccag cccatctccg tgcacgtctc catctgcctt
61 cccctctctg tcccactgtt tctctcagtc cccaccttgc ctgccccctg gatcccaggt
121 ttgggagagg ggcaggagtg acaggcctca cccccacagg cctggctgtg atgcactcac
181 agggcagcga ttacctggac atcggcaaca acccgagagt gggcaccaag cggtacatgg
241 cacccgaggt gctggacgag cagatccgca cggactgctt tgagtcctac aagtggactg
301 acatctgggc ctttggcctg gtgctgtggg agattgcccg ccggaccatc gtgaatggtg
361 agggcccacc ctacacaggg tagggaaagg ggaatcagcc tgtggagcca ggggcttcca
421 gccatggcca gtgcccatgg cctggnaggt ttgcagtcag acctcctggc accccttcca
481 tgctgcccac cagctggttc agctgagtga ccttttaagg ta
II
LOCUS HSALK06 413 bp DNA PRI 01-JUL-1997







Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Hominidae;
Homo.
REFERENCE 1 (bases 1 to 413)
AUTHORS Berg,J.N., Gallione.C., Stenzel.T. and Marchuk.D.
TITLE The activin receptor like kinase 1 gene - genomic structure of the
coding region
JOURNAL Am. J. Hum. Genet. (1997) In press
REFERENCE 2 (bases 1 to 413)
AUTHORS Berg.J.N., Gallione.C., Stenzel.T. and Marchuk.D.
TITLE Direct Submission
JOURNAL Submitted (08-NOV-1996) Department of Genetics, Duke University,







/note-'encodes a kinase domain"
/number=9
BASE COUNT 73 a 108 c 123 g 1091
ORIGIN
1 ttgcattata ctgtccctct caggggtagc gtgtccaggc cactggtttc tggcccttgg
61 atagagggta gaaaaggctc tcctctgggt ggtattgggc ctccttagag tcccaagtga
121 ttgtcctgtc cattctccat ttccaggcat cgtggaggac tatagaccac ccttctatga
181 tgtggtgccc aatgacccca gctttgagga catgaagaag gtggtgtgtg tggatcagca
241 gacccccacc atccctaacc ggctggctgc agacccggtg aggcctctgc tgggactagg
301 atggcgtggg gtggtggctc acggctggga tttctgggcc cgggaacttg tgtctgaggc
361 ctctgcttca tctcatagat actgagtgtc ctggttaggc acctctctag tac
//
LOCUS HSALK07 264 bp DNA PRI 01-JUL-1997








Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Hominidae;
Homo.
REFERENCE 1 (bases 1 to 264)
AUTHORS Berg.J.N., Gallione.C., Stenzel.T. and Marchuk.D.
TITLE The activin receptor like kinase 1 gene - genomic structure of the
coding region
JOURNAL Am. J. Hum. Genet. (1997) In press
REFERENCE 2 (bases 1 to 264)
AUTHORS Berg.J.N., Gallione.C., Stenzel.T. and Marchuk.D.
TITLE Direct Submission
JOURNAL Submitted (08-NOV-1996) Department of Genetics, Duke University,








/product-'activin receptor like kinase 1"





















/note="encodes a kinase domain"
/number=10
BASE COUNT 55 a 104 c 45 g 601
ORIGIN
1 tgacccacct ccctctgcat ctctctcccg accccctcct cttctctgca tctctctctc
61 tgcctcctct cctctgcacc tctctcccaa cccccaggtc ctctcaggcc tagctcagat
121 gatgcgggag tgctggtacc caaacccctc tgcccgactc accgcgctgc ggatcaagaa
181 gacactacaa aaaattagca acagtccaga gaagcctaaa gtgattcaat agcccaggag
241 cacctgattc ctttctgcct gcag
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Clinicaldatfromami y6.Thesisterfindiv dua s70nd4ec rebralhae orrhageca sedbyr b al arteriovenousmalformation






1. Approximately how old were you when you first had problems with HHT ?
2. Please tick the first sign Nosebleeds [ ]




3. Do you get nose bleeds Yes/No
a.) If so, how often do they happen: once or more daily [ ]
once or more weekly [ ]
once or more monthly [ ]
less than monthly [ ]
b.) Is the bleeding worst from Right Nostril ! j
Left Nostril | j
No Difference [ j
c.) How long do they last less than 5 minutes [ ]
5 to 15 minutes [ ]
Longer than 15 minutes [ ]
d.) Have you had any treatment for them Yes I No
e.) If so, what treatment ? cautery [ ]
Laser Treatment [ ]
Operation [ ]
Other [ ]
if other please specify
22222210/9/94 2
4. Do you get indigestion ? Yes/No
a.) If so, how often ? Daily [ ]
Weekly [ ]
Less often j j
b.) Do you take any treatment for it ? YfiS / No
If so, what do you take ?
c.} Have you ever had an ulcer ? Yes / NO
5. Have you ever had any bleeding into your digestive system ? YCS/NO
a.) If so, have you had any treatment for it ?
b.)What treatment have you had ?
If other, please specify.
Laser treatment [ ]
Operation [ ]
Other [ ]
6. Have you had any of the following tests ? Endoscopy Yes / No
Barium meal Yes / No
If so, was anything found ? Ulcer [ ]
Dilated blood vessels [ ]
Other [ ]
7.Are you on any other treatment for digestive problems ? Y6S/N0
If so, please specify
1333310/9/94
8.Have you ever had any chest problems ? Yes/No
a.)Please tick any in the list below :
"Abnormal Blood Vessels" (arteriovenous malformations) [ ]
Blood in your sputum [ ]
breathlessness on exercise [ ]
Other [ ]
please specify
b.)Have you ever had an Angiogram ? Yes/No
c.)Have you ever had embolisation treatment ? Yes/No
If so, what year did you first have it ?
How often have you had it since ?
9. Have you ever had a chest X-ray ? Yes/NO
Did it show anything ?
■44444410/9/94 4
10 Do you get headaches ? YBS/NO




b.) Do you ever get visual problems before a headache ? Yes/No
c.) Do you have any treatment for your headaches?


















Oxygen Saturation: supine standing
Any other findings:
Diagnosis ofHHT: Yes / No / Uncertain
-blood taken for DNA blood sent for transformation














I consent to give blood for research into Hereditary Haemorrhagic Telangiectasia.
I am happy for my records to be stored on a computer database.
I am happy for a photograph to be taken.
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Clinical heterogeneity in hereditary
haemorrhagic telangiectasia: are pulmonary
arteriovenous malformations more common in
families linked to endoglin?
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Abstract
Pulmonary arteriovenous malformations
(PAVMs) occur in up to 27% of patients
with hereditary haemorrhagic telangiec¬
tasia (HHT) and are associated with a
rate of paradoxical cerebral embolism at
presentation of up to 36%. At least two
different loci have been shown for HHT.
Mutations in endoglin have been found in
some families and the locus designated
ORW1. In other families this locus has
been excluded. In this paper we confirm
that in families linked to ORW1 there is
a prevalence of PAVMs among affected
members of 29-2%, compared to a pre¬
valence of 2-9% in families in which this
locus has been excluded (x2=19-2,
p<0-001). This information can be used to
decide how to screen HHT patients for
PAVMs.
(J Med Genet 1996;33:256-257)
Key words: hereditary haemorrhagic telangiectasia; pul¬
monary arteriovenous malformation; endoglin.
Hereditary haemorrhagic telangiectasia
(HHT), also known as Osler-Rendu-Weber
syndrome, is an autosomal dominant vascular
dysplasia characterised by mucocutaneous te¬
langiectasis (fig 1) and severe recurrent epi-
staxes. Pulmonary arteriovenous malforma¬
Famities used in this study: source of data and incidence of PA VMs within each family
Family source Endoglin Assessed by No of affected No of PA VMs
and reference (ORW1) linkage pulse oximetry family members assessed in those assessed
Family l12 No Yes 6 0
Family 212 No Yes 8 0
Family 312 No No 10 0
Family 4'2 No No 9 1
Family 5* No Yes 13 0
Family 17® No No 6 0
Family 33® No No 8 0
Family T7 No Yes 9 1
Total 69 2 (2-9%)
Family 01® Yesf No 45 13
Family 02® Yesf No 20 8
Family 32® Yesf No 11 3
Family 56® Yes* No 6 2
Family 6* Yes* Yes 5 2
Family 7* Yes* Yes 7 3
Family F7 Yes* Yes 9 3
Family A7 Yesf Yes 17 1
Total 120 35 (29-2%)
In non-ORWl linked families linkage was excluded across the candidate interval on multipoint
analysis, or by a lod of less than —2 at 0 = 0 02 with D9S61.
* Family previously unpublished (Porteous and Berg).
fORWl linkage was shown by a lod score of greater than 3 to a marker close to the candidate
region.
$Lod score of greater than 1 at 0 = 0 with D9S61, D9S63, or D9S65, close to the maximum
lod obtainable with the family.
tions (PAVMs) occur in between 4-8%
27%'2 of patients. PAVMs may be asympto-
matic, but can often cause hypoxaemia and
pulmonary haemorrhage. PAVMs also lead to
high incidence of cerebral abscesses, and ce¬
rebral thromboembolic complications occur in
up to 36% of patients at presentation.3 Most
authors recommend screening for asympto¬
matic PAVMs in HHT patients,3-5 with oc¬
clusion by embolisation of all lesions with a
feeding vessel greater than 3 mm.
Two loci for HHT have been identified. The
ORW1 locus, mapping to chromosome 9q34,
is endoglin, a TGF-|3 binding protein expressed
on endothelial cells.6-9 Recently, a second locus
on 12q has been reported.1011 Several authors
have noted a subjectively higher frequency of"
PAVMs in families showing linkage to'
ORW1.81213
In this paper we aim to address the size'J
of this difference, using data from three new!
families (fig 2) and 16 families previously^
published.71011
Diagnosis of HHT in the three new familiesj
was made by the presence of two of: recurrent!
epistaxis, mucocutaneous telangiectasis, and|
an affected first degree relative. Pulse oximetry!
was performed according to the method de-^|
scribed by Hughes4 to detect PAVMs. Three!
subjects from family 5 had a chest x ray ahdji
lung perfusion scans. Clinical details of the^j
thirteen families assessed by our group were ajj
collected before linkage data were available. Jg
For the newly assessed families, microns
satellite markers were run using accepted techr|f
niques and analysis of results was performed!
using MLINK or LINKMAP. ■ it
Of the 16 families included, eight
are not linked to endoglin on chromosomejf
Figure 1
patient.




X mO i 5 i
jAffected with telangiectasis and epistaxis © H
fAffected with PAVM, telangiectasis, and epistaxis 0 Q
^'Obligate carrier, no evidence of FIHT (•) f«1
^Unaffected O | |
fZ_cFigurs 2 Pedigrees of the three families not previously published.
pected to turn up a greater number ofasympto¬
matic PAVMs. All families were assessed
"blind" before linkage data were available.
The observed difference in PAVM frequency
is a biologically plausible finding. Endoglin
may well have a role in the development of
pulmonary vasculature which is not shared by
the other genes in which mutations can cause
HHT.
As all those with HHT are at some risk of
having a PAVM, it is important to offer screen¬
ing to all patients, at least by the method of
Hughes4 using supine and erect pulse oximetry
and chest x ray.
With members of endoglin linked families
having a 29-2% incidence of PAVMs, it is par¬
ticularly important to target screening on (1)
patients from families with HHT linked to
endoglin on 9q34, (2) patients who have a
family history of PAVMs. For these patients,
we feel that formal arterial oxygen measure¬
ment and measurement of right to left pul¬
monary shunt fraction using the 100% oxygen
method5 may be justified.
Firstly we wish to thank all the patients whose participation
made this study possible. We also wish to thank Professor J M
B Hughes for assessing members of family 5 for PAVMs and
Bernadette Farren for helping to collect samples. Particular
thanks are due to Catherine Cookson, who has funded much
of this work.
Proctor SJ. Hereditary haem-
clinical analysis. J Aled Genet
and eight families show evidence of linkage.
The majority of people in this group (93/120)
came from families large enough to achieve
a lod score of greater than 3. The data are
summarised in the table.
In the families linked to endoglin, 35/120
(29-2%) had pulmonary arteriovenous mal¬
formations. In the unlinked families, 2/69
(2-9%) had PAVMs. The difference between
these two groups is highly significant (%2= 19-2,
1 df, p<0-001).
In the endoglin linked group many of the
patients had symptomatic PAVMs. There may
be several small asymptomatic PAVMs in the
non-endoglin population, even though 36/69
were screened by pulse oximetry. This is an
unlikely source ofbias as more careful screening
of the endoglin population would also be ex-
1 Porteous MEM, Burn J,
orrhagic telangiectasia:
1992;29:527-30.
2 Plauchu H, de Chadarevian JP, Bideau A, et al. Age-related
clinical profile of hereditary haemorrhagic telangiectasia
in an epidemiologicallv recruited population. Am J Aled
Genet 1989;32:291-7.
3 White RI Jr, Lynch-Nyhan A, Terry P, et al. Pulmonary
arteriovenous malformations: techniques and long term
outcome of embolotherapy. Radiology 1988;169:663-9.
4 Hughes JMB. Intrapulmonary shunts: coils to trans¬
plantation. J R C Physicians Lond 1994;28:247-53.
5 Haitjema TJ, Overtoom TTh, Westermann CJJ, et al. Em-
bolisation ofpulmonary arteriovenous malformations: res¬
ults and follow up in 32 patients. Thorax 1995;50:719-23.
6 McDonald AIT, Papenberg KA, Ghosh S, et al. A disease
locus for hereditary haemorrhagic telangiectasia maps to
chromosome 9q33-34. Nature Genet 1994;6:197-204.
7 Shovlin CL, Hughes JxWB, Tuddenham EGD, et al. A
gene for hereditary haemorrhagic telangiectasia maps to
chromosome 9q3. Nature Genet 1994;6:205-9.
8 xVlcAllister KA, Grogg KM, Johnson DW, et al. Endoglin,
a TGF-P binding protein of endothelial cells, is the gene
for hereditary haemorrhagic telangiectasia type 1. Nature
Genet 1994;8:345-51.
9 Heutink P, Haitjema T, Breedveld GJ, et al. Linkage of
hereditary haemorrhagic telangiectasia to 9q34 and evid¬
ence for locus heterogeneity. J Aled Genet 1994;31:933-6.
10 Vincent P, Plauchu H, Hazan J, et al. A third locus for
hereditary haemorrhagic telangiectasia maps to 12q. Hum
Alol Genet 1995;5:945-50.
11 Johnson DW, Berg JN, Gallione C, et al. A second locus
for hereditary haemorrhagic telangiectasia maps to chro¬
mosome 12. Genome Res 1995;5:21-8.
12 Porteous MEM, Curtis A, Williams O, et al. Genetic hetero¬
geneity in hereditary haemorrhagic telangiectasia. J Aled
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Six novel mutations in the endoglin gene in hereditary hemorrhagic
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Hereditary Hemorrhagic Telangiectasia or Osler-Rendu-Weber
(ORW) disease is an autosomal dominant disorder characterized
by multisystemic vascular dysplasia. Genetic linkage for some
families was established to chromosome 9q34 (ORW1) (1,2)
but genetic heterogeneity was demonstrated with the identifica¬
tion of some families clearly not linked to this locus (2-5). A
predisposition for the development of pulmonary arteriovenous
malformations (PAVMs) appears to segregate in ORW1 families
(3-5). Recently, endoglin (ENG), a transforming growth factor
(3 (TGF-p) binding protein, was identified as the ORW1
locus, with three independent mutations identified in affected
individuals (6). We now report an additional six endoglin
mutations including two in previously described ORW1
families. The type of mutations observed and their location in
certain exons, with the apparent absence or under-representa-
tion of mutations in other exons, suggests a dominant-negative
mechanism of receptor malfunctioning as the molecular basis
of this disorder.
A panel of 80 DNA samples used in the initial mutation
screen included affected individuals from nine families previ¬
ously linked to 9q34 (1,3-5). Most of the remaining 71 samples
were from families with a history of PAVM involvement,
increasing the likelihood that each individual would harbor an
independent endoglin mutation.
Primers were designed to amplify 11 of the 14 endoglin
;xons as previously described (6), although some primer pairs
were redesigned to create smaller amplification products. The
revised primer sequences and reaction conditions are available
through GenBank Databank as entry G00-553-288. Hetero-
iuplex analysis was performed and PCR products were directly
sequenced as previously described (6). Table 1 catalogs the
;ndoglin mutation summary to date, including three previously
published mutations (6). Each of the mutations was seen only
in a single chromosome in over 160 total chromosomes
analyzed. Where additional family members were available,
the mutations were shown to co-segregate with the disease
ihenotype.
Newly described mutations include a C to T base pair
substitution creating a stop codon in exon 10 in a previously
described ORW1 family (4). The normal and mutant bases
were seen in direct sequencing of the PCR product (Fig. la).
Phis point mutation removes a BbvI restriction site. Exon 10
vas amplified from all available family members and digested
vith BbvI. All unaffected family members revealed the
esulting digested fragments (normal allele), whereas all affec-
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Figure 1. (a) Sequence of an exon 10 mutation in sample 1247 of family 32.
Direct sequencing reveals both the normal (C) and the mutant (T) at nucleotide
1414, which creates a premature termination at codon 472, CAG to TAG. (b)
Pedigree of family 32 denoting affected (closed symbols) and unaffected
(open symbols) individuals. Numbers beneath the symbols refer to lane
position in: (c) BbvI digests of amplified exon 10 from family 32. This
mutation removes a BbvI site in the amplification product. All unaffected
members reveal the digested doublet bands, whereas all affected individuals
show the presence of three bands, corresponding to the uncut (mutant) and
cut (normal) fragments of exon 10.
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Figure 2. Truncation mutations in relation to the structure of endoglin. A schematic of the endoglin protein is shown to scale with contributions from each
exon shown by the boxes numbered below. Amino acid residues from the first and a portion of the second exon are cleaved from the mature protein and are
shown separated from the main body of the protein. Exons 2-12 encode the extracellular domain, exon 13 encodes the transmembrane (TM) domain and exon
14 encodes the cytoplasmic domain. The position of the cysteine residues are marked with C. The approximate positions of truncation mutations, whether
nonsense or frameshifts, are shown with the asterisks. The bracket delineates the betaglycan-related amino-terminal domain of endoglin (8), which may
correspond to the TGF-fl binding domain (see text).
\
Table 1. Endoglin mutation summary r
Exon Sample no. Family no. Type of mutation
5 1152 Substitution at position 587*, creates stop codon TGG to TAG
7 8019 3186 (5) Deletion (39 bp) at position 882 (6)
7 1159 Substitution at position 831, creates stop codon TAC to TAG (6)
8 1275 56 (4) Substitution at position 1050, creates stop codon TGT to TGA
8 1160 Insertion (1 bp) at position 1111, frameshift creates premature stop codon
10 1247 32 (4) Substitution at position 1414, creates stop codon CAG to TAG
11 2061 Deletion (2 bp) at position 1553, frameshift creates premature stop codon (6)
11 1162 Deletion (1 bp) at position 1655, frameshift creates premature stop codon
11 2241 Deletion (2 bp) at position 1550, frameshift creates premature stop codon
*Positions in endoglin as in reference 6.
ted family members revealed the uncut fragment (mutant
allele) in addition to the digested fragments (normal allele)
(Fig. lb and c). Additional mutations are listed in Table 1.
Mutations have currently been identified in exons 5, 7, 8,
10 and 11, and all but one would produce a truncated protein
if translated. We have not detected mutations in exons 2, 4, 6,
12, 13 and 14 using heteroduplex analysis and we have yet to
develop PCR assays for exons 1, 3 and 9. The mutations
observed thus far appear to cluster in a defined region when
mapped to the endoglin protein (Fig. 2). For reference, exon
1 of the endoglin gene contains the cleaved signal peptide,
exons 2-12 contain the extracellular domain of the mature
endoglin, exon 13 contains the transmembrane domain and
exon 14 contains the intracellular domain (6).
We had originally proposed a cellular-recessive model sug¬
gesting that endoglin mutations were loss-of-function alleles
requiring somatic inactivation of the normal allele for vascular
lesion development (6). With the apparent clustering of prema¬
ture termination mutations observed in exons 5-11, we now
propose a model involving the translation of a truncated protein
product rather than a complete loss-of-function of the endoglin
gene product. This dominant-negative model would suggest
that the normal endoglin function is disrupted as a consequence
of an effect caused by the mutant protein.
Endoglin is a homodimeric integral membrane glycoprotein
expressed constitutively on vascular endothelial cells of capil¬
laries, arterioles and venules (7). Endoglin binds TGF-P 1 and
TGF-p3 with high affinity (8). Transforming growth factor-P
modulates several processes of endothelial cells including
migration, proliferation, adhesion and extracellular matrix
composition and organization (9). Perturbation of any one or
a combination of these effects may lead to the development
of the vascular lesions seen in ORW.
Endoglin is isolated from endothelial cells as a homodimer
that can be dissociated by reducing agents (7,10). In affected
individuals we postulate the assembly of normal/mutant hetero-
dimers which do not function properly or which lead to rapid
turnover of the receptor complex. Three cysteines are present
in the processed endoglin protein prior to the first known
truncation mutation in exon 5 (Fig. 2). One or more of these
may be required for inter-molecular disulfide linkage, which
might explain the apparent lack of truncation mutations prior
to exon 5. Binding of TGF-P may also be required for the
dominant-negative effect. The TGF-P binding domain of
endoglin is not known, but this domain has been mapped in
betaglycan (the type III TGF-P receptor), a related TGF-P
binding protein. Deletion of the amino-terminal endoglin-
related domain of betaglycan abolishes TGF-p binding activ¬
ity (11).
Alternatively, the mutant endoglin allele might produce a
soluble polypeptide which can bind and sequester the TGF-P
ligand. Deletion mutants of betaglycan which remove the
transmembrane and cytoplasmic domains produce soluble
polypeptides which can bind TGF-P and inhibit TGF-P binding
to membrane receptors (11). In the same way, soluble endoglin
may act as an antagonist of TGF-P signaling.
For either of the proposed mechanisms, and in light of the
observation that the vascular lesions of ORW are localized
and discreet, we hypothesize that an initiating event is required
to generate each lesion. This event could be endothelial wall
damage due to thrombus formation or local inflammation.
Endothelial cells having compromised endoglin function might
respond poorly to TGF-P and form abnormal vessels or be
deficient in repair of the vessel wall following such damage.
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Hereditary hemorrhagic telangiectasia (HHT) or Osler-Rendu-Weber (ORW) disease is an autosomal
dominant vascular dysplasia. Initial linkage studies identified an ORW gene localized to 9q33-q34 but with
some families clearly excluding this region. A probable correlation in clinical phenotype between the
9q3-linked families and unlinked families was described with a significantly lower incidence of pulmonary
arteriovenous malformations observed in the unlinked families. In this study we examined four unrelated
ORW families for which linkage to chromosome 9q33-q34 has been previously excluded. Linkage was
established for all four families to markers on chromosome 12, with a combined maximum lod score of 10.77
(0 = 0.04) with D12S339. Mapping of crossovers using haplotype analysis indicated that the candidate region
lies in an II-cm interval between D12S345 and DI2S339, in the pericentromeric region of chromosome 12. A
map location for a second ORW locus is thus established that exhibits a significantly reduced incidence of
pulmonary involvement.
Hereditary hemorrhagic telangiectasia (HHT) or
Osler-Rendu-Weber (ORW) disease is an autoso¬
mal dominant multisystemic vascular dysplasia.
The three primary types of angiodysplasia exhib¬
ited are telangiectases (mucosal, dermal, and vis¬
ceral), arterial venous malformations (AVMs, par¬
ticularly pulmonary, cerebral, and hepatic), and
aneurysms. Penetrance is age dependent but is
considered nearly complete by age 40 (Plauchu et
al. 1989; Porteous et al. 1992).
The most common clinical feature of ORW is
recurrent epistaxis from vascular lesions in the
nasal epithelium, which affects -90% of ORW pa¬
tients (Aassar et al. 1991). Cutaneous telang¬
iectases are seen in -70% of affected individuals
(Brant et al. 1989; Plauchu et al. 1989). Gas¬
trointestinal bleeding occurs in -20% of ORW pa¬
tients (Reilly and Nostrant 1984; Vase and Grove
1986). Pulmonary arteriovenous malformations
Corresponding author.
E MAIL march004@mc.duke.edu; FAX (919) 684 2790.
(PAVMs) occur in -20% of ORW patients (Dines
et al. 1974) and are associated with serious com¬
plications including stroke and brain abscess
(White and Pollak 1994). Neurologic manifesta¬
tions include cerebral arteriovenous malforma¬
tion, aneurysm, and migraine headache (Willin-
sky et al. 1990).
Incidence rates have been calculated for the
spectrum of symptoms in a number of retrospec¬
tive and prospective studies (Reilly and Nostrant
1984; Peery 1987; Plauchu et al. 1989; Porteous et
al. 1992). Great variability of expression and se¬
verity is seen even among members of the same
family, indicating that factors in addition to the
inherited germ-line mutation contribute to the
individual's phenotype. Until recently it was un¬
clear whether all families present the entire spec¬
trum of clinical features. Differences might be at¬
tributable to either allelic or locus heterogeneity.
Genetic linkage for some ORW families was
established with markers on 9q3 (McDonald et al.
1994; Shovlin et al. 1994). This locus (ORW1) was
5:21-28 ©1995 by Cold Spring Harbor Laboratory Press ISSN 1054-9803/95 $5.00 GENOME RESEARCH 21
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subsequently shown to be the endoglin gene that
encodes a transforming growth factor-p (TGF-P)-
binding protein of endothelial cells (McAllister et
al. 1994b). Locus heterogeneity was indicated by
families that excluded linkage to this region
(Heutink et al. 1994; McAllister et al. 1994a; Por-
teous et al. 1994; Shovlin et al. 1994). Several
reports (Heutink et al. 1994; McAllister et al.
1994a; Porteous et al. 1994) have documented a
significantly lower incidence (in some cases, an
absence) of PAVMs in non-9q-linked families
when compared to 9q-linked families (ORW1). In
this report we show that at least some of the ge¬
netic and clinical heterogeneity can be explained
by a second ORW locus mapping to chromo¬
some 12.
RESULTS
Our approach to establish genetic linkage with
these families included a candidate gene ap¬
proach, based on the known map positions of
-20 growth factors (and their receptors), mitoge-
nic or growth inhibitory for endothelial cells. In
addition to these loci, members of the TGF-P re¬
ceptor superfamily, including the activin recep¬
tors and activin receptor-like kinases, were con¬
sidered candidate genes based on the identifica¬
tion of endoglin, a TGF-P-binding protein, as the
gene for ORW1 (McAllister et al. 1994b).
Linkage analysis revealed that the disease
gene in four families (Fig. 1) is linked to markers
mapping to the pericentromeric region of chro¬
mosome 12. The pairwise lod scores between the
disease gene and these markers are given in Table
1. Markers D12S85 and D12S339 showed the
highest maximum combined iod scores of 9.06
(0 = 0) and 10.77 (0 = 0.04), respectively. Marker
informativity varied considerably among the
four families, causing large differences in lod
scores for closely spaced markers. For example, in
family 67, marker D12S368 showed a much lower
lod score (maximum 0.21 at 0 = 0.21) than
marker D12S339 (maximum 3.94 at 0 = 0.05)
which is only 3 cm distal, owing primarily to un-
informative genotypes for key affected parents
67-111-10 and 67-111-19. Each family showed
highly positive lod scores with at least one of the
markers in this region (Table 1).
Informative recombinant individuals were
identified to define more precisely the candidate
interval. Haplotypes were determined across a
37-cm interval for each family, but crossovers
were scored only from affected individuals, be¬
cause of potential nonpenetrance of unaffected
members. There were no unambiguous cross¬
overs in the disease haplotypes in families 2 and
17. Affected individuals from two families (33-
IV-1 and 67-IV-5) showed crossovers between
markers D12S310 and D12S333 (Fig. 2). An af¬
fected individual in family 67 (67-IV-2) showed a
crossover between D12S345 and D12S85. These
place the disease locus in the region between
D12S345 and 12qter. One affected individual in
family 33 (33-III-3; Fig. 1) showed a crossover be¬
tween markers D12S339 and D12S85 that pro¬
vided the distal boundary for the disease locus.
The candidate interval is thus bordered by D12S345
and D12S339, an interval of 11 cm (Fig. 2).
Several individuals diagnosed as unaffected
(17-IV-3, age 20; 33-I1I-5, age 31; 33-III-9, age 27;
67-III-2, age 45; 67-IV-7, age 40; 67-IV-10, age 34;
and 67-IV-ll, age 49) showed the disease haplo-
type through most or all of the region, including
the entire 11-cm candidate interval. These may
represent complex recombinants or, more likely,
nonpenetrant individuals. The four individuals
from family 67 caused the maximum lod score to
occur at a 0 = 0.13, rather than at zero with
marker D12S85.
Significantly, no individual diagnosed as af¬
fected from any of these families shows an unaf¬
fected (normal) haplotype. Diagnoses in our non-
9q3-linked families were often difficult, perhaps
because of lower penetrance or expressivity of the
ORW2 locus compared with ORW1. However,
only those individuals meeting the previously de¬
fined stringent diagnostic criteria were assigned
an affected phenotype. From our observations we
believe there also may be a delayed age of onset
of symptoms in ORW2, but the limited data do
not justify gross revision of the age-dependent
penetrance model used previously. Nonetheless,
when the model was changed from maximum
penetrance of 97% to 75% (age 40 and above),
evidence for linkage of ORW2 to the three most
closely linked markers remained strong (Table 2).
DISCUSSION
These data provide strong evidence for the exist¬
ence of an ORW locus mapping to chromosome
12. The centromere has been localized on the
physical map between markers D12S59 and
D12S85 (Kucherlapati et al. 1994). Based on a
comparison of physical and genetic maps,
D12S59 is located within the interval between
D12S345 and D12S85, an area contained within
22 GENOME RESEARCH
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Figure 1 Pedigree drawings of the four ORW families, using standard symbols. A




the ORW2 locus as peri-
centromeric, as our
data do not allow defin¬
itive assignment to a




ity of an ORW locus
mapping to chromo¬
some 3p22 (McAllister
et al. 1994b), based on
a two-point lod score of
1.43 in family 33 with
marker D3S1211. This
marker maps near the
TGF-|3 receptor II,
which was considered a
candidate for this lo¬
cus. The stronger statis¬
tical support for linkage
of the disease locus in
family 33 to chromo¬
some 12 (lod score of
2.64 at 0 = 0 for marker
D12S85, Table 1) sug¬
gests that the actual lo¬
cation for the ORW lo¬
cus in this family is the
pericentromeric region
of chromosome 12. No
additional families
have shown linkage to
this region of chromo¬
some 3. Thus, we have
no evidence for an
ORW locus mapping to
3p22. Likewise we have
no evidence for other
ORW loci, as we have
no families that ex¬
clude both the ORW1
locus on 9q and the
ORW2 locus on chro¬
mosome 12.
The absence of
PAVMs in ORW family
67 (first described in
this report) supports
the previously pub¬
lished observation of a
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Table 1. Pairwise lod scores between HHT and chromosome 12 marker loci
LOD scores (Z) at different recombination fractions 0
Locus Family 0.01 0.05 0.10 0.20 0.30 0.40 Zmax 0
D12S310 2 -0.90 -0.55 -0.33 -0.13 -0.06 -0.02 -0.02 0.40
17 2.12 1.97 1.77 1.35 0.88 0.37 2.15 0.00
33 -1.59 -0.37 0.01 0.18 0.12 0.03 0.18 0.20
67 -1.18 -0.38 0.01 0.29 0.28 0.15 0.31 0.24
Total -1.55 0.66 1.46 1.70 1.23 0.53 1.74 0.17
D12S333 2 -1.10 -0.46 -0.24 -0.09 -0.04 -0.02 -0.02 0.40
17 3.88 3.65 3.33 2.59 1.71 0.69 3.94 0.00
33 0.63 0.81 0.86 0.76 0.52 0.22 0.86 0.10
67 -2.92 -0.76 0.05 0.49 0.37 0.05 0.50 0.22
Total 0.50 3.24 4.00 3.75 2.55 0.94 4.08 0.13
D12S345 2 -0.97 0.22 0.56 0.63 0.43 0.14 0.65 0.16
17 3.55 3.30 2.96 2.24 1.43 0.56 3.61 0.00
33 1.20 1.36 1.37 1.15 0.74 0.27 1.38 0.08
67 -2.09 0.27 1.16 1.59 1.31 0.66 1.59 0.20
Total 1.69 5.15 6.06 5.61 3.91 1.63 6.13 0.12
D12S85 2 1.48 1.33 1.14 0.78 0.43 0.13 1.51 0.00
17 4.24 3.96 3.59 2.77 1.82 0.74 4.31 0.00
33 2.60 2.44 2.22 1.70 1.08 0.39 2.64 0.00
67 0.71 0.93 1.02 0.97 0.75 0.42 1.02 0.13
Total 9.02 8.66 7.98 6.22 4.08 1.69 9.06 0.00
D12S339 2 2.16 1.97 1.73 1.22 0.70 0.23 2.21 0.00
17 3.88 3.65 3.33 2.59 1.71 0.69 3.94 0.00
33 0.60 1.16 1.27 1.10 0.72 0.26 1.27 0.10
67 3.75 3.94 3.84 3.18 2.21 1.02 3.94 0.05
Total 10.39 10.73 10.16 8.09 5.34 2.20 10.77 0.04
D12S368 2 1.98 1.81 1.59 1.12 0.64 0.21 2.02 0.00
17 2.35 2.42 2.32 1.88 1.24 0.47 2.42 0.04
33 1.15 1.66 1.70 1.41 0.91 0.33 1.71 0.08
67 -0.70 -0.20 0.07 0.21 0.17 0.07 0.21 0.21
Total 4.78 5.69 5.68 4.63 2.96 1.07 5.75 0.07
D12S359 2 0.35 0.86 0.92 0.74 0.43 0.11 0.92 0.09
17 2.35 2.42 2.32 1.88 1.24 0.46 2.42 0.04
33 -1.18 -0.53 -0.28 -0.07 0.02 0.05 0.05 0.40
67 1.37 1.94 2.14 1.94 1.35 0.51 2.15 0.11
Total 2.89 4.69 5.11 4.49 3.03 1.13 5.11 0.11
D12S355 2 0.30 0.81 0.88 0.70 0.40 0.12 0.88 0.09
17 2.16 2.24 2.16 1.75 1.15 0.42 2.24 0.05
33 0.81 1.34 1.41 1.18 0.76 0.28 1.41 0.09
67 3.21 3.49 3.48 2.99 2.14 1.04 3.52 0.07
Total 6.48 7.88 7.93 6.63 4.46 1.85 8.00 0.08
Age-dependent penetrance of HHT was estimated using the following three liability classes: ages 0-20 (penetrance 0.2425); ages
21-40 (penetrance 0.7275); ages >40 (penetrance 0.9700).
much reduced incidence of PAVMs in other non-
ORW1 families (Heutink et al. 1994; McAllister et
al. 1994a; Porteous et al. 1994). Additional ORW1
and ORW2 families must be studied before accu¬
rate risk levels for the development of PAVMs can
be calculated.
With the establishment of a second locus for
ORW on chromosome 12, further studies are now
justified comparing both the incidence and se¬
verity of the clinical features between ORW1 and
ORW2 families. These might provide vital infor¬
mation resulting in more accurate counseling for
disease prognosis and more effective manage¬
ment of affected individuals.
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Figure 2 Graphic representation of the recombinant chromosomes
identified in ORW families that define the candidate interval. The
hatched boxes represent the minimum region where each recombina¬
tion occurred, and the dark boxes represent the chromosome 12 region
that segregates with the disease. The individuals harboring the recom¬
binants are indicated by a code consisting of the family number, the
generation number and, finally, the person number, each of which cor¬
responds to Fig. 1. Map distances are based on Gyapay et al. (1994). The
centromere is located between D12S345 and D12S85, based on a com¬
parison of genetic and physical maps.
The identification of endoglin as the gene
mutated in ORW1 (McAllister et al. 1994b) indi¬
cates the importance of TGF-P signaling path¬
ways in the pathology of this form of the disease.
The ORW2 gene may encode an endothelial cell
receptor involved in a similar process of cell sig¬
naling. Two potential candidate genes, ACVRLK1
and ACVRLK4 (activin receptor¬
like kinases), map to chromosome
12qll-ql4 based on hybridization
to a chromosome 12 hybrid map¬
ping panel (Kucherlapati et al.
1994). ACVRLK1 (ALK1) encodes a
putative cell-surface receptor with
a serine/threonine kinase domain,
expressed predominantly from en¬
dothelial cells (Attisano et al.
1993). It can associate with the
type II TGF-p receptor after overex-
pression in COS cells, although its
ligand in vivo remains unknown
(ten Dijke et al. 1994). ACVRLK4
(ALK4 or SKR2) encodes a ubiqui¬
tously expressed cell-surface recep¬
tor with a serine/threonine kinase
domain (ten Dijke et al. 1993) that
binds the growth factor activin
(ten Dijke et al. 1994). Growth of
vascular endothelial cells in cul¬
ture is inhibited by activin-A and TGF-p causes an
additive inhibitory effect (McCarthy and Bicknell
1993).
A third candidate gene that is under consid¬
eration is ITGA5, encoding the integrin oc5 sub-
unit, which together with the integrin pi subunit
forms the fibronectin receptor. The ITGA5 locus
Table 2. Pairwise lod scores between HHT and chromosome 12 marker loci, using a revised
penetrance model
Lod scores (Z) at different recombination fractions (0)
Locus Family 0.01 0.05 0.10 0.20 0.30 0.40 Zmax 0
D12S345 2 -1.22 -0.01 0.35 0.46 0.31 0.09 0.47 0.17
17 2.97 2.74 2.45 1.81 1.12 0.43 3.03 0.00
33 1.76 1.68 1.55 1.19 0.74 0.26 1.78 0.00
67 -1.21 0.60 1.22 1.44 1.12 0.54 1.45 0.18
Total 2.30 5.01 5.57 4.90 3.29 1.31 5.57 0.11
D12S85 2 1.24 1.10 0.93 0.61 0.32 0.09 1.27 0.00
17 3.41 3.17 2.86 2.16 1.37 0.53 3.47 0.00
33 2.35 2.21 2.00 1.52 0.95 0.34 2.38 0.00
67 1.22 1.20 1.14 0.97 0.71 0.38 1.23 0.00
Total 8.22 7.68 6.93 5.26 3.34 1.34 8.35 0.00
D12S339 2 1.91 1.74 1.51 1.04 1.57 0.17 1.96 0.00
17 3.05 2.86 2.59 1.98 1.26 0.47 3.10 0.00
33 0.35 0.93 1.05 0.92 0.59 0.22 1.05 0.11
67 4.54 4.27 3.89 3.03 2.02 0.09 4.60 0.00
Total 9.86 9.79 9.04 6.97 4.45 1.76 9.98 0.02
Age-dependent penetrance of HHT was estimated using the following three liability classes: ages 0-20 (penetrance 0.2425); ages
21-40 (penetrance 0.7275); ages >40 (penetrance 0.7500).
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has been mapped cytogenetically to 12qll-ql3
(Sosnoski et al. 1988). Integrin a5 is expressed in
cell types including endothelial cells, and its ex¬
pression in endothelial cells is modulated by
TGF-P (Enenstein et al. 1992). The a5pl fibronec-
tin receptor can be detected at the site of inter¬
cellular contact between endothelial cells where
it regulates the integrity and permeability of the
monolayer (Lampugnani et al. 1991). In addi¬
tion, extracellular matrix components, including
fibronectin mediate complex changes in the mi¬




Family members were interviewed and examined by a
medical geneticist. The interview included relevant medi¬
cal history information such as age of onset and pattern of
any epistaxis, evidence for the presence of pulmonary or
cerebral arteriovenous malformations, and history of gas¬
trointestinal or pulmonary bleeding. Pertinent medical
records, including chest angiography, were obtained and
reviewed when available. Individuals presenting with dys¬
pnea or cyanosis were referred for radiological examina¬
tion for PAVMs. Family history was reviewed. Physical ex¬
amination included a search for telangiectases on the lips,
tongue, oral or nasal mucosa, cheeks, fingers, or elsewhere.
Affected status was assigned based on the presence of at
least two of the following three criteria: telangiectasia, re¬
current epistaxis, and an affected first-degree relative
(McAllister et al. 1994a; McDonald et al. 1994). Informed
consent was obtained and blood samples were drawn for
DNA extraction, using standard methods.
Family Description
Four families (Fig. 1) for which linkage to the ORW1 locus
was excluded, were included in this study; family 2 (Por-
teous et al. 1994), families 17 and 33 (McAllister et al.
1994a), and family 67 (D.W. Johnson and D.A. Marchuk,
unpubl.). There were no affected individuals with clinical
evidence for PAVMs, despite attempts at uncovering po¬
tentially undiagnosed lesions. It appeared that the age of
onset of symptoms in these families was later than in the
9q-linked families described previously (McAllister et al.
1994a; McDonald et al. 1994). No other clear clinical dis¬
tinctions could be made between these and the previously
described ORW1 families.
Family 2 consists of 14 sampled individuals including
7 affected members (Porteous et al. 1994). There was a
wide range of severity of epistaxes and telangiectases
among affected individuals. Pulse oximetry and chest
X-ray showed no evidence of PAVMs. The pedigree draw¬
ings for this and the following families are shown in Fig¬
ure 1.
Family 17 consists of 24 sampled individuals, includ¬
ing 6 affected members (McAllister et al. 1994a). Frequent
epistaxis and telangiectases are also prevalent in this fam¬
ily. No family member has ever been diagnosed with a
PAVM.
Family 33 consists of 22 sampled individuals with 8
affected members (McAllister et al. 1994a). Symptoms in
the majority of affected members include epistaxis and
mucocutaneous telangiectases. One affected individual
was diagnosed as having a cerebral AVM, and one member
died of hepatic failure. No affected individuals had any
evidence of PAVMs.
Family 67 is a new kindred consisting of 30 sampled
individuals with 13 affected members. Epistaxis and mu¬
cocutaneous telangiectases are the common clinical fea¬
tures seen. One affected individual had a cerebral hemor¬
rhage, and one had a history of gastrointestinal hemor¬
rhage. Again, no affected individual had any evidence of
PAVMs.
Genotyping and Linkage Analysis
Analyses of simple sequence repeat markers was performed
as described previously (McDonald et al. 1994). Two-point
linkage analysis was also performed as described previ¬
ously (McAllister et al. 1994a). Briefly, ORW was analyzed
as an autosomal dominant disorder with age-dependent
penetrance. For estimating the age-dependent penetrance,
three liability classes were created with age ranges 0-20
(penetrance 0.2425), 21-40 (0.7275), and >40 (0.9700). For
the data presented in Table 2, penetrance for the final age
group was set at 0.7500. Disease frequency was set at
0.0001. Two-point linkage analysis was performed on a
Sun Sparc station 10 using the MLINK subprogram of the
LINKAGE computer package (v. 4.9; Lathrop et al. 1984).
Allele frequency estimates for the markers were obtained
from Genome Data Base.
NOTE ADDED IN PROOF
While this manuscript was under review a separate report
of linkage of an HHT locus to chromosome 12 was pub¬
lished (Vincent et al. 1995. Hum. Molec. Genet. 4: 945-
949).
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Mutations in the activin receptor-like
kinase 1 gene in hereditary
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T.T. Stenzel1'4, M. Speer5, M.A. Pericak-Vance5, A. Diamond6, A.E. Guttmacher7,
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Hereditary haemorrhagic telangiectasia, or Osler-Rendu-Weber (ORW) syndrome, is an
autosomal dominant vascular dysplasia. So far, two loci have been demonstrated for
ORW. Linkage studies established an ORW locus at chromosome 9q3; endoglin was
subsequently identified as the ORW1 gene. A second locus, designated ORW2, was
mapped to chromosome 12. Here we report a new 4 cM interval for ORW2 that does not
overlap with any previously defined. A 1.38-Mb YAC contig spans the entire interval. It
includes the activin receptor like kinase 1 gene (ACVRLK1 or ALK1), a member of the
serine-threonine kinase receptor family expressed in endothelium. We report three
mutations in the coding sequence of the ALK1 gene in those families which show linkage
of the ORW phenotype to chromosome 12. Our data suggest a critical role for ALK1 in
the control of blood vessel development or repair.
Hereditary haemorrhagic telangiectasia, or Osler-Rendu-
Weber (ORW) syndrome, is an autosomal dominant
multisystemic vascular dysplasia. It has an estimated
prevalence of 1 in 40,000, although this may be an under¬
estimate1. ORW is characterized by recurrent epistaxis,
muco-cutaneous telangiectases, gastro-intestinal haem¬
orrhage, and pulmonary, cerebral and hepatic arteriove¬
nous malformations; all secondary manifestations of the
underlying vascular dysplasia2. In general, affected indi¬
viduals from most ORW families present with an over¬
lapping constellation of clinical symptoms. Both variable
expression and pleiotropy of ORW can cause diagnostic
uncertainty, particularly in younger individuals, as many
of the disease features become more pronounced with
age.
Linkage studies have shown at least two distinct loci for
ORW. The first, ORW1, was located on chromosome 9q3
and subsequently shown to be the endoglin gene3-5.
Endoglin is a TGF-P binding protein expressed predomi¬
nantly by endothelial cells and placenta6'7. Most muta¬
tions in endoglin appear to be protein truncations,
suggesting a dominant-negative effect of binding protein
function8.
Locus heterogeneity for ORW was indicated by fami¬
lies which excluded linkage to endoglin4'9-11. Several
reports9-12 have documented a significantly higher
prevalence of pulmonary arteriovenous malformations
in ORW1 families when compared to non-ORWl. A sec¬
ond ORW locus (ORW2) was subsequently identified in
the pericentromeric region of chromosome 12 (refs 13,
14). ORW2 may exhibit reduced penetrance14, as a num¬
ber of unaffected adults in ORW2 families show the dis¬
ease haplotype over a broad region of chromosome 12.
We report further family assessment data and new
crossovers that narrow the candidate interval for
ORW2 to a 4-cM region on chromosome 12q. The new
candidate interval, which does not overlap that defined
previously, is based on the re-evaluation of the disease
status of the individual exhibiting a critical distal
crossover. A physical map over the region demon¬
strates that the activin receptor like kinase 1 (also
known as ALK1, ACVRLK1 or TSR1) gene maps with¬
in the ORW2 interval.
ALK1 is a type I cell-surface receptor for the TGF-P
superfamily of ligands. It shares with other type I
receptors a high degree of similarity in serine-threo¬
nine kinase subdomains, a glycine- and serine-rich
region (called the GS domain) preceding the kinase
domain, and the short C-terminal tail15'16. The ALK1
protein can associate with the TGF-P or activin type II
receptors after cotransfection in COS cells, with the
complex binding TGF-p or activin respectively15'17'18.
However the ALK1 ligand in vivo remains unknown16,
due to the promiscuity of ligand binding of type 1
receptors in cell culture overexpression systems19. The
high level of expression of ALK1 in endothelial cells
and other highly vascularized tissues (lung and placen¬
ta) and lower expression levels in other cells and tis¬
sues15 parallels that of endoglin. We report mutations
in the coding region of the ALK1 gene in ORW2
patients.
Genetic and physical map of the ORW2 interval
We originally reported an 11-cM candidate interval for
ORW2 in the pericentromeric region of chromosome
12, between D12S345 and D12S339 (Fig. I)14. New
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Fig. 1 Candidate intervals for 0RW2 based on crossovers in chromosome 12-linked ORW families. A genetic map of a portion of
chromosome 12 is shown, with distances between markers listed in cM20. A published 11-cM interval is shown as a dashed line14.
The distal crossover at D12S339 was re-examined due to uncertainty of map location of the marker and re-assignment of disease
status of the individual (see text). The remaining crossovers in clearly affected individuals give a 4-cM candidate interval between
D12S347 and D12S359, shown as a bold line. The inclusion of a crossover in an unaffected adult, shown with a dot, gives a 1-cM
candidate interval between D12S347 and D12S368.
ORW families were typed with markers in this region.
Family 3 showed a maximum pairwise lod score of
4.14 (0 = 0) with marker D12S297. Family 40 showed a
maximum pairwise lod score of 2.42 (0 = 0) with
marker D12S297, close to its maximum possible score
calculated under linkage simulation. The candidate
interval as defined by family 3 does not overlap with
the original region with regard to the distal boundary
defined by an individual from a previous ORW2 fami¬
ly. This boundary was defined by marker D12S339,
which shows a discordant position between the genet¬
ic20 and physical maps (I.M. and R.K., unpublished
observations).
In view of these apparent discrepancies, we elected
to reassess the clinical data from the discordant criti¬
cal individual from family 33 and to disregard data
from D12S339 in haplotype analysis. The distal
crossover individual from family 33 (ref. 14) has no
epistaxis or characteristic telangiectases; however, he
was previously designated as affected on the basis of
both a suspect lesion which had been excised from his
foot, and his son's epistaxis. We subsequently
obtained the micro-pathology report of the father's
lesion, which was a pyogenic granuloma, not a char¬
acteristic ORW lesion. The unreliability of epistaxis as
a diagnostic criterion was previously noted4. The
diagnosis of both individuals was thus designated
uncertain.
A crossover in an affected individual from family 3
(III-11) sets the new proximal boundary at marker
D12S347 (Fig. 2). An affected individual in family 67
(V-2) sets the new distal boundary at D12S359 (Fig.
3), giving a critical 4 cM interval for ORW2 (Fig. 1). A
crossover in an unaffected individual (67-V-8; Fig. 3)
would place the distal boundary for ORW2 at
D12S368, and would locate ORW2 within a 1-cM
interval between D12S347and D12S368 (Fig. 1).
A physical map comprising the ORW2 critical
region, defined by the flanking markers D12S347 and
D12S359, was established (Fig. 4). By adding the sizes
6 6 4 6 6 6 4
3 8 3 8 3
Fig. 2 Flaplotype analysis of Family 3 for markers on chromosome 12. The order of markers is shown at the
right of the figure. Alleles are number-coded and the disease haplotype is shown boxed. A critical crossover
that forms the proximal boundary of the ORW2 candidate region is shown in generation III, person 11.
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Fig. 3 Hapiotype analysis of family 67 for
markers on chromosome 12. The order of
markers is shown at the right of the figure.
Alleles are number-coded and the disease
hapiotype is shown boxed. A critical
crossover that forms the distal boundary
of the ORW2 candidate region is shown in
generation V, person 2. All of her affected
children show the same recombinant hap¬
iotype. The genotype at ACVRLK1 (ALK1)
is shown (D, deletion; N, no deletion).
of nonchimaeric YACs that constitute a minimal tiling
path between these two markers, the physical size of
the critical region is estimated to be 1.38 Mb. A contig
of 35 YACs and 2 cosmids in this region contains 36
markers, including ALK1, which was mapped previ¬
ously to 12ql 1—>ql4 (ref. 21). ALK4, also within the
interval, encodes the ubiquitously expressed activin
receptor IB22, and was not considered as strong a can¬
didate for this disorder.
Mutation analysis ofALK1
Although genomic sequence for
ALK1 was not available for muta¬
tion analysis, two groups have
reported sequence for its cDNA15,23.
Northern blot analysis of different
tissues shows two ALK1 transcripts,
of approximately 2.0 and 4.0 kb,
expressed in approximately equal
proportions. However both research
groups have sequenced multiple
cDNA clones for ALK1, and only a
single open reading frame has been
found. We obtained cDNA sequence
of ALK1 by RT-PCR of lymphocyte
or lymphoblast RNA from four
affected individuals, members of
families 17, 33, 40, and 67, which
show genetic linkage to this region.
(Family 3 was unavailable for resampling.)
A 3-bp deletion was detected in the sequence of the
amplified cDNA of ALK1 from an affected member of
family 67 (Fig. 5). The deletion segregates with the dis¬
ease phenotype in this large family (Fig. 3). A few
unaffected individuals also have this deletion, but
these all showed the disease hapiotype throughout the
entire candidate interval and are presumed non-pene-
trant. This deletion in the kinase subdomain II
Fig. 4 Physical map of chromosome 12
showing the ORW2 critical interval and
the location of ALK1. The horizontal line
at the top of the figure represents a por¬
tion of the q arm of chromosome 12, with
the centromere to the left and qter to the
right. Marker names are noted above the
horizontal line and correspond to the
symbols underneath. Markers whose rela¬
tive order could not be established unam¬
biguously are enclosed in a bracket. The
genetic distance in cM as derived from
the Genethon linkage map is indicated for
the appropriate markers as the number
below the horizontal line. Markers present
on individual YACs are shown by corre¬
sponding symbols: highly polymorphic
markers appear as circles, monomorphic
markers are represented as squares,
genes are denoted as triangles. YAC
addresses are shown next to individual
YACs. Square brackets on YACs point to
the absence of markers in that position.
YACs mapped using FISH are indicated
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Fig. 5 a, cDNA sequence of the middle section of ALK1 ampli¬
fied from RNA from the proband of family 67. The original
sequencing ladder showed normal sequence up to base number
695 (numbered from the ATG start codon) with a juxtaposition of
both normal and deleted sequence beyond this point. In this fig¬
ure the normal and the mutant sequence are separated (by pref¬
erential amplification) and shown side by side. A 3-bp deletion is
evident at bases 696 to 698. The deletion causes the loss of a
serine residue, b, Amino-acid composition of a portion of kinase
subdomain II for representative type I serine-threonine kinase
receptors16-24. Sequences for ALK1-5 (Z22533, Z22534,
Z22535, Z22536, and L11695) are from the human23'31. ALK6
(Z23143) is from the mouse17. ATR1 (activin receptor; U04692),
SAX (saxophone; U05209), and TKV (thick veins; U11442) are
from Drosophila32~34. The serine deleted in family 67 is shown in
bold-type and highlighted with an asterisk.
(according to the homologous structure protein
kinase, PKA-Ca)24 would result in the loss of one of
two adjacent serine residues which are conserved in
most of the type I TGF-|3 receptor family members
from mammals to Drosophila. The deletion was not
found in 390 chromosomes from a panel of unrelated
control genomic DNAs.
A point mutation was detected in the amplified
cDNA from an affected member of family 33. This
base pair substitution segregates with the disease phe-
notype in the family, and is found in unaffected mem¬
bers only when these individuals show the disease
haplotype throughout the candidate region. The
mutation was not found in 322 chromosomes in a
panel of unrelated control genomic DNAs. The change
of a T to G (coding strand) substitutes a positively
charged arginine for a highly conserved methionine in
the kinase subdomain VIII (Fig. 6).
A point mutation was detected in the amplified
cDNA from an affected member of family 40. The
mutation co-segregates with the disease haplotype in
the family, and was not found in 316 chromosomes in a
panel of unrelated control genomic DNAs. The change
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Fig. 6 a, cDNA sequence of the 3' end segment of ALK1 amplified from RNA from the proband of family 33.
The T to G substitution is evident at base 1127 which causes a methionine to arginine substitution in the pro¬
tein. b, Cosegregation of the methionine to arginine mutation in family 33 with disease status and haplotype.
The pedigree is shown with members of the family indicated by their lane number on the gel below. Individuals
rvgtkrymapevlde of uncertain diagnostic status are indicated by half-shaded symbols. Affected individuals exhibit a large,
undigested DNA product (mutant allele) in addition to the doublet (normal allele, digested) below. Unaffected
L. individuals show only the doublet, with the exception individual 21 (age 28), who shows the disease haplo-
— D type t|-iroUgtiout the ORW2 candidate interval and is therefore presumed non-penetrant for the disease phe-
notype. c, Amino-acid composition of a portion of kinase subdomain VIII for representative type I
~ serine-threonine kinase receptors16'24. Sequences are as described in Fig. 5b. The methionine which is
changed to arginine is shown in bold-type and highlighted with an asterisk.
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Fig. 7 a, cDNA sequence of the 3' end
segment of ALK1 amplified from RNA
from the proband of family 40. The G to A
substitution is evident at base 1232 which
causes an arginine to glutamine substitu¬
tion in the protein, b, Cosegregation of the
arginine to glutamine mutation in family 40
with disease status. The pedigree is
shown with members of the family indicated by their lane number on the gel below (symbols as in Fig. 6b). Affected individuals
exhibit a large, undigested DNA product (mutant allele) in addition to the doublet (normal allele, digested) below. Unaffected individ¬
uals show only the doublet, with the exception individual 13, who was classified as uncertain diagnostic status, c, Amino-acid com¬
position of a portion of kinase subdomain IX for representative type I serine-threonine kinase receptors16'24. Sequences are as
described in Fig. 5b. The arginine which is changed to glutamine in family 40 is shown in bold-type and highlighted with an asterisk.
neutral glutamine for a highly conserved positively
charged arginine in kinase subdomain XI (Fig. 7).
Discussion
Reassessment of the ORW2 candidate region defined a
maximum 4-cM interval which includes the ALK1
gene. Three mutations were found in the sequence
analysis ofALK1 in four ORW2 families. All three were
identified at the cDNA level, suggesting that these
result in functional changes to the protein. We were
unable to find the mutation in the RT-PCR products
of ALK1 from the proband of one family. This may be
due to a number of factors related to either the stabili¬
ty of the mutant message or the position of the muta¬
tion within the ALK1 gene structure. Alternatively, the
mutation in this family may be in a closely linked gene.
Each of the ORW2 mutations might be expected to
reduce kinase activity, due to removal or substitution
of critical residues in the proposed kinase subdomain
structure. The kinase subdomain II of serine-threo¬
nine protein kinases is comprised of a highly con¬
served (3-strand 3 and a more variable a-helix B. The
invariant lysine (Lys92 in PKA-Ca) in the p-strand 3 is
essential for maximal enzyme activity. It interacts with
a conserved residue in subdomain III and helps in
Fig. 8 A model for TGF-p receptor functions involved in ORW
(based in part on ref. 35). Endoglin is a homodimeric endothelial
cell membrane protein that binds TGF-p. ALK1 is a type I recep¬
tor which is also highly expressed in endothelial cells. It can bind
TGF-p or activin when co-expressed with the corresponding
type II receptor. There is as yet no evidence for an endothelial
cell-specific type II TGF-p receptor. In this scenario endoglin
sequesters TGF-p and presents the ligand to the signalling com¬
plex of ALK1 (a type I) and a type II receptor. Mutations within
endoglin and ALK1 have been shown to cause ORW1 and 2
respectively, presumably by disruption of this receptor complex
involved in TGF-p signal transduction. Defects in a type II recep¬
tor within this complex might also be expected to cause the
phenotype of ORW.
proper positioning of ATP in the hydrophobic adenine
ring pocket by interacting with the a- and (3-phos-
phates. Other residues in subdomain II are also
involved in stabilizing ATP, either by direct interaction
or by contributing to higher order structure of the
kinase necessary for enzyme activity24. Thus the delet¬
ed serine in the family 67 mutation, in the a-helix B
portion of kinase subdomain II, may affect proper
binding or positioning of ATP.
The kinase subdomain VIII plays a major role in
recognition of peptide substrates, providing a hydropho¬
bic pocket to accommodate hydrophobic residues of
typical substrates. The highly conserved alanine-proline-
glutamate (A-P-E) motif immediately follows a region of
7-10 residues which are conserved among the members
of different protein kinase families24. This includes the
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type I kinase receptors. This relatively non-polar
methionine residue is replaced by a charged arginine
residue in the family 33 mutation. This substitution may
affect the binding of protein substrate, as the hydropho-
bicity of the substrate pocket is lessened.
Subdomain IX comprises the large a-helix F,
thought to play a role in stabilizing the catalytic loop
region, as well as contributing to the hydrophobicity
(and thus stability of binding to the protein substrate)
of the substrate pocket24. The arginine to glutamine
substitution in family 40 might affect the stability of
this substrate pocket.
The specificity of ligand binding to the receptor
complex for the TGF-(3 superfamily is conferred mainly
by the type II receptor. The ALK1 protein can associate
with the TGF-P or activin type II receptors after
cotransfection in COS cells, with the complex binding
TGF-P or activin respectively15'17,18. This association
suggests that inactivating mutations within the kinase
domain of ALK1 might have a dominant-negative
effect on TGF-P or activin mediated signalling. Dele¬
tion of the kinase domain of the type II TGF-P recep¬
tor blocks ligand mediated signalling in a number of
systems including renal glomerular capillary endothe¬
lial cells25. The elucidation of the role of these ORW2
mutations on the receptor complex would require in
vitro analysis of these mutations on kinase activity, but
unfortunately there is no established method to evalu¬
ate the kinase activity ofALK1.
The variable response of different cell types to
activin and TGF-P may be modulated by tissue-specific
expression of multiple receptor isoforms forming the
functional signalling complexes. ALK1 and endoglin
may interact at the endothelial cell surface in a com¬
mon signal transduction pathway involving TGF-P
(Fig. 8). In this scenario, endoglin (acting in a manner
similar to betaglycan26) sequesters TGF-P and presents
it to an endothelial cell-specific signaling complex
containing ALK1. If another ORW locus exists, one
candidate might be a novel type II receptor that inter¬
acts with ALK1 to form this complex (Fig. 8). Alterna¬
tively, ALK1 and endoglin may act in separate
pathways (or in ones which converge in the cell)
involving different ligands which have similar effects
on vascular endothelium.
The vascular lesions in ORW are localized to dis¬
creet regions within the affected tissue, with no evi¬
dence of abnormal vascular structure or pathology
outside the lesions themselves. This suggests that some
genetic, physiologic or mechanical event initiates the
formation of each vascular lesion. The pathobiology of
the disease may be related to remodelling of the vascu¬
lar endothelium following an unknown initiating
event. TGF-P mediates vascular remodelling through
effects on extracellular matrix production by endothe¬
lial cells, stromal interstitial cells, smooth muscle cells,
and pericytes27. Responses of endothelial cells to TGF-
P depend on interactions with the surrounding extra¬
cellular matrix via integrins expressed on their surface,
and TGF-P itself regulates integrin expression of
endothelial cells27'28. Perturbations in the TGF-P sig¬
nalling pathway in ORW may lead to altered repair of
vascular endothelium and remodelling of the vascular
tissue via changes in expression profiles of extracellu¬
lar matrix proteins.
Methods
Clinical evaluation. In total five families were used to generate
the data presented in this report. Two of these, families 17 and
33, have been described' and are linked to this region of chro¬
mosome 12 (ref. 14). Family 67 was also described and is
linked to chromosome 12 (ref. 14). However, nine additional
members of this family were ascertained for this study, includ¬
ing an individual who contributed a new distal crossover.
Family 3 was described and excludes ORW1 on chromo¬
some 9 (ref. 10). Our data showed this family is linked to the
ORW2 locus on chromosome 12. In addition, this family pro¬
vides a critical proximal crossover.
Family 40 is a new family. It is a four generation pedigree for
which DNA samples have been collected for seventeen individ¬
uals, including seven affected members (Fig. 7b). Epistaxis and
muco-cutaneous telangiectases are present in most of the
affected individuals. Two of the affected persons reported gas¬
trointestinal bleeding. No affected individuals had any history
of pulmonary arteriovenous malformations.
New individuals and families in this study were assessed by
medical history and examination of skin, hands, and mucous
membranes. A positive diagnosis of ORW was made in the
presence of two of the following: affected first degree relative,
nosebleeds more than once per month, classical muco-cuta
neous lesions, and arteriovenous malformations, with the
exception that individuals with only an affected first degree rel¬
ative and nosebleeds were considered to be of uncertain diag¬
nosis. This approach was suggested4 as nosebleeds occur
frequently in the general population. Individuals were assessed
before marker genotype information was available. Peripheral
blood (20-30 ml ) was obtained with informed consent. DNA
extraction was performed as described14. RNA was prepared
from cultured transformed lymphoblasts or lymphocytes
derived from fresh blood, according to protocols furnished
with the RNAzol B reagent by the supplier (Tel-Test).
Genotyping and linkage analysis. Analysis of simple sequence
repeat markers was performed as described3. Two point linkage
analysis was also performed as described9,14.
Physical map construction. A high resolution map of the
genetically defined region of ORW2 was constructed using
Yeast Artificial Chromosome (YAC) clones. The map was con¬
structed as described29. Several subsets of YAC clones which
contained genetically mapped Genethon markers in the ORW2
interval were initially identified using the Quickmap database.
Pooling of these YAC subsets according to their presumed
genetic location (Quickmap-based Pooling Strategy) allowed
the placement of new, unmapped STSs in less than 60 PCR
reactions.
Mutation analysis. The search for mutations in ALK1 was
aided by the availability of the published sequence of the
cDNA15,23. This allowed specific PCR amplification of cDNA
prepared from patient blood lymphocytes or lymphoblasts
after reverse transcription with oligo dT. Oligonucleotide
primers were designed to amplify the cDNA in three segments,
each about 500-750 bp. The 5'-end segment was amplified
using a nested approach, with primers 5-ATTTC-
CTCTGGGCAGGAGGGAGCC-3' and 5-AACCTGCCGTGC-
CACTGTCCTCTG-3' for the first round, and primers
5-GCGCGTGTCACACTTCATGGCTCTTA-3' and 5-TGAG-
CCACTCCCTGTGGTGCAGTC-3' for the second round; the
middle segment was amplified with primers 5-CCTTGCTG-
GCCCTGGTGGCCCT-3' and CCACTCTCGGGTTGTTGCC-
GATGTCC-3'; and the 3' segment was amplified using primers
5'-GCGACTTCAAGAGCCGCAAT-3' and 5-AAGGAAT-
CAGGTGCTCCTGGG-3'. The amplification products were
then subjected to direct (cycle) sequencing to detect heterozy-
gotes. The reported cDNA sequence was compared to cDNA
sequence derived from one or more affected individuals from
each family. When a difference from the reported cDNA
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sequence was identified, a corresponding PCR assay was devel¬
oped to amplify a small segment of genomic DNA containing
the putative mutation. These assays were designed to differen¬
tially detect the divergent sequences, so that they could be used
to determine if the putative mutation cosegregated with the
disease locus in the corresponding ORW2 family, and to derive
data on frequency of the mutation in random unaffected indi¬
viduals.
Primers used to amplify the region flanking the deletion
mutation in family 67 were 5-TGTGGCACGGTGAGAGT-
GTGGCC-3' and 5-CCCGGAACCAGGACTGTTCATCC-
CTC-3'. Primers used to amplify the substitution mutation in
family 33 were 5'-ACTCACAGGGCAGCGATTACCT-3' and
5'-GTAGGACTCAAAGCAGTCCGTGC-3'; the mutation
destroys an Mall I site; this assay was used to show cosegrega-
tion with disease haplotype in family 33. This mutation also
creates a Bspl286I site, allowing the detection of an extra band
after restriction of the radiolabeled PCR product (used in the
survey of unrelated individual DNAs). Primers used to amplify
genomic DNA containing the mutation in family 40 were
5'-CACGGACTGCTTTGAGTCCTACAAGT-3' and 5-CAC-
GATGCCATTCACGATGGT-3'; the mutation destroys an
Hpall site, allowing detection of a larger uncut fragment in the
digest of affected members of family 40.
Control DNA samples were obtained from families seeking
genetic testing for either haemophilia or Duchenne muscular
dystrophy as described30.
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Summary
The activin receptor-like kinase 1 gene (ALK-1) is the
second locus for the autosomal dominant vascular dis¬
ease hereditary hemorrhagic telangiectasia (HHT). In
this paper we present the genomic structure of the ALK-
1 gene, a type I serine-threonine kinase receptor ex¬
pressed predominantly in endothelial cells. The coding
region is contained within nine exons, spanning <15 kb
of genomic DNA. All introns follow the GT-AG rule,
except for intron 6, which has a TAG|gcaag 5' splice
junction. The positions of introns in the intracellular
domain are almost identical to those of the mouse serine-
threonine kinase receptor TSK-7L. By sequencing ALK-
1 from genomic DNA, mutations were found in six of
six families with HHT either shown to link to chromo¬
some 12ql3 or in which linkage of HHT to chromo¬
some 9q33 had been excluded. Mutations were also
found in three of six patients from families in which
available linkage data were insufficient to allow cer¬
tainty with regard to the locus involved. The high rate of
detection ofmutations by genomic sequencing of ALK-1
suggests that this will be a useful diagnostic test for
HHT2, particularly where preliminary linkage to chro¬
mosome 12ql3 can be established. In two cases in which
premature termination codons were found in genomic
DNA, the mutant mRNA was either not present or pres¬
ent at barely detectable levels. These data suggest that
mutations in ALK-1 are functionally null alleles.
Introduction
Hereditary hemorrhagic telangiectasia (HHT) is an au¬
tosomal dominant disease of blood vessels that is charac-
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terized by severe recurrent nosebleeds, mucocutaneous
telangiectases, gastrointestinal hemorrhage, and a high
incidence of vascular malformations in the lung and
brain (Guttmacher et al. 1995). Most of the published
families with HHT fall into two linkage groups: HHT1,
mapping to chromosome 9q33 (McDonald et al. 1994;
Shovlin et al. 1994); and HHT2, mapping to chromo¬
some 12ql3 (Johnson et al. 1995; Vincent et al. 1995).
Patients with HHT linked to 9q33 may have a higher
incidence of symptomatic pulmonary arteriovenous mal¬
formations than is seen in those with HHT linked to
12ql3 (Heutink et al. 1994; McAllister et al. 19946;
Porteous et al. 1994; Berg et al. 1996), suggesting that,
in the pulmonary vasculature, the HHT1 gene has an
additional role not shared by HHT2. A third rare variant
of HHT has been reported in one large family with
hepatic involvement as the major manifestation (Pian-
tanida et al. 1996), with exclusion of linkage to both
chromosome 9 and chromosome 12.
The genes involved at the two major loci have been
identified. HHT1 is the endoglin gene on chromosome
9 (McAllister et al. 1994a); HHT2 is the ALK-1 gene
on chromosome 12 (Johnson et al. 1996). Both of these
genes are members of the TGF-fl receptor superfamily
(Cheifetz et al. 1992; Attisano et al. 1993; ten Dijke et
al. 1993). The ALK-1 protein has the properties of a
type I serine-threonine kinase receptor (Attisano et al.
1993; ten Dijke et al. 1993). It has been shown to bind
either activin or TGF-p in the presence of their respective
type II receptors but does not bind ligand alone (Atti¬
sano et al. 1993). The mechanism for downstream sig¬
naling of ALK-1 has yet to be elucidated, but it seems
probable that it involves pathways similar to those im¬
plicated in the signaling of other serine-threonine kinase
receptors (Niehrs 1996; Zhang et al. 1996). Expression
studies of cell lines by reverse-transcriptase-PCR (RT-
PCR) have shown that significant transcription of ALK-
1 occurs only in endothelial cell lines (Attisano et al.
1993), although we have demonstrated that it is possible
to amplify ALK-1 message from peripheral blood leuko¬
cyte mRNA. This has permitted identification of three
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mutations in ALK-1 in unrelated individuals affected
with HHT2 (Johnson et al. 1996).
In this paper we have identified the size and position
of introns in the coding portion of the ALK-1 gene. We
have developed PCR assays to amplify each exon of the
coding region of ALK-1, from genomic DNA. The ALK-
1 gene was sequenced in a panel of 12 unrelated patients
with HHT, 6 of whom have either evidence of HHT
linkage to markers on 12ql3 or exclusion of linkage of
HHT to 9q34; for the remaining 6 insufficient linkage
data were available. The position and type of each muta¬
tion found are discussed in relationship to both the func¬
tion of the protein and the pathobiology of the disease.
Subjects, Material, and Methods
Human Subjects
Individuals with HHT had been assessed in, and DNA
samples had obtained from, families 1-5, 17, and 92, as
described elsewhere (McAllister et al. 1994B; Porteous et
al. 1994; Johnson et al. 1995; Berg et al. 1996), after
informed consent had been obtained. Single samples had
also been collected from four unrelated individuals by
use of the same methods.
Identification of a Genomic PI Artificial Chromosome
(PAC) Clone Containing ALK-1
DNA from pools of a two-dimensional arrayed PAC
library (Ioannou et al. 1994) was screened by use of the
primers 5'-CGCGTGTCACACTTCATGGCTC-3' and
5' -ATCAGAAGGCCTTTCCTGGGGG-3', designed to
the 5' UTR of ALK-1 published by Attisano et al. (1993.
The positive clone from a single positive 384-well plate
(plate 265) was identified at position C14 by hybridiza¬
tion using standard protocols (Sambrook et al. 1989).
This clone was designated "265C14." Subclones were
generated by use of Bg/II-digested PAC cloned into
BamHI-digested pBluescript phagemid (Stratagene).
Localization of Introns
With a range of primers designed from the published
cDNA sequence, PCR reactions were performed to am¬
plify segments of genomic DNA containing the ALK-1
gene. Whenever a PCR fragment generated was larger
than that predicted from the cDNA sequence, it was
assumed to contain an intron and was sequenced. Where
sequencing was unclear, further sequence was generated
from the plasmid subclones by use of different primers
designed for the ALK-1 cDNA sequence. Intron size was
estimated by size of PCR product, or, for three of the
introns, sequence was generated for the entire intron.
PCR Amplification of Individual Exons
With the intronic sequence generated, primer pairs
were designed to amplify each exon of the coding part
of the ALK-1 gene. Primer sequence and conditions are
given in table 1. PCR was carried out for 35 cycles: 95°C
for 45 s, annealing temperature for 45 s, and 72°C for
1 min. One hundred nanograms of each primer, 1 X
buffer, 50 ng of genomic DNA, 0.2 mM dNTPs, and 1
unit of Gibco-BRL Taq polymerase were used in each
25-pl reaction. The buffer used was either that supplied
by Boehringer Mannheim Biochemicals (BMB) or that
originally used by Weissenbach (W; Gyapay et al. 1994);
in both cases the magnesium ion concentration was 1.5
mM.
Mutation Analysis
For each patient in the study, each exon was amplified
and sequenced. Sequencing was performed by use of
the Amersham Thermosequenase cycle sequencing kit,
which uses P33-labeled dideoxy terminators to reduce
artifactual bands. Samples of each nucleotide-specific
termination reaction were loaded in adjacent lanes,
making a mutation in any single lane very easy to iden¬
tify. In one instance, for family 92, it was necessary to
clone the exon into PCR Script by using the Invitrogen
TA cloning kit, prior to sequencing. Conservation of the
region affected by the mutation was determined by use
of the BLAST algorithm, to match the ALK-1 region
containing the mutation against the Genbank nonredun-
dant protein database.
RT-PCR
For RT-PCR, peripheral blood leukocyte mRNA was
reverse transcribed by use of a mixture of oligo dT and
random hexamers. A 250-bp segment of ALK-1 exon
VII was amplified by use of primers 5'-TGTGGCACG-
GTGAGAGTGTGGCC-3' and 5'-GTTGCTCTTGAC-
CAGCACAT-3'. A minus-reverse-transcriptase control
was included.
Polymorphism Screen
For each mutation, a panel of 100-120 normal indi¬
viduals was screened to ensure that the mutation did
not arise as a population polymorphism. The screening
was performed by altered restriction-enzyme site, where
possible. In one case in which no enzyme site was al¬
tered, the mutant PCR product gave a heteroduplex
band that could be resolved by gel electrophoresis as
described elsewhere (McAllister et al. 1995). For two
mutations it was necessary to screen the population sam¬
ples by sequencing the PCR product. In these instances,
only a single termination reaction was run for each indi¬
vidual screened.
Results
Genomic Structure of ALK-1
A single PAC clone containing the ALK-1 gene was
isolated from a human genomic PAC library (Ioannou
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Table 1
Primers for Amplification of ALK-1 Gene Exons
Annealing
Temperature Size
Exon 5' Assay Primer 3' Assay Primer <°C) Buffer (bp)
II CTCTGTGATTTCCTCTGGGCA TACATTCTCCCCAGCTTCTCAA 62a BMB 266
III AGCTGGGACCACAGTGGCTGA GGAGGCAGGGGCCAAGAAGAT 64 W 345
IV AGCTGACCTAGTGGAAGCTGA CTGATTCTGCAGTTCCTATCTG 60 W 318
V AGGAGCTTGCAGTGACCCAGCA ATGAGAGCCCTTGGTCCTCATCCA 68a BMB 242
VI AGGCAGCGCAGCATCAAGAT AAACTTGAGCCCTGAGTGCAG 60 BMB 294
VII TGACGACTCCAGCCTCCCTTAG CAAGCTCCGCCCACCTGTGAA 65a W 388
VIII AGGTTTGGGAGAGGGGCAGGAGT GGCTCCACAGGCTGATTCCCCTT 65 BMB 293
IX TCCTCTGGGTGGTATTGGGCCTC CAGAAATCCCAGCCGTGAGCCAC 68a BMB 256
X TCTCCTCTGCACCTCTCTCCCAA CTGCAGGCAGAAAGGAATCAGGTGCT 65' BMB 197
a Hot start improves amplification.
et al. 1994). This PAC clone was designated "265C14."
In Southern blot analysis, cDNA from the entire coding
region of ALK-1 hybridized to genomic fragments total¬
ing 15 kb. The position of each intron and the size of
each exon, as determined by PCR amplification from
the PAC clone, are shown in figure 1. Exon I contains
the 5' untranslated sequence published by ten Dijke et
al. (1993) and was shown, by sequencing of a subclone,
to be present in 265C14.
The 5' untranslated sequence of ALK-1 differs in the
two published descriptions of this gene (Attisano et al.
1993; ten Dijke et al. 1993). Genomic sequencing shows
that the 5' untranslated sequence published by Attisano
is part of exon II. ten Dijke et al.'s version is a splice
variant arising from splicing of exon I to a consensus
splice junction present 7 bp upstream of the start codon
in exon II, where identity with Attisano et al.'s version
of this sequence begins. This splice is marked with an
arrow in figure 1. A consensus splice is present at the
3' side of exon I. Both splice variants can be amplified
by RT-PCR of mRNA extracted either from endothelial
cell lines or from peripheral blood leukocytes.
The coding region of ALK-1 is contained within nine
exons. All except one intron follow the GT-AG rule.
Intron 6, between exons VI and VII, has a nonconsensus
sequence at the 5' junction. The most likely position for
the splice, however, gives the splice-junction sequence
TAG|gcaag, which is the sequence most commonly re¬
ported for nonimmunoglobulin eukaryotic nonconform¬
ing 5' splice sites (Senapathy et al. 1990). The 3' splice
of this intron would then have the usual consensus se¬
quence, cag | G. Sequence data from all the intron-exon
borders of the coding region are available as Genbank
accession numbers U77707-U77713.
Comparison with a Murine Type I Kinase
Another type I serine-threonine kinase receptor for
which the genomic structure has been published is the
mouse receptor TSK-7L (Ebner et al. 1993; Schmitt et
al. 1995), a homologue of human ALK-2 and activin
type I receptor. The amino acid sequence of the kinase
domain is 79% identical to human ALK-1, but the extra¬
cellular domain is only 23% identical. Comparison of
the intron-exon positions of ALK-1 with those of TSK-
IV v VI VII Vlll
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Figure 1 Diagrammatic representation of the ALK-1 gene, approximately to scale. The exons are marked by boxes—unblackened for
the coding regions and black for the noncoding regions. The exon number referred to in the text is given as a roman numeral above the exon.
Exact exon size (in bp) is given below the exon, in arabic numerals. The curved arrow marks the putative alternative splice, in the 5' UTR,
that would lead to the 5' sequence published by ten Dijke et al. (1993). For the 5' Attisano et al. (1993) sequence, transcription would start
farther 5' in exon 11.
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7L shows almost exact conservation of the position of
introns within the kinase domain. It is notable that four
of the intron-exon splices occur between the first and
second bases of a codon in the human sequence. Wher¬
ever this happens, the amino acid involved is uncharged.
This is also the case with the murine receptor. Although
the location of intron 6 is exactly conserved between
mouse and human, the mouse intron follows the GT-AG
rule, whereas the human intron 6 has a nonconsensus
sequence, as outlined above.
Novel Mutations Detected in the ALK-1 Gene
The entire coding portion and intron-exon borders of
the ALK-1 gene were sequenced in 12 unrelated individ¬
uals affected with HHT. Mutations were found in ALK-
1 in nine of the patients. Of these, six were from families
showing either strong evidence of HHT linkage to chro¬
mosome 12 (either a LOD score >3.0, with closely
linked markers, or a TOD score close to the maximum
predicted [in the previously published families 2, 3, and
17] or exclusion of chromosome 9 linkage with incon¬
clusive evidence of linkage to chromosome 12 [in pre¬
viously published families 4 and 5 and new family 92]).
Mutations were also found in three of six patients with
HHT who were from small families for which there were
inclusive linkage data. For each mutation, 100-120 un¬
related individuals were analyzed, to show that the se¬
quence change was a true mutation and not a population
polymorphism. When other family members were avail¬
able, the mutation was shown to be present in the other
affected individuals from the same kindred. The muta¬
tions and their positions in the gene are described in
table 2. Figure 2 shows sequence data and cosegregation
of the ALK-1 mutation with disease status in a part of
the previously unpublished family 92.
For two of the three individuals for whom no muta¬
tion was found, a genomic Southern blot of DNA di¬
gested with HmdIII, EcoRI, or Bglll and probed with
ALK-1 cDNA showed no evidence of a gross genomic
rearrangement. DNA available from the third individual
was insufficient for Southern blot analysis.
All 12 mutations seen so far (9 described here and 3
described elsewhere) leave the putative signal peptide
and the transmembrane domain of ALK-1 intact. Two
mutations lead to the change of a conserved amino acid
in the extracellular domain. Two mutations would lead
to premature truncation of the ALK-1 protein just after
the transmembrane domain, if translated. The remaining
eight mutations either change residues conserved in the
serine-threonine kinase family or lead to a frameshift
and premature stop in the kinase domain.
In order to determine whether a mutant protein is
required for the pathogenesis of the disease, we investi¬
gated the presence of mutant transcripts in patient
mRNA. In two cases in which a premature termination
codon is created in exon VII by either a frameshift or a
nonsense mutation, mRNA was isolated from peripheral
blood leukocytes from an affected family member and
was amplified by RT-PCR, by use of a single round
of PCR. In both cases, only the wild-type allele was
represented at any appreciable level in the product.
These procedures were replicated, with the same result.
Figure 3 shows this for a frameshift mutation in exon
VII, where no mutant transcript is visible.
Discussion
The position of introns within the kinase domain is
very highly conserved between mouse Tsk7L and human
ALK-1. In both genes, four of the splice sites fall between
the first and second bases of a codon that encodes a
neutral amino acid. It has been hypothesized that this
allows alternative splicing of the kinase domain, which
are still in frame but have variations in kinase activity
(Schmitt et al. 1995). Intron 6 of the ALK-1 gene has a
variant splice sequence at the 5' side—AG/gcaag, in¬
stead of the usual AG/gt. This has been observed in other
genes (Senapathy et al. 1990). The 3' splice junction is
the usual consensus, cag/G. The function of this variant
splice sequence is unknown, but it may represent a
means for controlling the amount of ALK-1 mRNA that
is spliced. This splice-sequence variation is not seen in
the mouse, but the splice location occurring between the
first and second bases of a glycine codon is the same.
Mutations were found in ALK-1 in all three of the
families in which the disease is known to be linked to
the ALK-1 region, as well as in all three families in which
linkage to HHT1 on chromosome 9 had been excluded.
When no linkage data were available, mutations were
found in three of the six individuals analyzed. The three
patients in whom no mutation was found may come
from families in which the disease is linked to other loci,
or they may have a form ofmutation not easily detected
by PCR and sequencing of the coding exons.
Genomic sequencing may prove a more reliable diag¬
nostic test than RT-PCR from peripheral blood leuko¬
cyte mRNA. A low level of the ALK-1 transcript in
leukocytes in addition to unstable mutant mRNA of
some mutations may lead to difficulties in detection of
the mutation by RT-PCR. Our comparatively high rate
of mutation detection and the small size of the ALK-1
gene make genomic sequencing a viable diagnostic test
for HHT2, particularly if a family has previously shown
linkage of the disease to chromosome 12ql3. Since a
clinical diagnosis ofHHT in young adults is often uncer¬
tain, presymptomatic diagnosis of HHT will allow
screening for the serious complications to be targeted
only to those at risk.
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Table 2
Summary of ALK-1 Mutations in HHT2
Exon Protein Region Mutation Found (Position) Effect on Protein
II Start None
Signal peptide
III Extracellular domain G->T (150) Trp (conserved)-»Cys
G-A (200) Arg (conserved)—>Gln
IV Extracellular domain G->A (423) Premature STOP (intracellular)
Transmembrane domain G->T (475) Premature STOP (intracellular)
Start of intracellular domain
V Glycine-Serine domain None
VI ATP binding site 3-bp deletion (694)" Deletion Ser in frame
Start of kinase domain
VII Kinase domain Ins T (865) Frame shift and premature STOP
C-»A (924) Premature STOP
G-T (998) Ser (conserved)->Ile
VIII Kinase domain C->T (1120) Arg (conserved)—>Trp
T-»G (1126)" Met (conserved)-»Arg
G->A (1232)a Arg (conserved)-»Gln
IX Kinase domain C-*A (1270) Pro (conserved)—>Thr
X End of kinase domain None
" Previously published by Johnson et al. (1996).
All 12 mutations identified in ALK-1 leave the signal
peptide and transmembrane domain intact. Two extra¬
cellular mutations cause changes of conserved amino
acids, and there are two premature stops before the gly¬
cine-serine domain. The remaining mutations disrupt
the kinase domain either by amino acid change or by
small insertion/deletion. Such mutations may function
in one of several ways, including a dominant-negative
effect of the mutant ALK-1 receptor, haploinsufficiency
of ALK-1 protein, or complete loss of functional ALK-
I because of a second somatic mutation in the normal
allele.
The hypothesis of a dominant-negative effect requires
that an altered protein be transcribed and translated
from the mutant allele—and that this protein interfere
with the function of the heteromeric receptor signaling
complex. Support for this mechanism includes the con¬
servation of signal peptide and transmembrane regions
in all mutations found to date. If translated, the abnor¬
mal ALK-1 protein may retain the ability to bind a type
II receptor in the presence of ligand; but it may not be
able to transduce signal, either because of disruption of
the kinase domain or because of failure to bind ligand
because of alteration of the extracellular domain. Simi¬
lar mutations in another type I receptor show a domi¬
nant-negative effect. Wild-type MvlLu cells, which ex¬
press the type I TGF-f) receptor, show reduced TGF-P
signaling after transfection with an inactivated TGF-P
type I receptor (Feng et al. 1995; Yamamoto et al. 1996),
created either by deletion of the cytoplasmic domain or
by point mutation in the kinase domain. This dominant-
negative effect is even more pronounced with truncated
forms of the type II receptor.
However, RT-PCR of two premature protein-truncat¬
ing mutations observed in exon VII exhibit very low to
undetectable levels of the mutant transcript from cDNA
of peripheral blood leukocytes, suggesting that some
mutant transcripts are unstable. Vascular endothelial
cells from patients were unavailable for this expression
study. Nonetheless, these data suggest that a mutant
protein product may not be present for at least some
ALK-1 mutations and that a dominant-negative effect is
not required for the pathogenesis of HHT.
The vascular lesions observed in HHT may develop
in response to reduced levels of ALK-1 that are due to
haploinsufficiency. The mutations identified to date are
consistent with the hypothesis that they are all function¬
ally null alleles. The inheritance of a single mutant copy
would then predispose the individual to develop the vas¬
cular lesions observed in HHT. Lesion formation itself
could be due to local environmental or mechanical ef¬
fects at the lumen of the vessel or to additional genetic
alterations.
Finally, it is possible that the development of a vascu¬
lar lesion initiates with a complete loss of ALK-1 signal¬
ing in an endothelial cell. This could be due to somatic
mutation of the normal ALK-1 allele. Some support for
the possibility of a "second hit" is given by the appar¬
ently random distribution of discrete lesions, the number
of which increases with age. Mucocutaneous telangiec-
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tases appear abruptly and are progressive (Plauchu et al.
1989). However, one study has shown that the classical
telangiectases arise as a result of dilatation of blood
vessels (Braverman et al. 1990) and do not appear to be
proliferative lesions. Also, studies on the development
and growth of pulmonary arteriovenous malformations
have shown gradual size increases with time, requiring
as long as a decade or more to double in diameter (Vase
et al. 1985; Masakazu et al. 1988). These studies suggest
that, if ALK-1 requires a somatic second mutation for











Figure 3 Unstable transcript of the mutant ALK-1 allele in fam¬
ily 17. DNA and mRNA from peripheral blood leukocytes of an af¬
fected individual (family 17) were used in genomic PCR and RT-PCR,
respectively. Both PCR products were then sequenced by use of an
identical primer within the exon. The sequence of the normal (N)
allele is apparent in both samples, whereas that of the mutant (M)
allele is seen only in the genomic PCR product. Insertion of a T (boxed
in the sequence at the left, indicated by an arrow to the right of
the band) produces, beyond the inserted nucleotide, superimposed




Figure 2 Molecular analysis of the ALK-1 mutation in family
92. a, Portion showing affected family members. The disease status
cosegregates with presence of a Stul site in the exon VII product shown
in panel b. b, Stul digest of the exon VII PCR product from family
92. The mutation creates a site that leads to generation of fragments
of —170 and —210 bp, as well as to an undigested fragment of 380
bp. In unaffected individuals, only the undigested fragment is seen. A
100-bp ladder is used as the size standard, c, Sequence from an affected
member of family 92. Exon VII product was subcloned as described
and was sequenced. Sequences from mutant and wild-type clones are
shown. In the mutant clone a C->A base change causes a premature
stop. This base change creates a Stul site in the mutant exon VII
product.
tumor-suppressor gene. Since TGF-J3 signaling in endo¬
thelial cells modulates vascular remodeling by inducing
changes in the extracellular matrix (Madri et al. 1989;
Merwin et al. 1990), complete loss of ALK-1 signaling
may induce remodeling of the vascular bed, rather than
directly affect the rate of endothelial cell proliferation.
The proof of this mechanism would require detection
of either loss of heterozygosity or somatic mutation of
the normal ALK-1 allele in the single layer of endothe¬
lium removed from an HHT-associated vascular lesion.
In a similar analysis of the renal cysts seen in autosomal
dominant polycystic kidney disease type 1, loss of het¬
erozygosity and somatic mutation of the normal PKD1
allele were observed only when methods were developed
to isolate the single layer of epithelium lining the renal
cysts (Qian et al. 1996).
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